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Investigation into the Rate-Determining Step of Mammalian Heme Biosynthesis:
Molecular Recognition and Catalysis in 5-Aminolevulinate Synthase
Thomas Lendrihas

Abstract

The biosynthesis of tetrapyrolles in eukaryotes and the -subclass of purple
photosynthetic bacteria is controlled by the pyridoxal 5’-phosphate (PLP)-dependent
enzyme, 5-aminolevulinate synthase (ALAS). Aminolevulinate, the universal building
block of these macromolecules, is produced together with Coenzyme A (CoA) and
carbon dioxide from the condensation of glycine and succinyl-CoA.

The three-

dimensional structures of Rhodobacter capsulatus ALAS reveal a conserved active site
serine that moves to within hydrogen bonding distance of the phenolic oxygen of the PLP
cofactor in the closed, substrate-bound enzyme conformation, and simultaneously to
within 3-4 angstroms of the thioester sulfur atom of bound succinyl-CoA. To elucidate
the role(s) this residue play(s) in enzyme activity, the equivalent serine in murine
erythroid ALAS was mutated to threonine or alanine. The S254A variant was active, but
both the K mSCoA and kcat values were increased, by 25- and 2-fold, respectively, suggesting
the increase in turnover is independent of succinyl-CoA-binding. In contrast, substitution
of S254 with threonine results in a decreased kcat, however the Km for succinyl-CoA is
x

unaltered.

Removal of the side chain hydroxyl group in the S254A variant notably

changes the spectroscopic properties of the PLP cofactor and the architecture of the PLPbinding site as inferred from circular dichroism spectra. Experiments examining the rates
associated with intrinsic protein fluorescence quenching of the variant enzymes in
response to ALA binding show that S254 affects product dissociation. Together, the data
led us to suggest that succinyl-CoA binding in concert with the hydrogen bonding state of
S254 governs enzyme conformational equilibria.
As a member of the -oxoamine synthase family, ALAS shares a high degree of
structural similarity and reaction chemistry with the other enzymes in the group.
Crystallographic studies of the R. capsulatus ALAS structure show that the alkanoate
component of succinyl-CoA is bound by a conserved arginine and a threonine. To
examine acyl-CoA-binding and substrate discrimination in murine erythroid ALAS, the
corresponding residues (R85 and T430) were mutated and a series of CoA substrate
analogs were tested. The catalytic efficiency of the R85L variant with octanoyl-CoA was
66-fold higher than that calculated for the wild-type enzyme, suggesting this residue is
strategic in substrate binding. Hydrophobic substitutions of the residues that coordinate
acyl-CoA-binding produce ligand-induced changes in the CD spectra, indicating that
these amino acids affect substrate-mediated changes to the microenvironment of the
chromophore. Pre-steady-state kinetic analyses of the R85K variant-catalyzed reaction
show that both the rates associated with product-binding and the parameters that define
quinonoid intermediate lifetime are dependent on the chemical composition of the acylCoA tail. Each of the results in this study emphasizes the importance of the relationship
between the bifurcate interaction of the alkanoic acid component of succinyl-CoA and the

xi

side chains of R85 and T430.
From the X-ray crystal structures of Escherichia coli 8-amino-7-oxonoanoate
synthase and R. capsulatus ALAS, it was inferred that a loop covering the active site
moved 3-6 Å between the holoenzymic and acyl-CoA-bound conformations.

To

elucidate the role that the active site lid plays in enzyme function, we shuffled the portion
of the murine erythroid ALAS cDNA corresponding to the lid sequence (Y422-R439),
and isolated functional variants based on genetic complementation in an ALA-deficient
strain. Variants with potentially greater enzymatic activity than the wild-type enzyme
were screened for increased porphyrin overproduction.

Turnover number and the

catalytic efficiency of selected functional variants with both substrates were increased for
each of the enzyme variants tested, suggesting that increased activity is linked to
alterations of the loop motif. The results of transient kinetics experiments for three
isolated variants when compared to wild-type ALAS showed notable differences in the
pre-steady-state rates that define the kinetic mechanism, indicating that the rate of ALA
release is not rate-limiting for these enzymes. The thermodynamic parameters for a
selected variant-catalyzed reaction indicated a reduction in the amount of energy required
for catalysis. This finding is consistent with the proposal that, in contrast to the wild-type
ALAS reaction, a protein conformational change associated with ALA release no longer
limits turnover for this variant enzyme.

xii

Chapter One

Introduction
The central function of heme: biogenesis, chemistry and health
Living organisms utilize tetrapyrroles in many important cellular processes.
Heme, a ferrous metallated tetrapyrolle, serves a crucial role as a prosthetic group in
cytochromes and globins, proteins responsible for respiration (1). As a cofactor, heme is
a component of reactions catalyzed by various enzymes including: catalases, peroxidases
and the cytochrome P-450s (2, 3). Heme also modulates both steps of the central dogma
of molecular biology.

Transcription is affected via a signal transduction cascade,

whereby heme activates transcriptional repressors such as Bach-1 (4, 5).

Message

translation is highly regulated through the phosphorylation of eucaryotic translation
initiation factor 2A (eIF2α) by a number of heme-dependent kinases (6-9).
Hierarchically, among eucaryotes and the α-subclass of purple photosynthetic
bacteria, the heme biosynthetic pathway consists of eight enzymes (Figure 1.1). The
biosynthesis begins with the condensation of glycine and succinyl-CoA and concludes
with the chelation of ferrous iron by protoporphyrin IX (10).

Among cells with

organelles, all eight enzymes are nuclear encoded; however, the enzymes are distributed
in both the cytosol and mitochondria (11). Porphyrias, congenital disorders characterized
by the accumulation of porphyrins and porphyrin precursors, occur when gene-derived
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defects are present among the pathway enzymes (12). Aberrant iron metabolism and
associated disorders stem from additional enzymatic deficiencies (13).
The catabolism of heme is a tightly regulated process involving heme oxygenase
and biliverdin reductase, which together degrade heme to carbon monoxide, iron and
bilirubin (14). Heme, present in hemoproteins, is degraded to bile pigments by the action
of heme oxygenase (15, 16). Typical inducers of heme oxygenase include: heme,
endotoxin, heavy metals and hypoxia (17-19).

The role of these molecules and

circumstances in the generation of reactive oxygen species has been documented,
suggesting that the action of the rate-limiting step of heme degradation is potently
cytoprotective (20).

Several disease states are associated with defects in heme

breakdown, including atherosclerosis and cancer, as well as a number of inflammatory,
autoimmune, and degenerative diseases (21, 22).
The enzymes of the heme biosynthetic and degradation pathways have been
crystallized. These three-dimensional structures provide the framework for identifying
structural components of both the molecular basis of heme-related disease and catalysis.
This introduction describes each enzyme of these pathways in terms of structure and
function with the congenital disorder at each step addressed.

The focus of this

dissertation is on aminolevulinate synthase, the enzyme on which my theses are based.
Enzymes in the heme biosynthesis pathway
Aminolevulinate synthase
5-Aminolevulinate synthase (EC 2.3.1.37) (ALAS), is the first, and key regulatory
enzyme of heme biosynthesis in non-plant eucaryotes and the α-subclass of purple
photosynthetic bacteria (Figure 1.1) (23). ALAS catalyzes the Claisen-like condensation
2

of glycine and succinyl-Coenzyme-A to yield coenzyme-A (CoA), carbon dioxide (CO2)
and 5-aminolevulinate (ALA) (23). For the remaining monera, and in all plants, ALA is
synthesized from an alternative pathway involving the five carbon skeleton of glutamate

(24, 25). Interestingly, the photosynthetic phytoflagellate Euglena gracilis synthesizes
ALA via both pathways, with non-plastid heme synthesized from glycine or the Shemin
pathway, and chloroplast heme coming from glutamate-derived ALA (26).
The ALAS-catalyzed reaction takes place in the mitochondria of non-plant
eucaryotes (11). This reaction is tightly regulated, and the rate of reaction determines the
anabolic production of downstream metabolites in the pathway (27, 28). Mammalian
genomes contain two genes which code for two isoforms of ALAS. The gene encoding
the non-specific, or housekeeping form of ALAS (ALAS1), which is constitutively
expressed in all tissues, has been localized to chromosome band 3p21 (29). The erythroid
specific form of the enzyme (ALAS2) is encoded by a gene located on the Xchromosome at band Xp11.21 (30). The nucleotide sequences of the two genes are
notably different; however, the two protein isoforms share significant similarity (29, 31).
Mitochondrial import of ALAS is determined by an N-terminal transit sequence, which is
cleaved prior to enzyme maturation (32). ALAS2 from Rattus rattus shows a ~9 kDa
difference in monomeric molecular weight after the presequence is clipped (33).
Heme and iron regulate both gene expression and sub-cellular localization of
ALAS.

Mammalian ALAS proteins contain heme regulatory motifs (HRM) which

consist of a conserved dipeptide, Cys-Pro (32). By way of HRMs, depleted intracellular
heme pools inhibit the mitochondrial translocation of ALAS1 (34). Plentiful heme on the
other

hand

in

differentiating

erythrocytes
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not

contribute

to
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Cytosol

Enzymes and intermediates of the heme biosynthetic pathway.

Mitochondrion

Figure 1.1.

mitochondrial import of the ALAS2 enzyme (34). Transcription of the ALAS1 gene is
upregulated by peroxisome proliferator-activated coactivator 1α (PGC-1α) (35), through
promoter-mediated interactions with both nuclear regulatory factor 1 (NRF-1) and the fox
head family member FOX01 (36). Transcription of the ALAS2 gene is regulated by
erythroid-specific factors including GATA-binding protein 1 (globin transcription factor
1), a protein which is chiefly responsible for the activation of globin production in red
cells (37). The resultant ALAS2 transcript contains a 5' iron regulatory element (IRE)
which binds with the IRE-binding protein (IRP) in iron-poor conditions, rendering
translation impossible (38). Under iron-rich conditions, the IRP-1 contains an Fe-S
cluster (38).

The incorporation of this prosthetic group within the protein restricts

formation of the IRE-IRP-1 complex, permitting message translation by the ribosome

(38). Ultimately, it is the bioavailability of iron that is the chief modulator of ALAS2
production in vivo (39).
The reaction catalyzed by ALAS is markedly similar to those of 2-amino-3ketobutyrate-CoA ligase (KBL), 7-amino-8-oxononanoate synthase (AONS), and serine
palmitoyl transferase (SPT) (40-43). Based on structure and function, ALAS is classified
as a fold-type I pyridoxal-5’-phosphate (PLP)-dependent enzyme and as a member of the
α-oxoamine synthase subfamily; AONS, KBL and SPT represent the closest structural
relatives, with the enzymes of the subfamily sharing a Cα RMSD of 1.5 Å (44). KBL
catalyzes the degradation of threonine (45), AONS, the committed step in biotin
biosynthesis (46) and SPT, the first step of sphingolipid biosynthesis (47). In all cases
the reduced coenzyme is liberated and the aminoketone product of the enzyme-catalyzed
reaction is further metabolized. Enzymes in the α-oxoamine synthase family function as
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homodimers, with each monomer containing a PLP cofactor at the subunit interface (44).
In ALAS, there is one active site per subunit, comprised of residues from adjacent
monomers at the dimeric boundary (48).
The three-dimensional structure of ALAS from Rhodobacter capsulatus has been
solved (49). The bacterial protein exists as a homodimer, where each monomer consists
of three domains. The N-terminal domain, discrete from the remainder of the enzyme, is
defined by an alpha-helix and an anti-parallel beta-sheet. The catalytic domain contains a
core parallel beta-sheet flanked by alpha helices. The C-terminal domain independently
interacts with the N-terminal domain through three alpha-helices and with the central
core domain of the enzyme via a three-stranded, anti-parallel beta-sheet. The orientation
of the PLP cofactor can be considered to occur through interactions with three specific
protein moieties. First, the phosphate group is bound tightly via 6 hydrogen bonds
(where three are intrasubunit, and three intersubunit). Second, pi-stacking interactions
between the conjugated systems of the cofactor and a conserved active site histidine also
stabilize the position of PLP. Third, hydrogen bonding between a conserved aspartate
residue and the pyridinium nitrogen enhance the electron withdrawing properties of the
cofactor.

This PLP microenvironment and adjacent C-terminal domain delimit the

substrate-binding channel, connecting the solvent exposed surface of the enzyme with the
hydrophobic core of the enzyme, where the acyl-CoA-binding cleft is located (49).
Studies focused on the role conserved amino acids play in the reaction catalyzed
by murine ALAS revealed several notable findings. First, the catalytic lysine (K313)
(ALAS2 numbering), essential for enzyme activity and involved in forming a Schiff-base
linkage with the PLP cofactor, has been elucidated (50). An aspartate residue (D279)
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involved in enhancing the electron withdrawing capacity of the PLP cofactor was also
found (51). Recognition of the carboxyl group of the glycine substrate and binding of the
PLP cofactor were found to be dramatically affected when mutations were made to
arginine residues, R149 and R439 (52-54).

More recently, an active site histidine

(H282), was reported to modulate the orientation and electronics of the PLP cofactor

(55).
The ALAS chemical mechanism (Scheme 1.1) is complex and involves: binding
of glycine (I); transaldimination with the active site lysine (K313) to yield an external
aldimine (II); abstraction of the pro-R proton of glycine (III); condensation with succinylCoA (IV) and CoA release to generate an α-amino-β-ketoadipate intermediate (V);
decarboxylation resulting in an enol-quinonoid rapid equilibrium (VI); protonation of the
enol to give an aldimine-bound molecule of ALA (VII); and ultimately release of the
product (ALA) (VIII) (28). Transient kinetic analyses have indicated that the ratedetermining step of the ALAS-catalyzed reaction is product release or a conformational
change leading to product release (27, 28). The latter of the two possibilities is supported
by the observation that the ALAS-catalyzed reaction rates, when measured with a variety
of acyl-CoA derivatives, are comparable (56).
The proposed model of ALAS catalysis, based on kinetic data obtained in both the
steady- and pre-steady-states involves transition between “open” and “closed”
conformations of the enzyme (28). The binding of the second substrate, succinyl-CoA, to
ALAS increased the ALAS-catalyzed reaction rate over 250,000 times (57). This finding
led to the proposal that part of the intrinsic binding energy of succinyl-CoA is utilized to

7

2-

R=OPO3

Scheme 1.1. The chemical mechanism of ALAS. The individual steps are: binding of
glycine (I); transaldimination with the active site lysine (K313, murine erythroid ALAS
numbering) to yield an external aldimine (II); abstraction of the pro-R proton of glycine
(III); condensation with succinyl-CoA (IV) and CoA release to generate an α-amino-βketoadipate intermediate (V); decarboxylation resulting in an enol-quinonoid rapid
equilibrium (VI); protonation of the enol to give an aldimine-bound molecule of ALA
(VII); and ultimately release of the product (ALA) (VIII).

8

favor the conversion of the population of equilibrium conformers to a population of
“closed” conformational species. This inter-conversion between the two conformational
states is associated with progression of the reaction and ultimately to restoration of the
open conformation, which is concomitant with ALA release.
Mutations found in the ALAS2 gene can lead to sideroblastic anemia (58).
Sideroblastic anemias are a group of disorders where the circulating erythrocytes appear
hypochromic and the marrow is encumbered by ringed sideroblasts (59). The nuclei of
these sideroblastic cells are surrounded by iron-laden mitochondria (60), and thus the
designation of ringed sideroblasts. Diminished ALAS2 activity in red blood cells is the
main reason why retained iron is a hallmark of a defect in heme biosynthesis (61).
The most common form of inherited sideroblastic anemia is X-linked
sideroblastic anemia (XLSA), a sex-linked, congenital disorder (61). Hemizygous males
present the most severe symptoms including: fatigue, disorientation and both hepato- and
splenomegaly (62, 63). The toxicity of excess iron has been well-documented and leads
to heart disease, liver and kidney failure (62, 63). Specifically, potent oxidation of the
cellular milieu by iron-burdened transferritin leads to decreased cell life via generation of
reactive oxygen species (60, 64, 65).
The majority of ALAS2 mutations leading to pathological conditions (e.g.,
XLSA) are missense and are manifested in regions of the protein responsible for
interactions between the enzyme and its cofactor (49, 66). In fact, these variants which
turn over ALA with less efficiency are, to some extent, responsive to pyridoxine
administration (61). Other cases, in which the stability or processing of the enzyme is
perturbed, are refractory to this line of therapy (67). Advances regarding protein-protein
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interactions between ALAS and the succinyl-CoA synthetase reveal that abrogation of
this association may be responsible for the pathological presentation of the defect (49,

68).
Until recently, all of the enzymes of the heme pathway in mammals, except
ALAS, were recognized to have a porphyrin-associated disorder when defective (69).
Now, ALAS2 gene deletions have been identified in eight families with the following
genetic manifestations c.1706-1709 delAGTG (p.E569GfsX24) or c.1699-1700 delAT
(p.M567GfsX24) (70).

The corresponding gene product is a truncated form of the

erythroid-specific ALAS enzyme (ALAS2), which may be responsible for increased
circulating concentrations of protoporphyrin IX.

Consequently, these variants

demonstrate the first instance of an erythroid ALAS-related porphyria, X-linked
dominant protoporphyria.

With this finding, several features of the biochemical

mechanism of this mode of disease require further research. First, since the experiments
were performed on lysates of bacterial cells harboring the expression plasmid for the
truncated proteins and not with deletion-variants purified to homogeneity, the opportunity
for other proteins and metabolites affecting the reaction cannot be ruled out. Next, while
the investigators measured ALAS activity in addition to the concentration of reaction
products and downstream heme pathway intermediates (71), they did not identify whether
the stability of the enzyme or its message was unchanged. Certainly, elimination of a
protein sequence of this magnitude could potentially affect protein degradation rates as
well as message turnover. Thorough biochemical experiments are required to elucidate
the complete nature of this intriguing finding.
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Porphobilinogen synthase
The means by which ALA exits the mitochondrion of eukaryotic cells remains to
be elucidated. Once in the cytosol, 2 molecules of ALA are asymmetrically condensed
by the metalloenzyme porphobilinogen synthase (EC 4.2.1.24; PBGS or ALA
dehydratase (ALAD)) (Figure 1.1) (72). The formation of porphobilinogen (PBG), a
monopyrrole, is the first common step of tetrapyrrole biosynthesis among all living
organisms. PBGS isolated from different organisms, from bacteria to humans, share a
high degree of sequence identity (73).

These enzymes are large, exhibiting homo-

octameric quaternary structure, and molecular masses in excess of 280 kDa (74). The
crystal structure for human PBGS has been determined (75). Each of the four compact
homodimers embrace one another using an N-terminal arm, resulting in tetragonal
trapezohedral (422) symmetry. With respect to oligomerization, PBGS is an example of
a prototypical morpheein ensemble (76). Morpheeins are the building blocks of a group
of polypeptides in which a monomer of an enzyme can exist in multiple conformations.
Each monomeric conformation affects quaternary structure differently, and the result is
an oligomer of distinctive functionality (77).
Catalysis by PBGS begins with the formation of independent Schiff base bonds
between 2 conserved active site lysine residues and the substrates (78, 79).

The

destination of the ALA molecule within the monopyrrole dictates the nomenclature of the
active site. The A-site refers to one half of the active site that binds ALA destined for
inclusion as the acetyl component of PBG, while the propionyl-coordinating half of PBG
derives from P-site ALA. P-site ALA binds before A-site ALA. Homo-bond formation
(C-C) occurs when A-site ALA (C3 position) links with ALA in the P-site (C4) position
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via an aldol addition (78). Hetero-bond formation (C-N) follows whereby the P-site
substrate amino group attacks the A-site Schiff base. The resultant Schiff-base exchange
and liberation of the A-site catalytic lysine permit the energetically favorable steps of
aromatization and product release (78). The role of metal ions in the reaction catalyzed
by PBGS has been an item of contention. Three-dimensional structures obtained with a
series of substrate and product analogs have been completed, and the role of an activesite zinc has been partially addressed (78, 80). A PBGS structure from Pseudomonas

aeruginosa shows that a magnesium ion can be replaced by a zinc ion through the
introduction of cysteine residues to the metal binding site (78). This suggests that the
direct involvement of magnesium ions in the mechanism of magnesium binding to
PBGSs, is relatively plastic.

Nevertheless, the functionality of metal ions in the

mechanism of PBGS remains to be fully elucidated.
Mutations that occur in the PBGS or ALAD gene result in a rare recessive
autosomal disorder called ALAD porphyria (81). Less than ten cases have been reported
that are consequence of a defective gene product (82). In addition to the inherited nature
of the disease, heavy divalent metal ions can also illicit symptoms associated with PBGS
deficiency (83). Over 80% of the lead found in the human body is bound to ALAD (84).
It has been proposed that ALAD porphyria is a disease where pathology stems from
defects in conformer equilibrium (85).

Gel filtration data obtained using variants

encoded by aberrant genes show that oligomerization of mutated enzymes occurs in a
manner that favors the less active hexameric state. These hexamers, resulting from eight
porphyria-associated variants, may be the first example of a morpheein-based
conformational disease. Diminished enzyme activity leads to the accumulation of ALA.
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Symptoms associated with the poor porphobilinogen production include: intermittent
acute neurovisceral attacks and a propensity toward poisoning by lead (86). Inhibition of
this enzyme by succinylacetone, a metabolite found in among individuals with hereditary
tyrosinemia type I, also causes pathological conditions similar to those of lead poisoning
and congenital ALAD (80, 87).
Porphobilinogen deaminase
A cytosolic polymerization reaction where four molecules of PBG are linked is
catalyzed by porphobilinogen deaminase (EC 4.3.1.8; PBGD) or hydroxymethylbilane
synthase) (Figures 1.1 and 1.2). The physiologically relevant reaction product is the
linear tetrapyrrole hydroxymethylbilane (HMB) a.k.a. pre-uroporphyrinogen (74). HMB
is exceedingly unstable and can undergo spontaneous cyclization to form the nonphysiological isomer uroporphyrinogen I (88). PBGD sequences are highly conserved
throughout evolution and among diverse phyla; to date, all isolated enzymes contain a
unique cofactor, dipyrromethane (89). PBGD functions as a monomer and the human
crystal structure was recently solved (90). Human PBGD consists of 344 residues with a
molecular weight of ~37 kDa. The three-dimensional structural analysis shows that the
monomeric protein is organized into three equal-sized domains. Domain I houses most
of the catalytic and substrate-binding residues, while domain II is responsible for cofactor
binding. The dipyrromethane cofactor is covalently linked to a loop of residues
comprising domain III and is perched at the opening of the active site cavity, now known
to be delimited by cleft formed by domains I and II (90). A novel mechanism defines the
generation of the unique dipyrromethane cofactor (91). During turnover, the enzyme first
binds HMB, then deaminates and polymerizes 2 molecules of PBG to form a
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A

B

Figure 1.2. The X-ray crystal structure of porphobilinogen deaminase from Homo
sapiens. (PDB code: 3ecr) The monomeric protein is organized into three equal-sized
domains, which are comprised of both α-helices (green) and β-sheets (rust) (A). Perched
at the top of the enzyme is the unique dipyrromethane cofactor (depicted as sticks in CPK
color format) (B).
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hexapyrrole. Subsequently, PBGD cleaves the distal tetrapyrrole and releases HMB. A
thioether linkage to an active site cysteine retains the dipyrrole cofactor for the lifetime of
the enzyme (91).
Acute intermittent porphyria (AIP) is due to an autosomal dominant pattern of
inherited mutations of the PBGD gene leading to diminished enzyme activity (12).
Hundreds of PBGD mutations have been identified, with acute attacks of porphyria
affecting 1:100000 individuals, with presentation more common in women than men

(92). However, only recently was a poly-deletion mutant identified in exon 15 of the
PBGD gene (93). The deletion occurs in a conserved region of the protein where other
disease causing mutations have been discovered (94). This particular defect clearly has a
more substantial negative effect on catalysis, as the ALA concentration identified in the
urine of the patient was 100 times that of normal (92). Symptoms of AIP include
abdominal pain and other neurovisceral and circulatory disturbances, ultimately resulting
in tachycardia (95). A majority of the mutations identified in the human PBGD gene
perturb carboxylate binding between conserved arginines and the cofactor or substrate

(96). However, recently, some of the mutations documented in patients suffering from
AIP were found to be located distal from the active site (94).
Uroporphyrinogen III synthase
HMB serves as the substrate for the fourth enzyme of the heme biosynthetic
pathway, uroporphyrinogen III synthase (EC 4.2.1.75) (UROS) (Figure 1.3). UROS
catalyzes closure of the tetrapyrrole macrocycle by inverting the D-ring of HMB (74).
All identified UROS enzymes function as a monomer with a molecular weight of ~30
kDa (97-100). UROS proteins from all kingdoms of life are similar with respect to
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Figure 1.3.

The three-dimensional structure of human uroporphyrinogen III

synthase. (PDB code: 1jr2)

The functional monomer contains two unambiguous

domains connected by a short β-ladder (yellow). Each domain is characterized by a βsheet core (magenta) surrounded by α-helices (teal).
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molecular mass; however significant sequence deviations have been observed (101).
Specifically, the sequence similarity between mammalian and bacterial UROS is less than
22%.

Notably, recent three-dimensional studies on UROS from the gram-negative

eubacterium Thermus thermophilus identified significant conformational information

(102).

In these experiments eight crystallographically unique UROS structures

(consisting of apoenzymic, ligand-bound and product-bound forms) were overlaid. From
these maps, significant enzyme flexibility was observed, including a snapshot of the
product-bound enzyme in the closed conformation (102). The X-ray crystal structure of
human UROS revealed that the enzyme contains two unambiguous domains connected
by a short β-ladder (103). Each domain is characterized by a β-sheet core surrounded by
α-helices. The substrate binding cleft is located at the domain interface and delimited by
a series of evolutionarily conserved residues.
The UROS-catalyzed reaction proceeds by way of a spirocyclic pyrrolenine
intermediate (104). This intermediate occurs after a rearrangement of the A-ring of
HMB, which results in the concomitant loss of the C20 hydroxyl group and the formation
of a carbocation at C20. C16 of the D-ring is then susceptible to electrophilic attack and
the spirocyclic pyrrolenine intermediate is generated.
formed

permitting

cyclization

and

D-ring

Subsequently, azafluvene is

inversion

to

yield

the

product

uroporphyrinogen III. From the structural data, it was inferred that the interactions of the
A and B ring carboxylate groups with both structural domains of UROS are the chief
modulators of the closed enzyme conformation (104). The C and D rings demonstrate
increased flexibility, a characteristic consistent with the sterically-mediated acts of
catalytic cyclization and D ring inversion. Biological relevance of all porphyrins is
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demarcated by asymmetry about the D-ring of tetrapyrolles.

Without enzymatic

conversion, HMB spontaneously cyclizes to a toxic dead end product, which in patients
with UROS deficiency results in accumulation of uroporphyrinogen I (105).
Mutations to the UROS gene manifest as a rare form of porphyria called
congenital erythropoietic porphyria (CEP) (105). The defective enzyme is inherited as an
autosomal recessive trait.

In CEP or Günther disease, HMB is non-enzymatically

converted to uroporphyrinogen I and is subsequently catalyzed by the fifth enzyme of the
heme biosynthetic pathway to coproporphyrin I (105). Recently, a thorough study was
conducted where 25 missense mutations were cloned into expression vectors, and the
respective proteins were purified to homogeneity and characterized (106).

Kinetics

experiments indicated that most mutated enzymes had significantly decreased activity,
while others maintained reaction rates comparable to those of the wild-type enzyme.
This suggested that mechanisms besides turnover may be responsible for the pathology
observed in CEP. Located in α-helix 3, perched above the active-site, a conserved active
site cysteine was the focus of experiments related to enzyme structure. Significantly,
unfolding experiments performed on variants of this cysteine residue may be crucial for
proper folding and turnover of uroporphyrinogen III (106).
Coproporphyrin I is the causative agent of erythrodontia or red staining of the
teeth (105). Patients are either homozygous for a single polymorphism or are compound
heterozygotes for a variant form of the enzyme (105). In one particular case, CEP was
diagnosed in a patient with a mutation-free form of the enzyme (107). The causative
agent for this pathology was faulty transcription, a defect which was linked to a mutation

18

in the erythroid-specific GATA1 transcription factor.

These particular data provide

evidence that the functional responsiveness of erythroid specific promoters is different.
Uroporphyrinogen decarboxylase

The acetate side chains of uroporphyrinogen III are decarboxylated in four
successive steps by uroporphyrinogen decarboxylase (EC 4.1.1.37; UROD), leaving the
four methyl groups characteristic of the product coproporphyrinogen III (Figure 1.1) (74,

108). UROD exists as a homodimer, with a monomeric molecular mass of ~40 kDa (109,
110). Unlike most decarboxylases, UROD activity is independent of a prosthetic group
or cofactor (111-113).

Sequence similarity among isolated UROD proteins is low;

however common structural features have been identified between the human and plant
enzymes (109, 114). Three-dimensional studies have shown that the monomer contains a
single domain characterized by a distorted (β/α) barrel, with the active site housed at the
end of a deep cleft, delimited by the C-terminal loops of the barrel. Evolutionarily
conserved residues line the cleft, and several invariant basic residues are crucial for
binding the propionate groups of the substrate (109, 110). A dynamic active site loop
located at the head of the active site undergoes conformational changes to allow substrate
entry and reorganization of the catalytic cleft (109, 115).
After the asymmetric D-ring of uroporphyrinogen III is decarboxylated,
sequential removal of the acetate groups proceeds in a clockwise manner (114, 116, 117).
To accomplish this, sequential decarboxylation requires the 180o reorientation of the
intermediate, a process whereby the substrate is flipped around its C10-C20 axis.
Controversy exists as to the mechanism by which the remaining steps take place. Several
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theories state that the dimeric structure of UROD implies a dimer-dependent catalysis

(114, 116). Since each subsequent decarboxylation only requires a 90o rotation, it has
been postulated that the two monomers collaborate during the decarboxylation of a single
uroporphyrinogen substrate. It has been proposed that the dimeric organization of UROD
protects the reactants from solvent exposure, allowing the reaction intermediates to be
passed and chemically modified between each monomer (114, 116). Further, analysis of
UROD compared with another cofactorless decarboxylase, orotidine 5'-monophosphate
decarboxylase (ODCase), indicates that a protonated basic residue assists the transition of
the polar carboxylate groups from water to the comparatively less polar hydrophobic core
by stabilizing the post-scission carbanion (118). Alternatively, based on the structure for
the human UROD bound to coproporphyrinogen, the UROD-catalyzed reaction may take
place at a unique site on the enzyme surface (117).
Mutations in the human gene are responsible for the familial form of porphyria
cutanea tarda (PCT) (119). The disease has been classified into three sub-types. Type I
PCT has decreased hepatic UROD activity, but normal erythrocyte UROD activity (119).
Type II PCT has decreased UROD activity both in red cells and hepatocytes (119). Type
III PCT is similar to type II, but erythrocyte UROD activity is normal (119). PCT is an
autosomal dominant trait; however symptoms are rarely present in heterozygotes.
Recently, three children from the same family presented with symptoms associated with
early onset PCT (120). Analysis of the UROD gene for all three probands indicated two
novel missense mutations and one previously identified polymorphism, giving these
patients an unique and previously unidentified compound heterozygote genotype (120).
Dermatitic photosensitivity is the hallmark symptom of PCT (119); a clinical
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manifestation which shows a marked increase in intensity among individuals with comorbidities such as: hepatitis, HIV infection, or proclivity to imbibe (86). Instances
where severe symptoms occur at early onset are indicative of an accessory condition
named hepatoerythropoietic porphyria (HEP).

HEP is frequently diagnosed in

homozygotes or among individuals with compound heterozygosity (121, 122).
Coproporphyrinogen oxidase
The antepenultimate enzyme of the heme biosynthetic pathway catalyzes the
sequential oxidative decarboxylation of rings A and B to form protoporphyrinogen IX
(Figure 1.1). Coproporphyrinogen oxidase (EC 1.3.3.3; CPO) in humans is oxygendependent, found in the intermembranous space of mitochondria and produces
coproporphyrinogen III, carbon dioxide and hydrogen peroxide (123, 124). The enzyme
is targeted to the organelle by way of an unusually long leader sequence of 110 amino
acids (125, 126). Oxygen-dependent CPOs are found in all eucaryotes and a select group
of aerobic procaryotes (127). Sequence similarity among the oxygen-dependent enzymes
is high, and to date a requirement for prosthetic groups or cofactors has not been
identified (127). The human enzyme exists as a homodimer, with a monomeric mass of
~37 kDa (Figure 1.4A) (128). CPO contains an elaborate subunit interface with multiple
conserved residues, suggesting a role of dimeric assembly in stabilizing the catalytically
competent conformers of the enzyme. Each monomer is composed of a central antiparallel β-sheet flanked by α-helices. The active site, delimited on both sides by the βsheet and helices, elegantly houses the substrate while minimizing contacts with the
solvent. At the head of the active site, an α-helix acts as a lid to modulate the solvationstate of the active-site cleft (128).
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A

B

C

Figure 1.4. The X-ray crystal structures of coproporphyrinogen III oxidase. Each
monomer of the dimeric human enzyme (PBD code: 2aex) is composed of a central antiparallel β-sheet (red) flanked by α-helices (green) (A). The E. coli enzyme (PDB code:
1olt) functions as a dimer (monomer shown) (B) and contains a catalytically essential Sadenosyl-L-methionine cofactor and a [4S-4S] cluster (C).
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Oxygen-independent CPOs are remarkably different from CPOs with oxygen
requirements. CPO from Escherichia coli is a complex monomer of ~53 kDa (Figure
1.4B) (129). The enzyme, a member of the “Radical SAM” family of proteins, utilizes a
particularly labile [4Fe-4S] cluster to facilitate electron transfer to S-adenosyl-Lmethionine (SAM) (Figure 1.4C). As an oxidizing agent, SAM accepts one electron from
the substrate in one catalytic turnover; and an as yet unidentified substrate accepts
another electron. The identity of this acceptor molecule is of particular interest because
anaerobes do not utilize oxygen, the physiological electron depository for the product of
the aerobic reaction.

With respect to the mechanism of catalysis, the anaerobic

conversion of coproporphyrinogen III to protoporphyrinogen IX is only partially
understood (130, 131), although two of the steps are well documented. These steps are
the generation of the 5'-deoxyadenosyl radical from the reductive cleavage of SAM and
the radical-mediated proton abstraction from the B-carbon of the propionate side chain.
A recent study, centered upon the conserved histidines of human CPO, suggests that
catalysis can occur despite alterations to these evolutionarily selected residues (132).
Further work by the same group using substrate analogs where the C and D rings were
modified to replace alkyl groups with the ring 13- and 17-propionate moieties led the
investigators to postulate that the propionate side chains of rings C and D play a
significant role in both substrate binding and turnover (133). Be that as it may, the order
of ring decarboxylation and how the processive reorganization of the substrate takes
place (i.e., the manner in which the substrate rotates) remains to be elucidated.
Mutation in the human CPO gene are associated with hereditary coproporphyria
(HCP), an acute condition of the liver (134).
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While the disease is inherited in an

autosomal dominant manner, variable penetrance of the trait is observed (12). Most of
the disease-causing mutations have been mapped to portions of the enzyme proposed to
be responsible for maintaining enzyme stability (135). Work done by Stephenson et al.
involving three invariant amino acids found in human CPO led to the identification of
their roles in both the deprotonation of the substrate and bifurcate interactions between
the carboxylate tail of the substrate and two arginine residues (136). However, only one
arginine residue (Arg401) has been reported to be mutated in porphyric patients,
suggesting that the pathological basis of HCP may be more complex.

The most

prominent biochemical feature of HCP is a marked increase in excreted
coproporphyrinogen III; concentrations are typically 10–200 times higher compared with
controls (137). A severe variant form of HCP is known as harderoporphyria. This
disorder is characterized by earlier onset of neurovisceral attacks compared to HCP, and
massive excretion of a tricarboxylated porphyrin (harderoporphyrin) in the feces (138).
Protoporphyrinogen oxidase
Protoporphyrinogen IX is aromatized to protoporphyrin IX by the penultimate
enzyme of the heme biosynthetic pathway, protoporphyrinogen oxidase (EC 1.3.3.4;
PPO) (Figure 1.1) (139). This step of the pathway constitutes a branch point whereby
protoporphyrin IX is supplied to produce chlorophyll or heme. PPOs from diverse phyla
require FAD as a cofactor (140). This cofactor is coordinated by the macromolecule via
a highly conserved N-terminal dinucleotide binding motif (GXGXXG) (141). Human
PPO exists as a homodimer, with a single cofactor per dimer (142). Conversely, PPO of
the facultative anaerobe Bacillus subtilis is a monomer of ~52 kDa (143). Structural
information has been deduced from the crystal structure of PPO from Nicotiniana

24

tabacum (144). This enzyme exists as a loosely associated dimer with three defined
monomeric domains. The domains are responsible for FAD-, protoporphyrinogen IX-,
and membrane-binding. The active site of PPO is located between the FAD- and the
substrate-binding domains. Mutations associated with the human condition, variegate
porphyria (VP) have been mapped using the plant model with notable success (145).
A binding mechanism for the PPO-catalyzed reaction has been proposed based on
experimental results obtained with the INH (4-bromo-3-(5'-carboxy-4'-chloro-2'-fluorophenyl)-1-methyl-5-trifluoromethyl-pyrazol) and acifluorfen inhibitors (144, 146). The
pyrazole ring of INH serves as an A ring model, which is coordinated in the active site by
pi-stacking interactions with a conserved phenylalanine residue.

Ring B of the

macrocycle substrate is stabilized by hydrophobic interactions provided by the side
chains of two highly conserved leucine residues. Oxidation of the C20 methylene bridge
between rings A and D occurs by way of the FAD cofactor. Next, imine-enamine
tautomerizations initiate all hydride transfers from C20. The three remaining oxidation
reactions involving FAD generate three hydrogen peroxide molecules. Curiously, the
candidates for the catalytic base involved in this reaction are not evolutionarily conserved

(144).

As such, a potential base which could execute proton abstraction from the

substrate is the FADH--derived peroxide anion.
PPO deficiency causes VP (147). Missense, nonsense, and splice site mutations
have been identified as the root of VP in most cases (145). The disorder, inherited as an
autosomal dominant trait, is highly prevalent in South Africans of European descent

(148). A founder mutation attributed to a missense mutation at position 59 (R59W) has
been traced to an immigrant from the 17th century and results in a PPO with reduced

25

catalytic activity (148). The genetic drift of the abnormal gene has resulted in very high
prevalence; as many as twenty thousand South Africans may carry this gene (149). VP
presents as acute neurovisceral attacks and/or dermatitic photosensitivity.

It is the

variability observed in pathological presentation of the disorder that is the basis of the
nomenclature of the disease (86). Sudden death associated with the acute visceral attacks
of VP, highlight the importance of identifying silent carriers of mutated genes (150).
Efforts to examine the mechanism of presentation and drift of the disorder are underway
by a team at Harvard University (151).

Their work involving a genetic screen of

hematopoeitic chordate mutants, identified a zebrafish (Danio rerio) variant that showed
defective PPO activity (151). This montalcino (mno) variant presented with hypochromic
anemia and porphyria, which was partially ameliorated when human PPO mRNA was
microinjected into mno embryos. Rescue of the mno phenotype by overexpression of
human PPO suggests functional conservation of the enzyme across chordates.
Consequently, mno appears an excellent model for investigation of PPO and a valuable
tool for identification of therapeutic agents of VP. Increased plasma porphyrin in VP is
detected by monitoring fluorescence emission at 626–628 nm, upon excitation at 405 nm

(152). Other porphyrias including EPP and PCT are marked by fluorescence emission
peaks 636 nm and 618–622 nm, upon excitation at 405 nm, respectively (153).
Incidentally, patients with a rare homozygous form of the disorder have a notable
increase in red cell Zn-protoporphyrin (154).
Ferrochelatase
Ferrochelatase (EC 4.99.1.1) (FC) is the last enzyme in the heme biosynthetic
pathway, and it catalyzes the insertion of ferrous iron into protoporphyrin IX to yield
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protoheme (Figure 1.1) (155, 156).

In vivo, the enzyme associates with the inner

membrane of the mitochondrial matrix (155). The penultimate enzyme of the pathway,
PPO, has been proposed to interact with FC directly, by transferring protoporphyrinogen
IX to the FC active site (155). However, experiments with isolated mitochondria have
shown complexation between the two enzymes is not required for heme biosynthesis

(157). Nevertheless, modeling based on the three-dimensional structure of PPO with FC
suggests early work on the topic is likely correct (144). Three X-ray crystal structures for
FC have been solved (158-160). FC from humans, the yeast Schizocassharomyces pombe

(161) and the Gram-negative oligotroph Caulobacter crescentus (161) contain a [2Fe2S] cluster. Curiously B. subtilis FC is devoid of this prosthetic group, and exists as a
monomer (160). The function of these iron-sulfur centers is largely unknown.
Human FC is dimeric, and each monomer is defined by two domains (Figure 1.5)

(158). The domains, structurally unrecognizable from each other, are composed of a
four-stranded parallel β-sheet delimited by an α-helix in a β-α-β motif (a Rossmann-type
fold). A gene duplication event has been proposed based on the topological similarities
shared between the two domains. A porphyrin binding model has been proposed based
on the three-dimensional structure of N-methyl-protoporphyrin bound-ferrochelatase and
and metallation kinetics using this inhibitor (160, 162). The substrate-binding cleft is
deep within the macromolecule and is interdomain in nature. Metal binding and catalysis
likely take place within this region and involve several evolutionarily conserved residues.
Sub-cellular localization studies with mammalian FC show that the active site is
positioned near the membrane-associating side of the enzyme (163). This interaction
includes formation of an active site access tunnel, which permits substrate association
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Figure 1.5. The three-dimensional structure of ferrochelatase from Homo sapiens
(PBD code: 1hrk). The 2Fe-2S cluster is coordinated by four cysteine residues. This
prosthetic group is located at the subunit interface of the functional dimer.
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and product release; a scenario mediated by the conserved hydrophobic residues which
partially define the site of catalysis.
The FC-catalyzed reaction is characterized by two key steps: the binding of the
substrate (protoporphyrin IX) and its subsequent metallation with ferrous iron (164).
Distortion of the tetrapyrrole macrocycle is proposed to occur after its binding to the
active site cleft of FC (165). This step has been identified as a defining feature of
ferrochelatase-catalyzed metallation. In fact, resonance Raman spectroscopic studies
showed that in the absence of metal, murine ferrochelatase is able to induce saddling of
the porphyrin substrate (166).

Additionally, quantum mechanical calculations of

porphyrin binding to B. subtilis ferrochelatase permitted Sigfridsson and Ryde (2003) to
describe a tilted pyrrole ring, according to a tetrapyrrole conformation which requires less
energy for the insertion of metal (167). In short, most investigators believe that the
microenvironment of the active site controls the planarity of the porphyrin, which in turn
affects metallation efficiency (165).
Chelatases catalyze the insertion of a metallic cation into a porphyrin to generate
a variety of metallated tetrapyrroles (168). Concerning the role of ferrochelatase in the
generation of metallated tetrapyrroles, several theories exist. Proponents of one theory
suggest that a channel is involved in shuttling metal ions from solution to the active site

(169, 170). Several conserved residues in bacterial ferrochelatase appear important in
facilitating this process. An active site histidine residue (H183) is required for metal
chelation (171), and together with a pair of nearby amino acids (glutamate and serine),
define an internal metal-binding site (162, 169). It has been suggested that this inner
coordination site is linked to a second solvent-exposed metal binding site (169, 172).
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This proposed channel is defined by conserved acidic amino acids comprising a π-helix.
While the function of this helix remains unclear, hypotheses regarding the regulatory
nature of this motif have been suggested (169, 172).

The mechanism by which

metallation takes places requires further research, however a notable theory regarding
iron delivery to FC exists. Frataxin, as a monomer is a small protein, localized to the
mitochondrion and plays a role in mitochondrial iron detoxification (173).

As an

oligomer, frataxin can be as large as a trimer to greater than a 48-mer (174). Based on
the structures solved for frataxin oligomer with iron bound, as well as in vitro assays
proving protein-protein interactions between this protein and FC, it is proposed that
frataxin delivers ferrous iron to FC (165, 175). Certainly, the channeling of metal atoms
by way of a chaperone-ferrochelatase complex has the advantages of minimizing Fenton
chemistry between the substrate and the aqueous environment.

Understanding the

relationship between iron-delivery and heme synthesis represents an intriguing future
direction of ferrochelatase-related research.
Mutations in the FC gene result in a congenital disorder called, erythropoietic
protoporphyria (EPP) (176). EPP is transmitted as an autosomal dominant trait; however
evidence suggests that a second defective copy is necessary for pathological presentation

(177, 178).

Accumulation of protoporphyrin is localized to reticulocytes, and is a

significant component of bile (12). Patients with protoporphyrin-rich bile often show
cholestasis, cirrhosis and remarkably fluorescent gall stones (12). Of all the porphyrias,
EPP results in the greatest dermatitic photosensitivity. Most EPP patients function with
FCs that turnover substrate at a rate less than 20% of that of the wild-type protein (12).
While this diminished activity likely stems from mutations in the protein; a common
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wild-type FC allelic variant has been identified and shows a marked reduction in
expression (179). This decreased protein availability may be a reason why the disorder is
not observed as exclusively dominant in nature. The overproduction of protoporphyrin is
also linked to acute liver damage, highlighting the necrotic effects of excess
protoporphyrin, a circumstance noted in the treatment of several cancers (177, 180).

Enzymes in the heme degradation pathway
Heme oxygenase
Heme oxygenase (EC 1.14.99.3; HO) (Figure 1.6) has 3 isoforms (14). The first,
HO-1, is a highly inducible 32-kDa protein, that catalyzes the first and rate-limiting step
in the degradation of heme from red blood cells, yielding equimolar quantities of
biliverdin IXa, carbon monoxide (CO), and iron (Figure 1.2) (181). Biliverdin (through
the action of biliverdin reductase) is converted to bilirubin, and iron is sequestered into
ferritin (181).

Interestingly, HO-1 utilizes heme as both a prosthetic group and a

substrate (182). The second isoform of hemoxygenase, HO-2, a constitutively
synthesized 36-kDa protein, is generally unresponsive to any of the inducers of HO-1

(181). The third isoform, HO-3, also catalyzes heme degradation, but much less so when
compared with HO-2 (183). Although heme is the typical HO-1 inducer, others include
endotoxin, heavy metals, oxidants, and hypoxia (182). A common feature of several of
these inducers is their ability to generate reactive oxygen species, suggesting that HO-1
provides potent cytoprotective effects (21).

These products have physiological and

pathological functions which include protection from oxidative stress, a circumstance
linked to: atherosclerosis and cancer, as well as a number of inflammatory, autoimmune,
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Figure 1.6.

The enzymes and intermediates of the heme catabolic pathway.
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and degenerative diseases (20, 184, 185). Further, the heme catabolic pathway is of
major importance to the degradation of the globins and other hemoproteins, many of
which are affective stressors of the aforementioned disordered states.
Mammalian HO-1 proteins share a high degree of sequence similarity. Among
eucaryotes, a conserved C-terminal hydrophobic tail of ~20 residues appears to function
in anchoring HO-1 to the microsomal membrane. A number of conserved histidine
residues are most likely to be important in heme binding (186). Human HO-1 is notably
similar to bacterial HO with respect to sequence. Several bacterial HOs, including that
from Neisseriae meningitides, have been crystallized and require an NADH reductase for
enzymatic activity (187). These enzymes function as water-soluble monomers of ~25
kDa. In procaryotes, HOs function to release iron to the environment, a process which
increases microbial survival and pathogenesis, and mitigates heme toxicity (187). The Xray crystal structure of human HO-1 reveals many structural similarities to the bacterial
proteins (188). Human HO exhibits a mostly helical content. Heme is found between
two buried α-helices (189). An evolutionarily conserved histidine in the proximal helix is
the axial ligand for the substrate (189). On the opposite side, an α-helix stretches over
the active site and the heme molecule, by way of a glycine-rich loop, and terminates in a
distal polar pocket. The α-meso edge of heme is pointed toward the protein interior and
is swaddled by a series of conserved hydrophobic residues.

Conformational

heterogeneity is observed in the HO-1-heme complex and is likely due to flexibility of
the distal pocket, a component of the enzyme which is proposed to contribute to the
opening and closing of the active site (189).
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The HO-1 reaction mechanism involves three oxygenation steps (16, 190). In the
first step, the α-meso heme position is oxidized by diatomic oxygen (O2) in the presence
of NADPH to yield α-hydroxyheme. Subsequently, the α-hydroxyheme intermediate is
further oxidized by O2 to release CO and verdoheme. Finally, verdoheme is oxidized by
O2 in the presence of NADPH to produce biliverdin and Fe3+. Among cyanobacteria,
algae and plants, HO is ubiquitously expressed and plays a key role in the synthesis of
photon-accepting chromophores for use in photosynthesis or light-sensing (191).
Specifically both cyanobacteria and algae use the HO catabolic product biliverdin as a
precursor for synthesis of phycobilin, the main photoreceptor for photosynthesis.
Transcriptional regulation of the HO-1 gene involves activators such as Nrf2 and
repressors such as the heme-binding protein Bach-1 (192). Both the activating and
repressing factors require heterodimerization with the small Maf proteins including
MafK, MafF or MafG, which bind to the Maf recognition elements (MAREs) in HO-1
gene enhancers; a circumstance which allows modulation of HO-1 gene expression (192).
To date, no congenital disorder has been identified associated with mutations in the HO
gene.
Biliverdin reductase
The conversion of biliverdin to bilirubin is controlled by biliverdin reductase (EC
1.3.1.24; BVR) (Figure 1.6 (193, 194), an enzyme that reduces the C10 bridge of
biliverdin. BVR is evolutionarily conserved among all metazoa; however a homolog
exists in red algae (195, 196). Protein sequence comparison among diverse phyla shows
a high degree of conservation. Among mammalian species, BVR is greater than 80%
identical, a degree of similarity bolstered by a series of sequence features (197). BVRs
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contain a leucine zipper motif (bzip), an adenine dinucleotide-binding motif, a
serine/threonine kinase domain, two Src homology (SH2)-binding domains and a
Zn/metal-binding motif (198-200). The reductase activity of BVR requires NADH as a
substrate at acidic pH; however, NADPH is utilized in the basic range (201).
While the structural basis for the unique cofactor/pH-dependence activity profile
is unclear, site-directed mutagenesis and X-ray crystallography have provided insight into
which residues are responsible for much of the reductase activity (202). An N-terminal
domain, complete with a Rossman fold, was identified from the three-dimensional
structures of BVR with and without the cofactor bound (203).

In the rat crystal,

extensive interactions between the enzyme termini occur by way of a β-sheet (203).
Several point mutations to residues involved in defining the conserved binding domains
of the enzyme (adenine dinucleotide, S/T kinase domain, “oxidoreducatse domain”)
abolish reductase activity (204). Most of these mutations have nearly the same negative
impact on activity with both NADPH and NADH. In contrast, the loss of S44, which
results in a 400% increase in only the NADH-dependant activity, is due to reduced
hindrance to NADH binding and NAD release (199). With respect to NADH-derived
enzyme activity, the BVR-catalyzed reaction is accelerated in human renal carcinoma

(205). The significance and cause of this increase in activity is ambiguous; however,
attenuation of this effect would be a valid therapeutic target.
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Content of the dissertation
This dissertation focuses on three aspects of the ALAS-catalyzed reaction. First,
the interconversion of ALAS between two forms, namely “open” and “closed”, is
addressed with respect to hydrogen bonding interactions between the enzyme and the
cofactor. Second, substrate specificity related to succinyl-CoA is examined through
molecular interactions between two conserved residues (Arg85 and Thr430 in murine
ALAS) and the chemical nature of the acyl-CoA-derived tail. Third, the rate-determining
step of the enzyme-catalyzed reaction is addressed in the context of the conformational
mobility of an active site loop. The conclusions set forth in each chapter are related to
the advancement of knowledge regarding not only the ALAS-catalyzed reaction, but
reactions catalyzed by members of the α-oxoamine synthase subfamily and PLPdependent enzymes as a group.
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Chapter Two

Serine-254 enhances an induced fit mechanism in murine 5-aminolevulinate
synthase
Abstract
5-Aminolevulinate synthase (EC 2.3.1.37) (ALAS), is a homodimeric pyridoxal
5'-phosphate (PLP)-dependent enzyme and catalyzes the initial step of the heme
biosynthetic pathway in animals, fungi, and some bacteria. This reaction involves the
condensation of glycine and succinyl-Coenzyme A to produce 5-aminolevulinate (ALA),
Coenzyme A (CoA) and carbon dioxide. The X-ray crystal structures of Rhodobacter

capsulatus ALAS reveal a conserved active site serine that moves to within hydrogen
bonding distance of the phenolic oxygen of the PLP cofactor in the closed, substratebound enzyme conformation, and simultaneously to within 3-4 angstroms of the thioester
sulfur atom of bound succinyl-CoA. To evaluate the potential roles of this residue in
enzymatic activity, the equivalent serine in murine erythroid ALAS was mutated to
alanine or threonine. The S254A variant is active, but both the K mSCoA and kcat values are
increased, by 25- and 2-fold, respectively, suggesting unusual functional complexity. In
contrast, the S254T mutation results in a significant decrease in kcat without
altering K mSCoA . Circular dichroism spectroscopy reveals that removal of the side chain
hydroxyl group in the S254A variant dramatically alters the PLP microenvironment as
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well as the responsiveness of this microenvironment to succinyl-CoA binding. Protein
fluorescence stopped-flow experiments confirm that the mutations differentially alter the
rates of conformational responsiveness to ALA binding. Taken together the data support
the postulate that this serine residue is important for formation of a competent catalytic
complex by coupling succinyl-CoA binding to enzyme conformational equilibria.
Similar functions of this residue may be postulated for the other α-oxoamine synthases.
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Introduction
5-Aminolevulinate synthase (EC 2.3.1.37; ALAS) is a homodimeric PLPdependent enzyme that catalyzes the first and key regulatory enzyme of the heme
biosynthetic pathway in non-plant eucaryotes and the α-subclass of purple bacteria,
involving the condensation of glycine and succinyl-CoA to produce CoA, carbon dioxide,
and ALA (1). Animal genomes encode two highly conserved but differentially expressed
ALAS genes, a housekeeping and an erythroid-specific (eALAS) gene (2). In humans,
mutations in the eALAS gene can result in X-linked sideroblastic anemia, (3) a
hypochromic and microcytic anemia characterized by iron accumulation within
erythroblast mitochondria (4). Approximately one-third of XLSA patients are pyridoxine
responsive. In these patients mutations in ALAS are commonly observed in the PLPbinding site (5, 6).
The ALAS chemical mechanism (Scheme 2.1) is complex and involves a high
degree of stereoelectronic control, with individual steps including: binding of glycine (I);
transaldimination with the active site lysine (K313, murine eALAS numbering) to yield
an external aldimine (II); abstraction of the pro-R proton of glycine (III); condensation
with succinyl-CoA (IV) and CoA release to generate an α-amino-β-ketoadipate
intermediate (V); decarboxylation resulting in an enol-quinonoid rapid equilibrium (VI);
protonation of the enol to give an aldimine-bound molecule of ALA (VII); and ultimately
release of the product (ALA) (VIII) (7). This mechanistic complexity is manifested
structurally as an enzyme with an unusually high degree of sequence conservation, as
exemplified by the observation that the catalytic core of human

capsulatus ALAS are 49% identical and 70% similar (8).
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eALAS and R.

Scheme 2.1. The role Ser-254 plays in the chemical mechanism of ALAS.
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PLP-dependent enzymes are classified based on structural and mechanistic
similarities (9). ALAS is evolutionarily related to transaminases and is grouped within
class II of the fold type I PLP-dependent enzyme superfamily, for which the prototypical
enzyme is generally considered to be aspartate aminotransferase (10-12). ALAS is most
closely related to the three other members of the α-oxoamine synthase subfamily, each of
which catalyze reactions between small amino acids and CoA esters to generate 1,3aminoketones, while also sharing high structural similarity (13, 14).

Studies have

demonstrated that aspartate aminotransferase exists in two predominant conformational
forms, “open” and “closed”, and reactions catalyzed by PLP-dependent enzymes have
been postulated to occur in a closed conformation, consistent with the induced fit
hypothesis, where electrostatic and hydrophobic interactions between the substrates,
cofactor, and amino acids comprising the active site provide the energetic impetus to
stabilize this catalytically optimal conformation (15, 16).
Prior to solution of an ALAS crystal structure, kinetic data led investigators to
propose that ALAS transitions between open and closed conformations during the
catalytic cycle (7, 17). Steady-state kinetic experiments demonstrate that the kinetic
mechanism is ordered, with glycine binding before succinyl-CoA, yet in transient kinetic
studies binding of succinyl-CoA accelerates the apparent rate at which glycine binds to
ALAS by over 250,000-fold (18). This enhancement might occur by utilization of part of
the intrinsic binding energy for succinyl-CoA to shift the enzyme conformer equilibrium
towards a closed conformation wherein transaldimination of glycine with the PLP
cofactor is rapid (17, 18). Return to the open conformation is considered to be the key
step limiting ALA release and the overall catalytic rate.
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The crystal structures of Rhodobacter capsulatus ALAS in holoenzymic and
substrate-bound forms adopt open and closed conformations, respectively, further
supporting the hypothesis that enzyme dynamics play a crucial role during the ALAS
catalytic cycle (8). While the structure in general collapses slightly around the bound
substrates, a more conformationally mobile loop of amino acids located between two βsheets at the subunit interface closes directly over the channel leading approximately 20Å
down into the deeply recessed active site (Figure 2.1) (8). A conserved threonine at the
apex of the mobile loop forms a strong hydrogen bond (~2.5Å) with the carboxylate tail
of succinyl-CoA in the substrate-bound structure and appears to simultaneously provide
molecular recognition for succinyl-CoA while helping to lock this substrate into optimal
position for catalysis.

Closer comparison of the active site structures reveals that,

coincident with these changes, the side chain of S189 migrates from non-covalently
associating with the peptide macroskeleton to within hydrogen bonding distance of the
PLP phenolic oxygen, as well as the sulfur atom of succinyl-CoA (8, 19, 20). These
interactions suggest that this serine may be an important determinant in conformer
equilibrium and catalysis by providing orientational binding energy between the cofactor
and substrate, while stabilizing a closed Michaelis complex conformation.

The

conservation of this residue in ALAS and the other α-oxoamine synthases suggests an
important functionality that may be general to these enzymes (Figure 2.2). Here we
present experiments aimed at probing the role of this serine in catalysis by murine
eALAS. We have generated and purified the positionally equivalent S254A and S254T
variants and investigated the effects of these mutations on the kinetic and spectroscopic
properties of the enzyme.

The results support the postulate that S254 is a key
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multifunctional residue that couples succinyl-CoA binding to enzyme conformational
equilibria and catalysis.
Figure 2.1.

Structural models for murine erythroid ALAS based on the R.

capsulatus crystal structures. (A) Michaelis complex modeled by alignment of open
holoenzyme and closed glycine and succinyl-CoA bound monomeric structures. Serine254 is hidden by the succinyl-CoA ester in this view from the perspective of the adjacent
subunit, which has been removed. The active site loop is shown in yellow cartoon for the
open and closed conformations, while all other structural features are for the closed
conformation. (B) Serine-254 in the open conformation. (C) Serine-254 in the closed
conformation with succinyl-CoA bound.

A

B

C
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Figure 2.2. Multiple sequence alignment of phylogenetically diverse members of the
α-oxoamine synthase family in the region of murine eALAS serine-254. The amino
acid sequences were retrieved from public databases (NCBI) and aligned using
CLUSTAL W (21). The conserved serine residue is high-lighted in cyan. The amino
acid numbering in red refers to that of murine erythroid ALAS (mALAS2). Represented
proteins are: M. mus. AL2, Mus musculus erythroid ALAS (156255176); H. sap. AL2,

Homo sapiens erythroid ALAS (28586); H. sap. AL1, Homo sapiens housekeeping
ALAS (40316939); S. cer. ALA, Saccharomyces cerevisiae ALAS (151942209); R. cap.
ALA, Rhodobacter capsulatus ALAS (974202); A. nig. AON, Aspergillus niger AONS
(61696868); A. tha. AON, Arabidopsis thaliana AONS (42573269); M. mar. AON,

Methanococcus maripaludis AONS (1599054); E. col. AON, Escherichia coli AONS
(85674759); H. sap. KBL, Homo sapiens KBL (3342906); C. kor. KBL, Candidatus

korarchaeum cryptofilum (17017433); E. col. KBL, Escherichia coli KBL (169753078);
H. sap. SPT, Homo sapiens SPT (4758668); A. tha. SPT, Arabidposis thaliana SPT
(17221603); S. cer. SPT, Saccharomyces cerivisiae SPT (706828), E. col. SPT,

Escherichia coli SPT (170517920).
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NDPGHLKKLLEKSDPK---------TPKIVAFETVHSMDGAICPLEELCD
NDPDHLKKLLEKSNPK---------IPKIVAFETVHSMDGAICPLEELCD
NDVSHLRELLQRSDPS---------VPKIVAFETVHSMDGAVCPLEELCD
NDLNELEQLLQSYPKS---------VPKLIAFESVYSMAGSVADIEKICD
NDVAHLRELIAADDPA---------APKLIAFESVYSMDGDFGPIKEICD
SCPRSLEDVLRREVEGDE-MVRNGKKNVFLVIESIYSMDGDIAPIREFVE
CDMYHLNSLLSNCKMKR----------KVVVTDSLFSMDGDFAPMEELSQ
NNTVDLIEIL-EKN-KN-------YENKFIVTDAVFSMDGDIAPVGELKK
NDVTHLARLLASPCPGQ----------QMVVTEGVFSMDGDSAPLAEIQQ
LDMADLEAKLQEAQKH---------RLRLVATDGAFSMDGDIAPLQEICC
CDLADLEDKL-RQVHKK-------YNKILIITDGVFSMDGDIAPLDGITK
NDMQELEARLKEAREAG-------ARHVLIATDGVFSMDGVIANLKGVCD
NNMQSLEKLLKDAIVYGQPRTRRPWKKILILVEGIYSMEGSIVRLPEVIA
GDMVGLEKLIREQIVLGQPKTNRPWKKILICAEGLFSMEGTLCNLPKLVE
NTPGHLEKVLKEQIAEGQPRTHRPWKKIIVVVEGIYSMEGEICHLPEIVS
NDAKDLERRMVRLGER--------AKEAIIIVEGIYSMLGDVAPLAEIVD
*
:
.: : .** *
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Materials

Reagents.

The following were purchased from Sigma-Aldrich Chemical

Company (St. Louis, MO): ampicillin, DEAE-Sephacel, Ultrogel AcA-44, mercaptoethanol, PLP, bovine serum albumin, succinyl-CoA, ALA-hydrochloride, ketoglutaric acid, -ketoglutarate dehydrogenase, HEPES-free acid, MOPS, tricine,
thiamine pyrophosphate, NAD+, and the bicinchoninic acid protein determination kit.
Glucose, glycerol, glycine, disodium ethylenediamine tetraacetic acid dihydrate,
ammonium sulfate, magnesium chloride hexahydrate, and potassium hydroxide were
acquired from Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulfate polyacrylamide
gel electrophoresis reagents were acquired from Bio-Rad. Xba I, Bam HI restriction
enzymes, Vent DNA Polymerase, and T4 DNA ligase were from New England Biolabs
(Ipswich, MA). Oligonucleotides were synthesized by Integrated DNA Technologies
(Coralville, IA).
Methods

Mutagenesis. The pGF23 expression plasmid encoded the full-length sequence for
the murine, mature eALAS (22). Site-directed mutagenesis for the S254A and S254T
mouse ALAS variants was performed on the whole plasmid pGF23 using a previously
described method (23). The mutagenic oligonucleotides for S254A and S254T were: 5’GAG ACT GTT CAT GCC ATG GAT GGT GCC-3’ and 5’-GAG ACT GTT CAT ACC
ATG GAT GGT GCC-3’, respectively, with the introduced codon substitutions
underlined. The PCR-generated DNAs were sequenced between the Blp I and Bam HI
restriction enzyme sites to confirm the presence of the intended mutation. The products
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were then digested with Blp I and Bam HI and subcloned into pGF23 that was digested
similarly.

Protein purification, SDS-PAGE, protein determination and steady-state analysis.
Recombinant murine eALAS and the S254 variants were purified from DH5

Escherichia coli bacterial cells containing the overexpressed protein as previously
described (22). Purity was determined by SDS-PAGE (24) and protein concentration
determined by the bicinchoninic acid method using bovine serum albumin as the standard

(25). All protein concentrations are reported on the basis of a subunit molecular weight
of 56 kDa. Enzymatic activity was determined by a continuous spectrophotometric assay
at 30oC (26).

Structural analyses. The protein data base files 2BWN, 2BWO, and 2BWP,
corresponding to the holoenzyme, succinyl-CoA-bound, and glycine-bound R. capsulatus
ALAS crystal structures, were used as templates to model the PLP-binding core of the
murine eALAS (8). Hydrogen bond determinations were accomplished using
Deepview/Swiss-PdbViewer software (27, 28).

Spectroscopic measurements. All spectroscopic measurements were performed
with dialyzed enzyme in 20 mM HEPES, pH 7.5 with 10% (v/v) glycerol to remove free
PLP. Circular dichroism (CD) spectra were collected using an AVIV CD spectrometer
calibrated for both wavelength maxima and signal intensity with an aqueous solution of
D-10 camphorsulfonic acid (29). CD spectra recorded from 190-240 nm were analyzed
by the ridge regression method using a modified version of the computer program
CONTIN developed by Provencher and Glöckner (30). Protein concentrations were 10
M and 100 M for the near and far CD spectra, respectively. The final concentration of
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succinyl-CoA was 100 M, giving a 1:1 molar ratio of enzyme to ligand for collection of
the latter spectra. At least three CD spectra were collected per experiment and averaged,
using a 0.1 cm path length cuvette with a total volume of 300 l. Blank CD spectra
contained all components of the solution except enzyme. CD spectra containing the
enzyme samples were collected immediately after adding the enzyme. The spectra of the
samples containing enzyme were analyzed after substracting the blank spectra. Co-factor
fluorescence spectra were collected on a Shimadzu RF-5301 PC spectrofluorophotometer
using protein concentrations of 2 μM. Spectra were measured at pH 7.5, 50 mM HEPES,
and 20% (v/v) glycerol. Excitation was at 331 nm and the excitation and emission slit
widths were each set to 10 nm. Emission was measured over the wavelength range 350
to 600 nm. Buffer blanks were subtracted from the spectra.

Stopped-flow spectroscopy. All of the experiments were carried out at 30°C in 100
mM HEPES, pH 7.5 and 10% (v/v) glycerol. The concentration of reactants loaded into
the syringes were always 2-fold greater than that present in the cell compartment after
mixing. Because of the difference in Km for succinyl-CoA between the two variant
enzymes, two different succinyl-CoA concentrations were used to ensure the
identification of a single enzyme-catalyzed event. For the S254A-catalyzed reaction, the
final concentrations were: 120 μM S254A, 130 mM glycine, and 30 μM succinyl-CoA.
The final concentrations of the reactants for S254T were: 50 μM S254T, 130 mM
glycine, and 10 μM succinyl-CoA. Rapid scanning stopped-flow kinetic measurements
were conducted using an OLIS model RSM-1000 stopped-flow spectrophotometer. The
dead time of this instrument is approximately 2 ms, and the observation chamber optical
path length is 4.0 mm. Scans covering the wavelength region 270-550 nm were acquired
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at a rate of either 62 or 31 scans per second in order to condense the resulting data files to
a tractable size for data fitting analysis. An external water bath was utilized to maintain
constant temperature of the syringes and observation chamber. Specifically, spectral data
covering the 270 – 550 nm range were analyzed by global fitting to a triple exponential
using the SIFIT program supplied with the stopped-flow instrument (OLIS, Inc.).(31).
The quality of fits were judged by visual analysis of the calculated residuals in
conjunction with the Durbin-Watson statistic (32). Single turnover data were interpreted
using a three kinetic step mechanism as described by Equation 2.1.

(Equation 2.1)
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The observed rate constants were determined from at least three replicate
experiments, and the reported values represent the average and standard error of
measurement for each experimental condition. The forward and reverse rate constants
depicted in the kinetic mechanism (Figure 2.7) were obtained by modeling single
wavelength kinetic traces at 510 nm with KinTekSim (Austin, TX) kinetic simulation
software (33). The eight interior rate constants were allowed to float, while the KD values
were held constant as determined separately.

Transient kinetics of the reaction of glycine with the variant enzymes. The
reactions of the murine eALAS variants with glycine were performed using the same
instrument as was described for the single turnover reactions with the enzyme-glycine
complex and succinyl-CoA. The final enzyme concentration was 60 μM. The glycine
concentration was always at least 10-fold greater than the enzyme concentration to ensure
that pseudo-first order kinetics were observed. The treatment of the data was performed
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using the fitting software supplied with the instrument. The time courses at 420 nm were
fitted to Equation 2.2
3

At  ( ai e  k i t )  c

(Equation 2. 2)

n 1

where At is the absorbance at time t, a is the amplitude of each phase, k is the observed
rate constant for each phase, and c is the final absorbance. The quality associated with
the fit was determined by the calculated residuals and from the Durbin-Watson ratio (32).
The observed rate constants were plotted against increasing concentrations of glycine and
the resulting data were fitted to a two step reaction process represented by Equation 2.3.
Data fitting to Equation 2.4 used the nonlinear regression analysis program SigmaPlot10
(Systat, San Jose, CA)
1
k obs

2
kobs

(Equation 2.3)
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(Equation 2.4)
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where S is the concentration of substrate, k1 and k-1 are the forward and reverse rate
constants, KD is the dissociation constant and kobs, the observed rate constant.
Intrinsic protein fluorescence quenching. The pre-steady state kinetics of the
product binding reaction of ALAS and the two serine variants were examined by
measuring changes in the intrinsic protein fluorescence intensity. An OLIS RSM-1000F
rapid mixing spectrofluorimeter, equipped with a high-intensity xenon arc lamp, was
used to monitor the reaction. The enzyme and ligand in 20 mM HEPES (pH 7.5) and 10%
glycerol were maintained at 30oC in separate syringes prior to their mixing in the reaction
chamber. The concentrations of enzyme and ligand in the reaction chamber were 1/2 of
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those in the syringes. The intrinsic protein fluorescence, as measured with 5 μM enzyme,
was evaluated in the presence of increasing concentrations of the product, ALA. The
excitation wavelength and the slit width were 280 and 5 mm, respectively. The emitted
light was filtered using a cutoff filter (WG 320; 80% transmittance at 320 nm, (Edmund
Optics, Barrington, NJ)). Typically, 500 time points were collected for varying lengths
of time, and three or more experiments were averaged. Each averaged data set was then
fitted to Equation 2.5, using the Global fitting software provided with the instrument.
(Equation 2.5)

Fobs (t )  A1e  kobs t  A0

where Fobs(t) is the observed fluorescence change (in arbitrary units) at time t, kobs is the
observed first-order rate constant, A1 is the pre-exponential factor and A0 is the offset. The
observed rate constants were then plotted against ligand concentration and the data were
fitted to Equation 2.6 by nonlinear regression. The rates of dissociation (koff) and
association (kon) as well as the ligand binding constants (KD) were calculated from the
asymptotic maximal observed rate, the ordinate intercept, and the ligand concentration (x)
in Equation 2.6.

(Equation 2.6)

f ( x)  k on 
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k off x
KD  x

Results

Kinetic characterization of the S254 variants. The steady-state kinetic parameters
of the S254 variants were determined and the results are summarized in Table 2.1. The
mutation of serine-254 to alanine resulted in a kcat 2-fold higher than that of the wild-type
ALAS value. The Km for succinyl-CoA was increased 25-fold relative to ALAS, while
the Km for glycine was not significantly affected. The overall catalytic efficiency for
succinyl-CoA decreased 36-fold, while the value for glycine remained unchanged as
compared to ALAS values.

The replacement of serine-254 with threonine caused a 2-

fold decrease in the wild-type kcat value. The Michaelis constants for both substrates
were indistinguishable from those of the wild-type enzyme.

Spectroscopy.

The orientation and average positioning of the PLP cofactor

relative to the conserved serine and the active site were perturbed by the replacement of
the serine with either an alanine or a threonine. Gross structural changes evidenced by
changes in the alpha helix and beta sheet content of proteins can be identified from CD
spectroscopic changes in the far-UV (ultraviolet) (34). The analysis of the UV CD
spectra (Figure 2.3A) by CONTIN-CD indicates any changes in the secondary structure
between wild-type ALAS and the two ALAS variants are negligible. Locally chiral
substructures that comprise the PLP microenvironment modulate the visible CD
characteristics of the chromophore. Spectra for the wild-type and variant enzymes, as
holo- and succinyl-CoA-bound enzymes, were collected (Figure 2.3). The spectra for
wild-type ALAS and S254T holoenzymes displayed positive dichroic bands at 330 and
420 nm. However, in relation to the wild-type ALAS, the S254A variant showed a
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decrease in amplitude of the 330 nm band, while the amplitude in the 420 region
increased.

Table 2.1: Summary of steady-state kinetic parameters

Enzyme
Wild-type
S254A
S254T

K mGly
(mM)
25 ± 4.2
18 ± 1.7
27 ± 2.9

K mSCoA
(µM)
1.3 ± 0.9
32 ± 7.7
1.2 ± 0.3

kcat
(s-1)
0.14 ± 0.02
0.27 ± 0.01
0.050 ± 0.004
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kcat / K mGly
(mM·s-1)
0.01
0.02
2.0 x 10-3

kcat / K mSCoA
(µM·s-1)
0.11
9.0 x 10-3
0.05

Figure 2.3. Circular dichroism and fluorescence emission spectra of ALAS and the
S254 variants. Spectra of wild-type ALAS (—), S254A (····) and S254T (---) (A) and

(B) Holoenzymes; (C) in the the presence of 100 μM succinyl-CoA; (D) upon excitation
of the cofactor at 331 nm.
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(Figure 2.3B).

Wild-type ALAS and variant enzymes responded differently to the

presence of 100 μM ligand (Figure 2.3C).

Comparison of the CD spectra for the

holoenzymes with succinyl-CoA showed that spectra of wild-type and S254T changed in
the presence of substrate, while that of S254A maintained dichroic characteristics that
were indistinguishable from those observed under ligand-free conditions. Specifically, in
wild-type and S254T, the amplitude of both dichroic bands decreased and the 330 nm
peak red shifted to ~350 nm. The cofactor fluorescence spectra obtained at pH 7.5 for the
S254T variant enzyme with excitation at 331 nm is similar to that of the wild-type
enzyme with a well-formed emission maximum ~385 nm (Figure 2.3D).
deviation in emission maximum is observed for the S254A variant.

A notable
Specifically,

excitation of S254A at 331 nm results in a broader fluorescence emission band centered
around 450 nm. The changes in the fluorescence emission profile for the alanine variant
suggest that the tautomeric equilibrium between at least two forms of the PLP cofactor
aldimine linkage with the catalytic lysine is perturbed.

Reaction of glycine with the S254 variants. The reaction of 60 M S254 variants
with increasing amounts of glycine resulted in an increased absorbance at 420 nm (Figure
2.4). A global fit of the data for the reaction of S254A with glycine yielded values for k1
of 0.159 ± 0.04 s-1, k-1 of 0.072 ± 0.001 s-1, and a KD of 6.6 ± 0.57 mM. The fitting of the
data corresponding to the reaction of the S254T variant with glycine provided parameters
of k1 of 0.11 ± 0.01 s-1, and k-1 of 0.070 ±0.004, and a KD of 1.5 ± 0.39 mM.

ALA binding kinetics monitored by intrinsic protein fluorescence. The observed
rates of intrinsic protein fluorescence quenching were determined as a function of ALA
concentration, and the results are presented in Figure 2.5. The hyperbolic nature of the
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Figure 2.4. Reaction of the S254 variants (60 µM) with increasing concentrations of
glycine.

Data were fit to Equation 2.2 for a two-exponential process, yielding

equilibrium and rate constants for S254A of KD = 6.6 ± 0.57 mM, k1 = 0.159 ± 0.04 s1

, and k-1 = 0.072 ± 0.001 s-1. The fitted constants for S254T were: KD =1.5 ± 0.39 mM,

k1 = 0.11 ± 0.01 s-1 and k-1 = 0.070 ± 0.004 s-1.
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Figure 2.5.

Reaction of wild-type

ALAS and the S254 variants (5 µM)
with ALA. The observed rate constants

were calculated by fitting the decrease in
intrinsic protein fluorescence over time
to Equation 2.3 for a single-exponential
process. The resolved equilibrium and
rate constants for wild-type ALAS (A)
were:

KD = 500 ± 16 µM,

k1 = 0.120 ± 0.015 s 1, and k-1 = 0.140
± 0.05 s-1. For the S254A variant (B) the
constants

were:

KD = 855 ± 66 µM,

k1 = 0.235 ± 0.006 s 1,

and

k-1 = 0.29

± 0.02 s-1, and for the S254T variant
were:

KD = 832 ± 49 µM,

k1 = 0.19

± 0.09 s-1, and k-1 = 0.057 ± 0.007 s 1.
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binding data indicate a two-step process, and may be ascribed to formation of a collision
complex followed by the conformational change associated with ALA binding (7).
Significantly, for each of the three enzymes the resolved rate constants for the off rate
conformational change (k-1) coincide with the kcat values determined through steady-state
kinetics.

The dissociation constants of the variants for ALA are increased by

approximately 60% over that of the wild-type enzyme.

Pre-steady-state reaction of the variant enzyme-glycine complexes with succinylCoA.

ALAS catalysis involves the sequential binding of glycine first (I-II), then

succinyl-CoA (III-IV), followed by formation of an enol-quinonoid equilibrium (VI-VII)
after the liberation of CO2 (Scheme 2.1) (7). In order to determine the microscopic rates
associated with the lifetime of the quinonoid intermediate we monitored the time course
of the ALAS-catalyzed reaction under single turnover conditions. The time courses of
the absorbance change were best fit to a sequential, three-step mechanism outlined by
Equation 3.1.

Among all the enzymes tested, a single step assigned to quinonoid

intermediate formation, followed by a biphasic step of its decay were observed (Figure
2.6). For each enzyme, the global fit of the spectral data at 510 nm is shown as a solid
line overlaid with the time course data at 510 nm (dots). The rate constants associated
with quinonoid intermediate formation (Qf) differ between the two variants. For S254A,
the value is 4.8 ± 0.2 s-1, a rate similar to that of the wild-type enzyme (7). However, the
rate value for the S254T variant was decreased, showing a 4-fold reduction with a rate of
1.4 ± 0.3 s-1. These data suggest that the loss of the hydroxyl group at position 254 has
only a modest effect on quinonoid intermediate formation, and therefore does not appear
to play any obvious role in active site chemistry during catalysis. The rates assigned to
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Figure 2.6.
ALAS-

and

Reaction of wild-type
S254

variant-glycine

complexes with succinyl-CoA under
single turnover conditions. The data for

single turnover quinonoid intermediate
formation and decay reaction kinetics
were fitted with the SIFIT program (OLIS,
Inc.). The data (●●) are overlaid with the
line representing the fitted data. (▬). (A)
The rate constants for the three step
sequence in the wild-type enzyme were
6.0 s-1, 2.0 s-1, and 0.075 s-1. (B) The rate
constants for the three steps in S254Acatalyzed reaction were 4.8 s-1, 0.8 s-1, and
0.19 s-1. (C) The rate constants for the
three steps in S254T-catalyzed reaction
were 1.4 s-1, 0.2 s-1, and 0.037 s-1.
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the two-step quinonoid intermediate decay (Qd1 and Qd2) also differ among the variants.
Both variants have initial quinonoid intermediate decay rates that are at least 2-fold lower
than that of the wild-type enzyme (i.e., 0.8 s-1 and 0.25 s-1 vs. 2.0 s-1). However, the
second step of quinonoid intermediate decay, which most closely approximates kcat for
the overall reaction, is 40% faster for the S254A variant, in comparison to that of the
wild-type enzyme. This increased value agrees with the greater kcat that was determined
from the steady-state kinetic analysis (Table 2.1). As such, the rates for S254A observed
during the lifetime of the quinonoid intermediate indicate fast transformation of the
enzyme-substrate complex to the enzyme-product complex (Qf and Qd1), followed by a
comparatively faster rate of product dissociation and the return of the conformational
equilibrium to the catalytically favored open conformation (Qd2).
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Discussion

The spectroscopic and kinetic properties of the S254A and S254T murine ALAS
variants were examined and compared to those of the wild-type enzyme in an effort to
better understand the role of this residue in the catalytic process. Mutation of serine to
alanine removes the side chain oxygen atom and eliminates the possibility of hydrogen
bond formation with the PLP cofactor and succinyl-CoA.

The conservative S254T

mutation adds a methyl group, and is predicted to allow for hydrogen bonding, although
some steric constraints may be introduced due to the tight packing in this region of the
active site. Comparison of the steady-state kinetic parameters of the variants to those of
the wild-type enzyme determined under similar conditions reveals the unusual kinetic
significance of S254 (Table 2.1). Point mutations typically result in increased Michaelis
constants and decreased turnover numbers, but significantly, in the S254A variant both of
these parameters are increased. The Km for succinyl-CoA is increased 25-fold over that
of the wild-type enzyme, while kcat is increased 2-fold. It is notable that mutation of an
evolutionarily conserved residue in such a metabolically important enzyme leads to an
enhanced kcat, even though the effect is not dramatic.
The kcat for murine eALAS is considered to be defined by a conformational
change of the enzyme accompanying ALA release (7). This is further supported here by
the stopped-flow data in Figure 6, where the protein fluorescence associated ALA off
rates (k-1) are indistinguishable from the steady-state kcat values (Table 2.1). These data
also indicate that the rate-limiting step of the reaction cycle is unaltered in the mutated
enzymes. The increase in kcat observed for the S254A variant may be attributable to
diminished stability of the closed conformation, leading to faster reversion to the open
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conformation and product release. In this interpretation, the large concomitant increase
in Km for succinyl-CoA in the S254A variant would result not only from the direct effect
of loss of hydrogen bonding to the substrate, but also from the less direct effect of
impaired enzyme conformational responsiveness to the substrate that is believed to be
required for optimal binding. The three-fold decrease in kcat without any effect on the Km
for succinyl-CoA resulting from the more conservative S254T mutation would then arise
primarily from enhanced stability of the closed conformation.

Both mutations

substantially diminish the catalytic efficiency with succinyl-CoA (kcat/ K mSCoA ), but in
different ways, and while the effects of these very conservative mutations on the steadystate kinetic parameters may appear relatively modest, they are presumably sufficient to
have metabolically harmful effects in vivo, given the strong evolutionary selection for
serine at this position.
The S254A mutation has significant effects on the cofactor microenvironment, as
determined by fluorescence and CD spectroscopies. The fluorescence spectra suggest a
rather dramatic alteration in cofactor tautomeric equilibria occurs upon loss of hydrogen
bonding interactions between the phenolic oxygen of PLP and the side chain of S254
(Fig. 2.3D). The diminished enolamine tautomer emission at 386 nm in the S254A
mutant is consistent with loss of hydrogen bonding at the cofactor phenolic oxygen, and
an increased proportion of the cofactor maybe in the ketoenamine (35).

CD

spectroscopic evaluations of the conformational effects of the S254A and S254T
mutations in the far-UV region verify the mutations do not significantly alter the overall
secondary structure of the enzymes (Fig. 2.3A). Any alterations in the conformational
equilibria of the active site loop, which adopts an extended conformation and is thus not

75

CD active, are not apparent in these spectra, but the visible CD spectra of the S254A
variant does diverge substantially from those of the wild-type and the S254T variant.
The S254A holoenzyme maximum at 435 nm is blue shifted towards ~420 nm, and the
ratio of the mean residual ellipticity at this wavelength to the one at 330 nm was
increased (Fig. 2.3B). These ellipticities arise from Cotton effects associated with the
ketoenamine (435 nm) and enolamine (330 nm) cofactor aldimine bond tautomers, and
are indicative of the microenvironment surrounding this linkage between the cofactor and
the active site lysine (36). Succinyl-CoA binding to the wild-type and S254T variants
induce decreases in asymmetry of the cofactor, while the S254A mutant is relatively
unchanged under similar conditions (Fig. 2.3C). A logical interpretation is that the
decrease in asymmetry observed for the wild-type and S254T variants arises from partial
conversion of the internal aldimine to free PLP aldehyde bound at the active site, as is
observed in three out of four R. capsulatus crystal structure active sites upon succinylCoA binding (8). In the crystal structures these events are accompanied by transition to a
closed conformation, from which it might be concluded that the S254A variant retains the
internal aldimine in the presence of succinyl-CoA, and may not be induced to adopt a
closed conformation upon binding of this substrate.
The quinonoid intermediate single-turnover profiles of the two S254 variants
indicate that they follow a chemical mechanism similar to that of the wild-type enzyme
(Fig. 2.6A, B). A rapid step of ALA-bound quinonoid intermediate formation upon
decarboxylation is followed by two successively slower decay steps, associated with
protonation of the ALA-quinonoid intermediate and ALA release, respectively (7). The
quinonoid intermediate formation rate decreased 4-fold for the S254T variant, which
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could be explained by a change in the flow of electrons from the site of bond scission
throughout the cofactor, precipitated by a shift in the conformational equilibrium towards
closed. In the ALAS crystal structure, PLP is noted to change position by 15 degrees
when substrate is bound (8). Changes to the stereoelectronic relationship between the
cofactor and the α-carbon bonds of the external aldimine can influence the chemical
mechanism dramatically (7). Therefore, it is possible that the hydrogen bond between
serine-254 and the phenolic oxygen of PLP may be an influential part of maintaining the
angle of PLP during not only formation and decay of the quinonoid intermediate, but also
during the complete reaction cycle.

The increase observed in the second step of

quinonoid intermediate decay in the S254A variant is also consistent with the increases in

kcat and the ALA off rate determined from enzyme fluorescence quenching.
By utilizing the microscopic parameters obtained from the single turnover
reactions of the variant enzymes, coupled with the product and substrate reaction data, we
were able to model the kinetic mechanisms as shown in Figure 2.7. Additionally, the
Gibb’s free energy associated with the glycine and ALA were calculated (Table 2.2).
The kinetic simulations revealed that the S254T mutation significantly retards the
chemical mechanism.

Conversely, the modeled pathway for S254A highlights the

increases observed in the kinetics of the variant. Overall, the mechanistic data for both
variants support the hypothesis that the interaction between S254 and the O3’ of PLP is a
limiting factor in enforcing an induced fit mechanism by coupling substrate recognition
to conformational equilibria.

However, how the structural differences between the

variant enzymes with ligand bound accomplish this, awaits three-dimensional structural
information.
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A

B

Figure 2.7. Kinetic mechanisms of the S254 variant enzymes. The single turnover

quinonoid formation and decay reaction kinetics of the variant enzymes and the reactions
with glycine and ALA and were used to model the kinetic mechanisms. The fits ((A)
S254A) and ((B) S254T) were indistinguishable from those completed based on the
global fit of spectral data. E, ALAS; G, glycine; EG, ALAS-glycine complex; SCoA,
succinyl-CoA; EGSCoA, ALAS-glycine-succinyl-CoA complex; EQ, observable
quinonoid intermediate; EALA1, ALAS-ALA internal aldimine with active site loop
closed; and EALA2, ALAS-ALA internal aldimine with active site loop open.

Table 2.2.

Gibb’s free energy associated with the wild-type ALAS- and S254

variant-catalyzed reactions.
Enzyme

Wild-type
S254A
S254T

ΔGALA
(kcal/mol)
4.18
4.08
4.07

ΔGGly
(kcal/mol)
3.34
3.97
2.78
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Chapter Three

Arg-85 and Thr-430 in murine 5-aminolevulinate synthase coordinate acyl-CoAbinding and contribute to substrate specificity
Abstract

5-Aminolevulinate synthase (ALAS) catalyzes the rate-limiting step of heme
biosynthesis in mammals through the condensation of succinyl-Coenzyme A and glycine
to produce 5-aminolevulinate, Coenzyme-A (CoA) and carbon dioxide. ALAS is a
member of the α-oxoamine synthase family of pyridoxal 5'-phosphate (PLP)-dependent
enzymes and shares high degree of structural similarity and reaction mechanism with the
other members of the family. The X-ray crystal structure of ALAS from Rhodobacter

capsulatus reveals that the alkanoate component of succinyl-CoA is coordinated by a
conserved arginine and a threonine. The functions of the corresponding acyl-CoAbinding residues in murine erythroid ALAS (R85 and T430) in relation to acyl-CoA
binding and substrate discrimination were examined using site-directed mutagenesis and
a series of CoA-derivatives. The catalytic efficiency of the R85L variant with octanoylCoA was 66-fold higher than that of the wild-type protein, supporting the proposal of this
residue as key in discriminating substrate binding. Substitution of the acyl-CoA-binding
residues with hydrophobic amino acids caused a ligand-induced negative dichroic band at
420 nm in the CD spectra, suggesting that these residues affect substrate-mediated
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changes to the PLP microenvironment. Transient kinetic analyses of the R85K variantcatalyzed reactions confirm that this substitution decreases microscopic rates associated
with formation and decay of a key reaction intermediate and show that the nature of the
acyl-CoA tail seriously affect product binding. These results show that the bifurcate
interaction of the carboxylate moiety of succinyl-CoA with R85 and T430 is an important
determinant in ALAS function and may play a role in substrate specificity.
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Introduction

5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) is a pyridoxal 5’-phosphate
(PLP)-dependent enzyme consisting of two identical subunits, each containing one
molecule of covalently bound PLP. ALAS catalyzes the Claisen-like condensation of
glycine and succinyl-CoA to yield carbon dioxide (CO2), CoA, and 5-amino-4oxopentanoate (5-aminolevulinate; ALA), and represents the first step of porphyrin
biosynthesis in animals, fungi, and some bacteria.

The structural and mechanistic

properties of ALAS are markedly similar to those of 8-amino-7-oxononanoate synthase
(AONS), serine palmitoyl transferase (SPT), and 2-amino-3-ketobutyrate-CoA ligase
(KBL) (1-3).
The x-ray crystal structure of the holo form of Rhodobacter capsulatus ALAS
was solved at 2.1 Å resolution and also as enzyme-substrate complexes with either
glycine (2.7 Å) or succinyl-CoA (2.8 Å) (4). ALAS is classified as a member of the αoxoamine synthase subfamily of fold type I PLP-dependent enzymes. AONS, SPT, and
KBL are the other members and represent the closest structural relatives, with the
enzymes of the subfamily sharing a Cα root mean square deviation of approximately 1.5
Å (5, 6).

The reaction chemistries are also highly similar, all involving small amino

acids, CoA esters, and 1,3-aminoketones. AONS catalyzes the committed step in biotin
biosynthesis,(7) SPT catalyzes the first step of sphingolipid biosynthesis,(8) and KBL
catalyzes the degradation of threonine (9).
Despite the remarkable structural and mechanistic similarities in this important
group of enzymes the molecular mechanisms underlying substrate specificity remain
largely unexplored. SPTs utilize palmitoyl-CoA as the preferred physiological substrate
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(10), however, Han et. al. have shown that the SPT of a Coccolithovirus is more active
when utilizing myristoyl-CoA, a substrate similar to palmitoyl-CoA, but shorter by two
carbons (11). Prior to the elucidation of the X-ray crystal structure of R. capsulatus
ALAS, the bacterial enzyme-catalyzed reaction was examined with non-physiological
acyl-CoA derivatives as substrates (12). Results of this investigation indicate that some
naturally occurring three, four, and five carbon CoA thioesters can act as substrates and
that both acyl chain length and hydrophilicity of the acyl-CoA substrate are important
factors in determining specificity. The CoA substrate specificity of ALAS is of interest
due to localization of the eukaryotic enzyme in the inner mitochondrial matrix.
Specifically, 90% of cellular acetyl-CoA and between 92- and 97% of short and long
chain acyl-CoAs are located within this organelle, providing an abundant supply of
possible alternative substrates for meALAS.

As such, promiscuous reactions with

alternative CoA substrates would produce highly reactive 1-3-aminoketones of unknown
biological significance, that are potentially capable of dimerizing to form toxic
dihydropyrazines (13, 14).
Previous investigations regarding the binding of the amino acid substrate of
ALAS and substrate specificity led to the conclusion that the ALAS active site only
accommodates the smallest naturally occurring amino acid, namely glycine (15).
Variants of R. sphaeroides ALAS in which the glycine-binding threonine (T83) is
mutated to the subtly smaller amino acid serine show a dramatic improvement in
acceptance of non-physiological amino acid substrates (15). This finding along with the
crystal structures suggest that steric factors within the glycine-binding region of the
active site are the major determinants of amino acid substrate specificity.
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The ALAS active site is within a cleft at the subunit interface and is delimited by
a β-strand bent around the PLP cofactor, in which the pyridinium ring of the cofactor lies
at the bottom of the cavity (4). Connection between the surface of the enzyme and the
active site is by an amphipathic channel, which is occupied by succinyl-CoA in the
substrate-bound structure (Figure 3.1). Two distinct moieties of succinyl-CoA interact
with the enzyme: the solvent accessible adenosyl component and the buried succinate.
The alkanoic acid moiety of succinyl-CoA is bound to the active site via a strong
hydrogen bond network that stabilizes a closed enzyme conformation (Lendrihas et. al.,
submitted) (4, 16). At the end of a hydrophobic tunnel, the guanidino group of the highly
conserved R21 (R85 in murine erythroid ALAS (meALAS)) donates a hydrogen bond to
the carboxylate constituent of succinyl-CoA (Figure 3.1). Simultaneously, the hydroxyl
group of the conserved T365 (T430 in meALAS), which is positioned at the apex of a
conformationally dynamic active site loop, bridges both the carboxylic acid moiety of
succinyl-CoA and the side chain of R21 to complete a hydrogen bonding triad (Figure
3.1) (4). Accordingly, the chemical characteristics of the acyl-tail of the CoA substrate
may be a determining factor for the enzyme in discriminating substrate entry into the
active site.
In this study, we investigate the role of the conserved R85 and T430 residues of
meALAS in recognition and binding of the acyl-CoA substrate in relation to catalysis.
Substitutions of the conserved residues with more hydrophobic amino acids (i.e., R85L
and T430V) were introduced to examine the effect of hydrophobicity and steric hindrance
on specificity toward the CoA-derived substrate. Such a difference would alter the
aliphaticity of the substrate-binding cleft, which, in turn, could affect the acyl chain-
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Figure 3.1 The acyl-CoA binding cleft in R. capsulatus ALAS. The ALAS dimer

appears above the hydrogen bond network maintained between the alkanoic acid
component of succinyl-CoA and the side chains of the conserved residues (R21 and
T365) is indicated by dashed yellow lines. The PLP cofactor, succinyl-CoA substrate
and the corresponding R and T residues (R85 and T430) are shown in stick format.
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binding properties of this channel. The results presented here for the R85 and T430
variants of meALAS show that these residues are involved in both the orientation and
binding of the succinyl-CoA substrate in the active site and may also, following the
substrate binding, assist in enzyme closure.
Materials

Reagents. The following reagents were purchased from Sigma-Aldrich Chemical
Company (St. Louis, MO): ampicillin, DEAE-Sephacel, Ultrogel AcA-44, mercaptoethanol, PLP, bovine serum albumin, succinyl-CoA, ALA-hydrochloride, ketoglutaric acid, -ketoglutarate dehydrogenase, HEPES-free acid, MOPS, tricine,
thiamine pyrophosphate, NAD+, and the bicinchoninic acid protein determination kit.
Glucose, glycerol, glycine, disodium ethylenediamine tetraacetic acid dihydrate,
ammonium sulfate, magnesium chloride hexahydrate, and potassium hydroxide were
acquired from Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulfate polyacrylamide
gel electrophoresis reagents were acquired from Bio-Rad. Sal I, Blp I, Xho I, Bam HI
restriction enzymes, Vent DNA Polymerase, and T4 DNA ligase were from New England
Biolabs (Ipswich, MA).

Oligonucleotides were synthesized by Integrated DNA

Technologies (Coralville, IA).
Methods

Mutagenesis. The pGF23 expression plasmid encodes the full-length sequence for
the murine, mature eALAS (17). The R85L variant was generated using a previously
described method (18). The mutagenic primers used for the R85L mutation were 5’GAC CAC ACC TAC CTT GTG TTC AAG ACT GT-3’ and 5’-ACA GTC TTG AAC
ACA AGG TAG GTG TGG TC-3’, with the introduced codon substitution underlined.
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The PCR-generated fragment containing the R85L mutation was used as a megaprimer in
an independent round of PCR. The PCR-generated fragment was sequenced to verify the
presence of the desired mutations. Subsequently, the PCR product was then digested
with Sal I and Bam HI and subcloned into pGF23 digested similarly. The site-directed
mutagenesis for the T430V variant was performed on the whole plasmid pGF23 using a
previously described method (19). The mutagenic oligonucleotide for T430V was: 5’ATC AAC TAC CCA GTT GTG CCT CTG GGT-3’, with the introduced codon
substitution underlined. The PCR-generated DNA was sequenced between the Blp I and

Bam HI restriction enzyme sites to confirm the presence of the mutation. The product
was then digested with Blp I and Bam HI and subcloned into pGF23 digested similarly.
The pMAL2 expression plasmid, described above, encodes the full-length sequence for
the murine, mature eALAS, with the arginine at position 85 mutated to leucine. The
R85L/T430V double mutated variant was constructed by digesting the T430V-encoding
plasmid (pTL30) with Xho I and Bam HI. This T430V mutation-encoding fragment was
subcloned into pMAL2 digested similarly.

Protein purification, SDS-PAGE, protein determination and steady-state analysis.
Recombinant murine eALAS and the R85 and R85/T430 variants were purified from
DH5 Escherichia coli bacterial cells containing the overexpressed protein as previously
described (17). Sufficient expression of the T430V variant could not be obtained. The
protein purity was over 90% judged by SDS-PAGE (20) and protein concentration was
determined by the bicinchoninic acid method using bovine serum albumin as the standard

(21). All protein concentrations are reported on the basis of a subunit molecular weight
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of 56 kDa. Enzymatic activity was determined by a continuous spectrophotometric assay
at 30oC (22).

Structural analyses. The protein data base files 2BWN, 2BWO, and 2BWP,
corresponding to the R. capsulatus ALAS holoenzyme, succinyl-CoA bound, and glycine
bound crystal structures were used as templates to model the the murine eALAS
Michaelis complex structure (4). Hydrogen bond determinations were accomplished
using Deepview/Swiss-PdbViewer software (23, 24).

Circular dichroism spectroscopic measurements. Spectroscopic measurements
were performed with enzyme that was dialyzed in 20 mM HEPES, pH 7.5 with 10%
glycerol to remove free PLP. Circular dichroism (CD) spectra were obtained using an
AVIV CD spectrometer calibrated for both wavelength maxima and signal intensity with
an aqueous solution of D-10 camphorsulfonic acid (25). Protein concentrations were 100
μM for each enzyme tested. The final concentration of each CoA-derivative was 100
M, giving a 1:1 molar ratio of enzyme to ligand. At least three CD spectra were
collected per experiment and averaged, using a 0.1 cm path length cuvette with a total
volume of 300 l. Blank CD spectra contained all components of the solution except
enzyme. CD spectra containing the enzyme sample were collected immediately after
adding the enzyme. The spectra of the samples containing enzyme were analyzed after
subtracting the blank spectra.

Stopped-flow spectroscopy. All of the experiments were carried out at 30°C in 100
mM HEPES, pH 7.5 and 10% (v/v) glycerol. The concentration of reactants loaded into
the two syringes was always 2-fold greater than that present in the cell compartment after
mixing, with glycine and the enzyme pre-incubated in one syringe and the CoA-
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derivative in another. Because of the difference in Km values for the CoA-derivatives
among the two enzymes tested, different CoA-derivative concentrations were used to
ensure the identification of a single enzyme catalyzed event. For the wild-type reaction,
the final concentrations were: 120 μM wild-type ALAS, and 130 mM glycine. The final
concentrations of each independently examined CoA-derivative were: succinyl-CoA, 10
μM; octanoyl-CoA, 10 μM; butyryl-CoA, 20 μM; β-hydroxybutyryl-CoA, 30 μM;
glutaryl-CoA, 30 μM. For the R85K-catalyzed reaction, the final concentrations were:
120 μM R85K, and 130 mM glycine. The final concentrations of each independently
examined CoA-derivative were: succinyl-CoA, 20 μM; octanoyl-CoA, 10 μM; butyrylCoA, 10 μM; β-hydroxybutyryl-CoA, 10 μM; glutaryl-CoA, 20 μM. Rapid scanning
stopped-flow kinetic measurements were conducted using an OLIS model RSM-1000
stopped-flow spectrophotometer. The dead time of this instrument is approximately 2 ms,
and the observation chamber optical path length is 4.0 mm.

Scans covering the

wavelength region 270-550 nm were acquired at a rate of 31, 7 or 3 scans per second in
order to condense the resulting data files to a tractable size for data fitting analysis. An
external water bath was utilized to maintain constant temperature (30oC) of the syringes
and observation chamber. Observed rate constants were determined by global fitting of
the acquired spectral data sets, using the single value decomposition software provided
by OLIS, Inc.(26) The quality of fits were judged by visual analysis of the calculated
residuals in conjunction with the Durbin-Watson statistic (27). Single turnover data were
interpreted using a three kinetic step mechanism as described by Equation 3.1.

(Equation 3.1)
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The observed rate constants were determined from at least three replicate experiments,
and the reported values represent the average and standard error of measurement for each
experimental condition.

Intrinsic protein fluorescence quenching. The pre-steady state kinetics of the
product binding reaction of ALAS and the R85 and T430 variants were examined by
measuring changes in the intrinsic protein fluorescence intensity. An OLIS RSM-1000F
rapid mixing spectrofluorimeter, equipped with a high-intensity xenon arc lamp, was
used to follow the reaction. The enzyme and ligand in 20 mM HEPES (pH 7.5) and 10%
glycerol were maintained at 30oC in separate syringes prior to their mixing in the reaction
chamber. The concentrations of enzyme and ligand in the reaction chamber were 1/2 of
those in the syringes. The intrinsic protein fluorescence, as measured with 5 μM enzyme,
was evaluated in the presence of increasing concentrations of the product, ALA. The
excitation wavelength and the slit width were 280 and 5 mm, respectively. Scheme 3.1
illustrates the relationship between wavelength maximum and the dynamic process being
monitored.

The emitted light was filtered using a cutoff filter (WG 320; 80%

transmittance at 320 nm, (Edmund Optics, Barrington, NJ)). Typically, 500 time points
were collected for varying lengths of time, and three or more experiments were averaged.
Each averaged data set was then fitted to Equation 3.2, using the global fitting software
provided with the instrument.

(Equation 3.2)

Fobs (t )  A1e  kobs t  A0

where Fobs(t) is the observed fluorescence change (in arbitrary units) at time t, kobs1 is the
observed first-order rate constant, A1 is the pre-exponential factor and A0 is the offset. The
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observed rate constants were then plotted against ligand concentration and the data were
fitted to Equation 3.2 by nonlinear regression. The rates of dissociation (koff) and
association (kon) as well as the ligand binding constants (KD) were calculated from the
asymptotic maximal observed rate, the ordinate intercept, and the ligand concentration (x)
in Equation 3.3

(Equation 3.3)

f ( x)  k on 

k off x
KD  x

Results

Kinetic characterization of the R85 and R85/T430 variants. The steady-state
kinetic parameters of the ALAS variants were determined and the results are summarized
in Table 3.1. Wild-type ALAS was active with all of the CoA-derivatives tested. The Km
for octanoyl-CoA was the lowest with a value of 0.51 μM compared to 2.9 μM for
succinyl-CoA. This decreased value contributed to a catalytic efficiency value that was
2-fold higher than the reaction completed with the physiological substrate succinyl-CoA.
Glutaryl-CoA and β-hydroxybutyryl-CoA were the least catalytically efficient, due to 6fold increases in the Km for both substrates. Changing R85 to leucine (R85L) imparted
dramatic changes with respect to the physiological substrate succinyl-CoA. The kcat
associated with the R85L-catalyzed reaction using succinyl-CoA as the substrate
decreased greater than 11-fold, while the K mSCoA increased 7-fold. The 66-fold increase in
catalytic efficiency toward octanoyl-CoA as well as the 4-fold increase found with
butyryl-CoA for the R85L variant highlight a shift toward acceptance of more
hydrophobic CoA-derivatives within the acyl-CoA-binding cleft of this enzyme. The
replacement of R85 with lysine (R85K) yielded a turnover number that was similar to
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that of the wild-type enzyme. When the different acyl-CoA substrates were tested, this
pattern continued with the exception of the reaction with glutaryl-CoA. This CoAderivative reacted slower than the physiological substrate succinyl-CoA as evidenced by
a 21-fold decrease in kcat.

Among the catalytic efficiencies calculated for R85K,

octanoyl-CoA yielded the highest with a value 13-fold greater than that of the same
reaction containing succinyl-CoA.

The steady-state data obtained from the double

variant (R85L/T430V) suggest that steric hindrance as well as hydrophobicity of the
active site are important determinants for preference of CoA-derivative. Affinity for
octanoyl-CoA in the double variant is diminished, resulting in a 2-fold higher Km.
Conversely, the reaction of the double variant with butyryl-CoA gave a Km value of 0.54
μM, a value indistinguishable from octanoyl-CoA in the R85L variant, and 31-fold lower
than octanoyl-CoA in the double variant. The double variant-catalyzed reaction with
glutaryl-CoA, a derivative similar to succinyl-CoA but longer by one methylene carbon,
showed undetectable activity as measured under the assay conditions tested. These data
are shown graphically as normalized specificity constants in Figure 3.2, in which the ratio
of the catalytic efficiency of each variant for a particular substrate is compared to the
catalytic efficiency of the variant with succinyl-CoA.
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Table 3.1 Comparison of steady-state kinetic constants for wild-type ALAS, R85K,
R85L, and R85L/T430V with CoA derivatives as substrates.
Parameter

10.0 ± 0.2
2.9 ± 0.1

R85K
R85L
Succinyl-CoA as a Substrate
6.4 ± 0.2
0.94 ± 0.10
12.4 ± 0.6
20.3 ± 1.0

0.11 ± 0.03
9.6 ± 0.8

kcat/ K m ,app , min-1· μM-1

3.6 ± 0.2

0.53 ± 0.04

0.050 ± 0.003

0.010 ± 0.002

K mGly , mM

24.2 ± 0.4

20.0 ± 0.4

63.1 ± 2.2

98.4 ± 3.5

kcat/ K m , min-1·mM-1
Gly

0.43 ± 0.04

0.32 ± 0.06

0.010 ± 0.002

0.001 ± 0.002

kcat, min-1

3.4 ± 0.2
0.51 ± 0.04

Octanoyl-CoA as a Substrate
10.3 ± 0.4
1.8 ± 0.3
1.5 ± 0.04
0.55 ± 0.03

(1.0 ± 0.1) x 10-3
17.2 ± 0.6

6.8 ± 0.8

7.0 ± 0.2

3.3 ± 0.1

(5.6 ± 0.2) x 10-5

K mGly , mM

17.1 ± 0.9

25.2 ± 1.1

55.2 ± 5.0

74.2 ± 3.3

kcat/ K m , min-1·mM-1

0.14 ± 0.01

0.52 ± 0.02

0.030 ± 0.005

(1.0 ± 0.08) x 10-5

kcat, min-1

6.3 ± 0.3
6.1 ± 0.09

Butyryl-CoA as a Substrate
10.2 ± 0.3
2.01 ± 0.08
2.7 ± 0.1
9.3 ± 1.0

0.060 ± 0.002
0.54 ± 0.03

kcat/ K m ,app , min-1· μM-1

1.0 ± 0.1

3.7 ± 0.4

0.21 ± 0.04

0.03 ± 0.002

K mGly , mM

29.3 ± 4.6

17.2 ± 0.7

70.3 ± 6.6

88.2 ± 3.9

kcat/ K m , min-1·mM-1

0.26 ± 0.03

0.50 ± 0.01

0.030 ± 0.005

(6.1 ± 0.8) x 10-4

kcat, min-1

4.0 ± 0.8
9.8 ± 1.0

β-Hydroxybutyryl-CoA as a Substrate
2.8 ± 0.1
0.65 ± 0.03
5.5 ± 0.2
6.1 ± 0.8

(1.0 ± 0.2) x 10-4
74.2 ± 0.6

0.41 ± 0.04

0.51 ± 0.04

0.11 ± 0.02

(1.3 ± 0.4) x 10-6

K mGly , mM

22.1 ± 0.8

18.2 ± 3.2

59.1 ± 4.7

92.2 ± 6.0

kcat/ K m , min-1·mM-1

0.17 ± 0.06

0.14 ± 0.03

0.011 ± 0.003

(1.0 ± 0.3) x 10-6

kcat, min-1

7.0 ± 0.4
17.0 ± 1.6

Glutaryl-CoA as a Substrate
0.30 ± 0.03
2.2 ± 0.1
7.5 ± 0.6
30.1 ± 1.1

n/d
n/d

kcat/ K m ,app , min-1· μM-1

0.41 ± 0.05

0.04 ± 0.003

0.07 ± 0.006

n/d

K mGly , mM

28.4 ± 0.8

21.2 ± 0.2

70.6 ± 4.2

n/d

kcat/ K m , min-1·mM-1

0.29 ± 0.02

0.010 ± 0.002

(8.0 ± 0.7) x 10-4

n/d

kcat, min-1

K

CoA
m , app

, μM

CoA

K

CoA
m , app

kcat/ K

, μM

CoA
m , app

, min-1· μM-1

Gly

K

CoA
m , app

, μM

CoA

Gly

K

CoA
m , app

kcat/ K

, μM

CoA
m , app

, min-1· μM-1

Gly

K mCoA
, app , μM
CoA

Gly

Wild-Type ALAS

n/d, not determined
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R85L/T430V

Circular dichroism spectroscopy.

To verify whether the R85K, R85L or

R85L/T430V amino acid substitutions introduced substantial changes in secondary
structure, CD spectra in the far-UV region (200-270 nm) were recorded for the wild-type
and variant enzymes (data not shown).

All enzymes displayed similar CD spectra

indicating that the introduced residue exchanges did not result in gross differences in the
overall conformation of the ALAS protein. The enzyme-bound cofactor gives rise to a
defined CD spectrum in the visible region (300-500 nm) because of anisotropic
interactions between the amino acid side chains and the chromophore in the active site
(Figure 3.3). The CD spectrum thus contains information about the asymmetric
orientation of the bound PLP cofactor in the active site, including the aldimine linkage
between the PLP cofactor and the active site lysine (Scheme 3.1)(28, 29). The visible CD
spectra of the WT ALAS (Figure 3.3A) show that in the presence of either succinyl- or
octanoyl-CoA there is a positive Cotton effect. However, close inspection of the results
indicates that there is a distinct difference in the CD maximum in relation to that of the
WT ALAS; the wavelength maximum for succinyl-CoA blue shifts 15 nm to ~420 nm,
while the octanoyl-CoA dichroic band at ~435 nm increases. The spectra observed for
the R85K variant are different (Figure 3.3B). The changes caused by succinyl-CoA
binding to the R85K variant mimic those observed upon octanoyl-CoA interacting with
WT ALAS, in that the spectral differences between the two are unremarkable.
Substitutions of polar residues with non-polar amino acids yielded proteins (R85L and
R85L/T430V) in which ligand binding induces changes in the PLP environment and,
consequently, display CD spectra (visible region) that are markedly different from those
of wild-type ALAS and the R85K variant. Within the R85L enzyme, succinyl-CoA
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binding does not cause a shift in the microenvironment of the chromophore (Figure
3.3C). However, all of the remaining CoA-derivatives cause a negative Cotton effect,
decreasing the amplitude of the spectra ~5 θ.

Steric hindrance and enhanced

hydrophobicity of the acyl-CoA-binding cleft are hypothesized to be the most
exaggerated in the double variant. This theory is supported by the CD data which suggest
that R85L/T430V is affected most by the binding of octanoyl- and butyryl-CoA (Figure
3.3D). The positive Cotton effect observed in the spectra for the enzyme in the presence
of these two hydrophobic ligands could suggest that the exclusion of water and degree of
active site aliphaticity are crucial components for determining substrate specificity.
Overall, a comparison of the CD spectra of the wild-type and R85K variant enzymes with
those of the hydrophobic variants (R85L and R85L/T430V) show that the distinct change
in the microenvironment of the PLP pocket correlates well with the degree of
hydrophobicity inherent to the bound ligand.
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Figure 3.2. Comparison of normalized specificity constants for murine eALAS
variants with different CoA substrates.

The specificity constant (kcat/ K mCoA
, app ) with

Normalized Specificity Constant

succinyl-CoA as substrate was arbitrarily defined as equal to 1.00 for each ALAS variant.

70
65
60

Succinyl-CoA
Octanoyl-CoA
Butyryl-CoA
Hydroxybutyryl-CoA
Glutaryl-CoA

15

10

5

0

wt

R85K

R85L

R85L/T430V

ALAS Variant

Scheme 3.1. The absorbance maxima of chemical species in the ALAS-catalyzed
reaction.

R=OP O32
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Figure 3.3. Visible circular dichroism spectra of wild-type ALAS and the R85 and
R85/T430 variants. (A) wild-type ALAS, (B) R85K, (C) R85L, and (D) R85L/T430V.

Spectra of the holoenzymes are in purple. Spectra of the holoenzymes (100μM) in the
presence of 100 μM CoA derivative are indicated according to the following color
scheme: pink, succinyl-CoA; green, octanoyl-CoA; blue, β-hydroxybutyryl-CoA; black,
butyryl-CoA; red, glutaryl-CoA.
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ALA-binding kinetics monitored by the transient intrinsic protein fluorescence.
To determine whether a change in the degree of hydrophobicity of the acyl-CoA-binding
pocket could influence the product binding and concomitant quenching of the intrinsic
protein fluorescence, wild-type ALAS and the enzyme variants were rapidly mixed with
excess ALA and the changes in intrinsic protein fluorescence were monitored. The
observed pseudo first-order decay rates of these kinetic traces were dependent on ALA
concentration, and differed among the enzymes tested (Figure 3.4). In all cases the
change in observed rate as a function of ALA concentration was hyperbolic, indicating
two binding steps. Presumably these two steps are indicative of rapid formation of an
initial collision complex followed by a slower shift to the closed conformation observed
in the crystal structures of the R. capsulatus enzyme. While the resolved ALA “off” rates
(i.e. k-1) coincide with the kcat values determined through steady-state kinetics, suggesting
that a conformational change associated with ALA release defines kcat for each enzyme,
the collision complex dissociation constants of the variants are increased. The resolved
on and off rates for the reaction between ALA and wild-type ALAS were

k1 = 0.120 ± 0.015 s-1 and k-1 = 0.140 ± 0.005 s-1, respectively, with a KD of 500 ± 16 μM.
The rates for the reaction of the R85K variant with ALA were ~2-fold lower with

k1= 0.090 ± 0.003 s-1 and k-1 0.079 ± 0.003 s-1; however, the dissociation constant was 3fold higher at 1470 ± 30 µM, indicating decreased affinity for ALA. Among the more
hydrophobic variants, the rates of protein quenching with ALA were the most rapid for
R85L with on and off rates of 0.039 ± 0.009 s-1 and 0.024 ± 0.003 s-1, respectively, values
3-fold lower that those of the wild-type enzyme.

A KD value of 1130 ± 27 μM

corresponding to a 3-fold greater dissociation of ALA from the R85L variant than that of
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wild-type ALAS was calculated. The double variant bound ALA less tightly, with a KD
13-fold lower than that for wild-type ALAS and an estimated value of 6710 ± 33 μM.
Figure 3.4. Reaction of wild-type ALAS, R85K, R85L and R85L/T430V (5 µM) with
ALA. The observed rate constants were calculated by fitting the decrease in intrinsic

protein fluorescence over time to Equation 3.2 for a single exponential process. (A) wildtype

ALAS

(B)

R85K

(C)
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R85L

(D)

R85L/T430V.

The on and off rates for R85L/T430V were also the lowest of the enzymes tested, with
rates measuring k1= 0.007 ± 0.0001 s-1, and k-1 0.005 ± 0.001 s-1, respectively

Pre-steady-state reaction of the variant enzyme-glycine complexes with acyl-CoAderivatives. The R85L and R85L/T430V variant enzyme-glycine complexes did not
yield a measurable absorbance change at 510 nm, previously assigned to a quinonoid
reaction intermediate (Scheme 3.1), when rapidly mixed in the presence of any of the 5
acyl-CoA derivatives tested (16, 30, 31). Consequently, the investigation of the transient
kinetics associated with the formation and decay of the quinonoid intermediate was based
upon the reactions catalyzed by wild-type ALAS and the R85K variant, both of which
demonstrate a quantifiable absorbance change at 510 nm upon the addition of the acylCoA substrates to the enzyme-glycine complexes. The rates associated with the lifetime
of the quinonoid intermediate, measured during the enzyme catalyzed reactions, were
elucidated (Table 3.2). The absorbance change timecourses were fitted to a sequential,
three-step mechanism outlined by Equation 4.1.

An initial burst of quinonoid

intermediate formation, followed by a two-step decay was characteristic of each of the
enzymes tested (Figure 3.5).

Of all the acyl-CoA derivatives examined, only β-

hydroxybutyryl-CoA, when rapidly mixed with the wild-type enzyme-glycine complex,
failed to produce an absorbance change at 510 nm. Overall, faster rates of quinonoid
intermediate formation were observed for the wild-type enzyme, as compared to the
R85K variant (Table 3.2). The rates of quinonoid formation when octanoyl-CoA was
used as the substrate (2.3 s-1 and 1.9 s-1) were of the same order of magnitude as the
values recorded for succinyl-CoA (6.0 s-1and 4.2 s-1) for both the wild-type and R85K
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Table 3.2. Rates of quinonoid intermediate formation and decay under singleturnover conditions.
Parameter

succinyl

octanoyl

Qf
Qd1
Qd2

(s-1)
6.0 ± 0.6
2.00 ± 0.30
0.072 ± 0.005

(s-1)
2.3 ± 0.4
0.071 ± 0.004
0.020 ± 0.003

Qf
Qd1
Qd2

(s-1)
4.20 ± 0.1
1.10 ± 0.1
0.050 ± 0.004

(s-1)
1.91 ± 0.20
0.11 ± 0.02
0.070 ± 0.003

butyryl
β-hydroxybutyryl
Wild-type ALAS
(s-1)
0.41 ± 0.04
n/d
0.070 ± 0.005
n/d
0.011 ± 0.003
n/d
R85K
(s-1)
(s-1)
0.323 ± 0.020
0.121 ± 0.021
0.002 ± 0.0001
0.022 ± 0.005
0.041 ± 0.007
0.013 ± 0.001

glutaryl
(s-1)
0.220 ± 0.03
0.091 ± 0.005
0.0010 ± 0.0004
(s-1)
0.192 ± 0.042
0.134 ± 0.071
0.0010 ± 0.0001

n/d, not determined; Qf, quinonoid intermediate formation; Qd1, first step of quinonoid
intermediate decay; Qd2, second step of quinonoid intermediate decay
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Figure 3.5.

Reaction of wild-type ALAS- and R85K-glycine complexes with

different CoA derivatives under single turnover conditions. The data (●●/●●) are

overlaid with the line representing the best-fit curve (▬). The rate constants for the three
step sequence corresponding to both enzymes are listed in Table 3.2. Green and red data
points correspond with wild-type ALAS and the R85K variant, respectively.

(A)

octanoyl-CoA, (B) butyryl-CoA, (C) succinyl-CoA, (D) glutaryl-CoA, (E) βhydroxybutyryl-CoA.
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enzymes, respectively. These data support the increased catalytic efficiency observed
from the experiments performed in the steady-state. Further comparison of the reaction
catalyzed by wild-type ALAS with butyryl-CoA vs. glutaryl-CoA showed that quinonoid
intermediate formation was accelerated 90%. A similar enhancement was observed for
the R85K-catalyzed reaction which showed a 70% increase in the rate of quinonoid
intermediate formation with butyryl-CoA vs. glutaryl-CoA. The preference for butyrylCoA over glutartyl CoA suggests that in addition to the hydrogen bonding properties of
R85 and T430, the amino acids that line the hydrophobic tunnel leading to the terminal
guanidino group may play a role in substrate acceptance and orientation. Curiously, only
the R85K-glycine complex, when rapidly mixed with β-hydroxybutyryl-CoA, gave a
time-dependent absorbance change at 510 nm and rate associated with quinonoid
intermediate formation (0.12 s-1). This is in stark contrast to the observations made of
wild-type ALAS, where no quantifiable change with this substrate was detected. This
slow rate may be explained by the mixed polarity of the substrate tail, an attribute which
simultaneously imparts hydrogen bonding character, as well as aliphaticity to the acylCoA-binding cleft of the variant enzyme.
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Discussion

The reactions catalyzed by the highly related members of the α-oxoamine
synthase subfamily of PLP-dependent enzymes can be compared with respect to the
specificity of the acyl-CoA substrate due to the elucidation of the three-dimensional
structures of subfamily members together with mutagenesis, spectroscopic and kinetic
methods (1, 4-6, 32). Both of the variant enzymes constructed for the arginine residue
(R85L and R85K) as well as the doubly mutated enzyme (R85L/T430V) were expressed,
overproduced, and then purified as holoenzymes, indicating that cofactor binding by the
apoprotein was not affected by the introduction of the amino acid substitutions.
However, replacement of the invariant threonine residue with valine (T430V) resulted in
a poorly expressed, unstable, and proteolytically susceptible enzyme that was never
purified to homogeneity (data not shown). All of the purifiable variants were active with
the physiological substrate succinyl-CoA. Since the threonine to valine replacement at
position 430 appears to dramatically affect protein stability, we suggest that T430 is
essential not only for optimal molecular recognition of succinyl-CoA, but also for stable
folding. R85 may be less crucial for proper enzyme function, a finding supported by the
crystallographic data for SPT (6). Given that this enzyme lacks the arginine residue
implicated in salt bridge formation with the carboxylate group of CoA substrates in the
other three members of the α-oxoamine synthase subfamily and utilizes palmitoyl-CoA,
an acyl-CoA derivative of increased aliphaticity, it is proposed that acyl-CoA binding in
ALAS may be driven by non-covalent interactions between the two residues and the
substrate. However, considering the structural and mechanistic data for ALAS and SPT,
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turnover likely remains orchestrated by amino acids that are proximal to the site of αcarbon bond scission (16, 33).
Comparison of the active sites of AONS and ALAS showed that the coordination
of the acyl-CoA substrate is assisted by way of pantetheine association with the enzyme
face and tail interactions with the buried hydrophobic tunnel (1, 4, 6). Both R85 and
T430 coordinate the carboxylate tail of the acyl-CoA substrate in meALAS. The steadystate kinetic analysis of the variants (R85K, R85L, and R85L/T430V) with the family of
CoA-derivatives showed that the apparent Michaelis parameters ( K mCoA
, app ) are dramatically
different when compared to those of wild-type ALAS. Acyl-CoA substrates of increased
hydrophobicity (e.g., octanoyl- and butyryl-CoA) demonstrated greater affinity for the
variants where the substituted amino acid was aliphatic in nature (R85L and
R85L/T430V). The 36-fold decrease in the ( K mCoA
, app ) for octanoyl-CoA in the R85L
variant leads us to suggest that the exclusion of water from the acyl-CoA-binding tunnel
is a determining feature of substrate binding. Further, in the double variant, an 18-fold
reduction in the Michaelis constant for butyryl-CoA also supports this hypothesis. The
introduction of valine at position 430 would reduce the diameter of the hydrophobic
tunnel, making steric hindrance a more significant consideration for substrate binding.
These differences identified between the variant enzymes and wild-type ALAS suggest
that reaction specificity is driven by the chemical characteristics of the CoA-derived tail
and the hydrogen-bonding potential of the invariant acyl-CoA-binding residues, a
phenomenon recognized in the acyl-CoA thioesterases of the peroxisome (34, 35).
The chemical characteristics of the acyl-CoA tail are a determining factor in the
substrate specificity of another family of enzymes that utilize related substrates in
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turnover, the crotonase family (36, 37). Among those enzymes, octanoyl-CoA has been
shown to bind in a characteristic bent conformation (36). This substrate conformation is
accomplished by two structurally conserved hydrogen bond-donating groups to the
carbonyl moiety of the substrate and through the entropically driven loss of water
coordinated by the hydrophobic amino acids that line the binding cleft (36). The CD data
for butyryl-CoA with the double variant in addition to the substrate configuration
observed in enzymes that physiologically utilize octanoyl-CoA led us to suggest that
octanoyl-CoA, which differs from butyryl-CoA by a four methylene bridge, most likely
bends in the ALAS active site. This hypothesis is further supported by the data obtained
for both wild-type ALAS and R85L with octanoyl-CoA. For wild-type ALAS, the
catalytic efficiency for the non-physiological substrate octanoyl-CoA is ~100% greater
than that of succinyl-CoA (Table 3.1 and Figure 3.2). Congruently, the specificity
constant for octanoyl-CoA compared to that of succinyl-CoA in the R85L variant is 66fold higher, indicating a significant change in substrate specificity.

Therefore, we

hypothesize that octanoyl-CoA, devoid of a salt bridge to anchor with the guanidino
group of R85, likely bends, excludes water from the active site, and assists in enzyme
closure, a conformation postulated to be essential for turnover (16).
Interestingly, the specificity constant for the wild-type enzyme with octanoylCoA is higher than the physiological substrate, succinyl-CoA, albeit at the cost of a threefold reduction in the specificity constant for the other substrate, glycine. Nevertheless,
this finding and the activity of the enzyme with the other CoA esters tested here lead us
to raise the question as to what extent ALAS may catalyze formation of 1,-3aminoketones other than ALA in vivo. This is currently unknown, but may warrant
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further investigation. Conceivably, the potential toxicity, associated with the generation
of other aminoketones rather than ALA, could be minimized through the action of a
regulatory acyl-CoA-binding protein. In fact, studies have demonstrated that the acylCoA binding protein binds long-chain acyl-CoA esters with high specificity and affinity
(with Kd values of 1–10 nM); hence by interacting with acyl-CoA utilizing enzymes, the
acyl-CoA-binding protein may provide a mechanism for control of free acyl-CoA esters
and regulation of the activity of acyl-CoA utilizing enzymes.

Further substrate

specificity in vivo might be enhanced via a substrate channeling mechanism involving
interaction of ALAS with succinyl-CoA synthetase (38). The requirement for such a
mechanism is emphasized by the evidence presented here.
The chromophoric properties of PLP in ALAS provide a valuable probe for
positional alterations to the amino acids that comprise the cofactor binding cleft. Since
PLP is not a chiral molecule, the Cotton effect of PLP bound in the active site must result
from certain asymmetric distortion of the PLP molecule through interaction with the
enzyme. Binding of acyl-CoA substrates to ALAS (or ALAS variants) most likely
induced changes, even if subtle, in the PLP-protein interaction, as reflected by the
different visible CD spectra (Fig. 3). Curiously, for each of the enzymes tested, the most
noticeable spectral deviations from the spectra obtained in the absence of substrate were
produced by CoA-derivatives with tails that matched the chemical nature of the amino
acid substitution introduced in ALAS.

In the R85L/T430V double variant, binding of

either octanoyl- and butyryl-CoA induced a marked positive Cotton effect (Figure 3.3).
A definite interpretation for the relationship between substrate binding and induced
Cotton effect of the PLP cofactor cannot be provided at this point. Perhaps the observed
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effects could be explained, in part, by a shift in the enzyme conformational equilibrium
towards the closed conformation, which has been hypothesized for the wild-type enzyme
to be energetically driven by succinyl-CoA binding (Lendrihas et al., unpublished data)
(16, 18). However, a decrease in active site diameter, triggered by the entropic loss of
water upon the binding of a more hydrophobic substrate, could also explain the change in
the cofactor microenvironment as evidenced by the CD data. This scenario is supported
by ligand binding to the asymmetric protein host. It is therefore premature to assign the
observed CD spectral differences to a particular molecular event (e.g., a protein
conformational change, a PLP reorientation or a perturbation of the electronic system of
the chromophore).

Nevertheless, the CD spectra in the UV region of all the variants

were indistinguishable from that of the wild-type enzyme (data not shown), indicating no
gross alterations in secondary structure, and thus suggesting that the differences observed
in the visible CD spectra, upon substrate binding, are confined to the PLP-binding cleft.
Although specific contributions by single amino acid substitutions cannot be easily
disentangled using CD, the CD spectral differences in the visible range among ALAS
variants with the family of CoA-derivatives of different hydrophobicities lead us to
propose that interactions between key residues (e.g., R85 and T430) that bind the tail of
CoA play a role in determining substrate specificity.
The proposed kinetic mechanism of the ALAS-catalyzed reaction is limited by
product release, or opening of the active site loop coincident with product release (16).
Utilization of protein fluorescence to study the reverse catalytic reaction, i.e., the reaction
of the enzyme with the product, resolves the ALA “off” rate, and confirms it to be
indistinguishable from kcat (16). With this in mind, we investigated whether mutations to
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the acyl-CoA-binding residues affect the rates of product release and/or perturb the
enzyme-product equilibrium (Figure 3.4). Quenching of the ALAS intrinsic fluorescence
with ALA obeyed first-order decay kinetics. For all the variant catalyzed-reactions, rates
of product release and capture are diminished. The most dramatic decrease is seen in the
double variant; this enzyme exhibited a 13-fold reduction in the “on” and “off” rates (kon
and koff) for the reaction with ALA. Since CoA-derivatives of increased hydrophobicity
bind with greater affinity to the non-polar variants (R85L and R85L/T430V), it is
possible that the decreased affinity for the product, a δ-aminoacid, may be reversed for
aminoketones of decreased polarity. In this scenario and in agreement with a mechanism
in which a conformational step follows ligand binding, the affinity of the aminoketones
towards ALAS would not be reduced. The Kd values would either increase or remain
unchanged; this hypothesis, however, awaits further experimentation with aminoketones
of differing hydrophobicity.
The three-dimensional structures of ALAS and AONS

revealed a hydrogen

bonding network between the invariant arginine and threonine residues and the
carboxylate moieties of acyl-CoA substrates (1, 4).

Accordingly, how the use of

chemically different acyl-CoA-derivatives would affect the transient kinetic parameters
of the enzymes was evaluated.

Single turnover reactions with a family of CoA-

derivatives were used to determine the rates of quinonoid intermediate formation and
decay. The reaction catalyzed by wild-type ALAS with glutaryl-CoA as the substrate
exhibited a 30-fold lower rate corresponding to quinonoid intermediate formation vs. the
rate calculated with succinyl-CoA. One possible explanation for the retarded rate is that
the binding of glutaryl-CoA affects the hydrophobic acyl-CoA-binding tunnel in such a
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way that cofactor-mediated electron transfer from the site of bond scission to the
resonance stabilized pyridinium ring of PLP is perturbed. This phenonmenon is further
supported by the dramatic 70-fold reduction in the second step of quinonoid intermediate
decay, where the absorbance change at 510 nm appears to stabilize to a level that
approaches a steady-state (Figure 3.5D). The R85K variant demonstrated a change in the
first step of quinonoid intermediate decay, with a 10-fold lower rate for both octanoylCoA and glutaryl-CoA when compared to the physiological substrate succinyl-CoA.
When R85 is mutated to a lysine, the enzyme is chemically similar to wild-type ALAS in
many respects, presumably because this conservative replacement retains the positive
charge and hydrogen bonding capabilities. In addition, in silico protonation of the lysine
amino group to create the ε-ammonium charge center would contribute charge and polar
interactions characteristic of the guanidinium group (23, 24). However, the molecular
volume of the amino acid side chain is different, as is the electrostatic charge distribution.
With respect to their n-alkyl moieties, the n-propylguanidine side chain of arginine is
longer than the n-butylamine side chain of lysine by 1.6 Å (40). The R85K substitution
could therefore accommodate the additional sp3 hybridized carbon atom present in
glutaryl-CoA, allowing for a reduction in steric strain and/or unfavorable Van der Waals
interactions.

Further, the increased hydrophobic tunnel length could also assist the

bending of octanoyl-CoA within the cleft, a circumstance rationalized above.
In summary, the spectroscopic and kinetic studies detailed here demonstrate not
only the role played by R85 and T430 in determining acyl-CoA substrate specificity, but
also provide insight into the structure-function relationships in ALAS and the αoxoamine synthase subfamily as a whole. Although R85 and T430 recognize a part of
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the substrate that is distal from the bulk of the ligand and the active site, the ability of all
the enzymes to turnover non-physiological substrates remains intact. Changing these
residues to leucine and valine abates succinyl-CoA binding and catalytic efficiency, as
well as increases the affinity of the enzyme for CoA-derivatives of greater aliphaticity.
These observations indicate that a mutation-mediated decrease in substrate binding
energy could be accountable for the enhanced affinity measured for the hydrophobic
CoA-derivatives, instead of a direct mechanistic linkage between these residues and the
site of bond cleavage. Certainly, the conserved amino acid duo (R85 and T430) are at
some distance from the PLP-binding site, and therefore the coupling of substrate binding
to di-α-carbon cleavage in the active site presumably involves coordinated movement of
the enzyme upon acyl-CoA binding. However, further experiments to prove this await
the development of tractable fluorescent probes and the elucidation of three-dimensional
crystal structures with CoA-derivatives bound.
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Chapter Four

Hyperactive enzyme variants engineered by synthetically shuffling a loop motif in
murine 5-aminolevulinate synthase
Abstract

The regulatory step of the heme biosynthetic pathway in mammals is catalyzed by
the pyridoxal 5'-phosphate-dependent enzyme, 5-aminolevulinate synthase (EC 2.3.1.37).
Aminolevulinate is biosynthesized by condensing succinyl-CoA and glycine to yield
coenzyme-A and carbon dioxide. A conserved active site lid was shown to change
conformation 3.5 Å between the holoenzymic form and succinyl-CoA-bound forms of

Rhodobacter capsulatus ALAS. We employed synthetic shuffling and pre- and steadystate kinetic analyses to determine the role of the lid motif in the ALAS-catalyzed
reaction. Functional variants containing mutations to residues that comprise the lid
(Y422-R439) were isolated based on genetic complementation in Escherichia coli strain
HU227 and fluorescence microscopy. All of the positive isolates showed a spectrum of
amino acid substitutions, a finding which validates our screening method. Each of the lid
variants examined showed increases in kcat and catalytic efficiency with both substrates,
observations which support a crucial role for the active site lid in product turnover. The
single turnover reaction data for the shuffled variants reveal that this lid has an important
role quinonoid intermediate decay and product release.
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Energetically favorable

thermodynamic activation parameters for a library isolate also suggest that the entire
active site lid is involved in stabilizing the reaction coordinate. Overall, our data support
a hypothesis whereby the lid closes over the active site during catalysis; once chemistry
has taken place, lid dynamics determine the rate of product release.
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Introduction

Aminolevulinate (ALA) is the universal building block of tetrapyrolle
biosynthesis (1). In eucaryotes and the α-subclass of purple bacteria the production of
ALA is catalyzed by 5-aminolevulinate synthase (ALAS) (EC 2.3.1.37) (2). ALAS is
classified as a fold-type I pyridoxal 5’- phosphate (PLP)-dependent enzyme, and like the
evolutionarily related transaminases (3) functions as a homodimer, with a PLP cofactor
bound at each of the two active sites, which occur in clefts at the subunit interface (4).
The reaction catalyzed by ALAS is the Claisen-like condensation of succinyl-CoenzymeA (CoA) and glycine to yield CoA, carbon dioxide (CO2) and ALA. This reaction type,
coupled with the structural information about the protein, include it as a member of the αoxoamine synthase subfamily of PLP-dependent enzymes; a family which includes 7amino-8-oxononanoate synthase (AONS) (5). Genetic defects in the gene corresponding
to the erythroid specific isoform of the enzyme are associated with a congenital disorder,
X-linked sideroblastic anemia (XLSA) (6).
X-ray crystal structures of ALAS and AONS reveal that they share similar active
site geometry and proximal active site motifs (7, 8). Whereas the three dimensional
structure of ALAS contains the substrate succinyl-CoA, the AONS structure was cocrystallized with the product 7-amino-8-oxononanoate (AON).

In both cases, each

enzyme has an active site lid, comprised of amino acids which stretch from one hinge of
the lid to other, with the apex of the lid coordinating the carboxylate group of the ligand.
Comparison of holoenzymic ALAS and AONS, with the substrate and product bound
forms of the enzymes indicate that binding of these ligands within the active site
precipitates active site lid dynamics that may signify a change in conformation. The
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active site lid of ALAS contains 18 residues; 8 of these are completely conserved, while
10 vary considerably according to nature. One corresponding residue in murine erythroid
ALAS (mALAS2) that is positioned at the apex of the lid, T430, generates pathological
affects associated with XLSA when mutated in humans (9). This residue appears crucial
for catalysis and may be an important determinant of substrate specificity (Lendrihas et.

al, in press) (7). Two β-sheets flank the position of the lid (β12 and β13) in the Cterminal domain of the enzyme, where further interactions between the carboxy terminal
portion of the lid occur between two α-helices on the adjacent subunit (α2 and α3).
While evidence is available for the role of discrete active site residues in ALASfunction, no studies have been carried out on the role of the active site lid that surrounds
the site of catalysis and interacts with the acyl-CoA substrate (10-12). One glycine-rich
loop identified in mALAS2 formed by residues 142-154, sandwiched between α3 and α4
was proposed to be involved in cofactor binding (13). Several residues of this sequence
(G142, G144 and R149) did not tolerate mutation (13). However, mutations to residues
N150 and I151 in the same study generated variants with turnover numbers greater than
that of wild-type ALAS. Further, this loop is implicated in succinyl-CoA binding, and
based on the position of these residues deep within the three dimensional structure,
mutations are likely to acutely disrupt the mobility of the motif (7).
The importance of the active site lid in the condensation mechanism of an acylCoA substrate and amino acid donor was first identified in AONS (8). According to the
X-ray crystal structures the β-sheet of the C-terminal domain undergoes a conformational
transition. This conformational change includes the 5.5 Å displacement of the active site
lid. From the ALAS crystal structure with succinyl-CoA bound the change in position of
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the outermost top of the lid moves inward by 3.5 Å when compared to the position of the
lid in the holoenzymic form (Figure 4.1) (7). Accordingly, the poor electron density
evidenced in the corresponding AONS motif coupled with the non-covalent interactions
identified between the lid and the residues that comprise the active site indicate that these
active site lids are probably disordered during unliganded conditions, a circumstance
likely reversed in the presence of substrate or product.
In order to examine the role of the active site lid in the ALAS-catalyzed reaction,
we used synthetic shuffling to identify functional amino acid mutations and to evaluate
the contribution of lid residues to catalysis. The reported analysis of the catalytic role of
the active site lid in the mechanism of ALA production suggests that the ALAS chemical
mechanism may have evolved so as to be limited by a conformational change. The lid
presumably closes over the active site during catalysis, thereby facilitating enzymemediated chemistry. Once chemistry occurs, the dynamics of the active site lid determine
the rate of product release.
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Figure 4.1. The position of the active site loop in the R. capsulatus ALAS crystal
structure. In (A), the overlap of one monomer of holoenzymic (magenta) and succinyl-

CoA-bound (green) ALAS from R. capsulatus. In (B) the active site lid in the closed
position (teal) is perched above the catalytic cleft of the enzyme. Succinyl-CoA and the
co-factor PLP are shown as sticks. The image was constructed using Pymol and PDB
entries 2BWN and 2BWO.

A

B

The primary amino acid sequence of the lid is
+
NH3—YVQAINYPTVPRGEELLR—COO-
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Materials

Reagents.

DEAE-Sephacel, -mercaptoethanol, PLP, bovine serum albumin,

succinyl-CoA, ALA-hydrochloride, -keto-glutarate, -ketoglutarate dehydrogenase,
Bis-Tris, HEPES-free acid, MOPS, thiamin pyrophosphate, NAD+, and the bicinchoninic
acid protein determination kit were purchased from Sigma-Aldrich Chemical Company.
Ultrogel AcA 44 was from IBF Biotechnics.

Glycerol, glycine, disodium

ethylenediamine tetraacetic acid dihydrate, ammonium sulfate, ascorbic acid and
magnesium chloride hexahydrate were acquired from Fisher Scientific. Sodium dodecyl
sulfate polyacrylamide gel electrophoresis reagents were acquired from Bio-Rad. PD-10
columns were from Amersham Biosciences. Restriction enzymes and polymerases were
from New England Biolabs. Synthetic oligonucleotides were obtained from Integrated
DNA Technologies.
Methods

Construction of the ALAS synthetic shuffled library. The design and experimental
approach for construction of the synthetic shuffled library was based on previously
described methods (14-16). Codons for 10 of the 18-amino acid loop were targeted for
mutagenesis using synthetic shuffling, so that multiple amino acid variations could be
introduced in these 10 positions (Table 4.1).

The ALAS active site loop-encoding

fragment was reconstituted from partially overlapping oligonucleotides using PCR, with
each of the codons for the 10 positions harboring, in addition to the wild-type amino acid,
alternative amino acids encoded by nucleotide degeneracies (Table 4.1). Following the
assembly by PCR, the reaction product was amplified with another round of PCR having
as primers oligonucleotides which annealed against the 5’ and 3’ ends of the generated
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Table 4.1. Designed mutations for incorporation at indicated positions within the ALAS active site loop1.
Position

WT

V

V

V

V

V

V

V

V

V

V

V

V

1

2

3

4

5

6

7

8

9

10

11

12

423

V2

L1

I2

M1

425

A2

S2

P2

G2

R2

W1

C1

428

Y2

F2

H2

S2

C2

I2

L2

N2

R2

432

P3

A3

G3

T3

D2

S2

H2

N2

R1

E1

K1

433

R6

V4

G4

L4

I3

S2

K2

D2

E2

H2

N2

434

G2

K1

D1

E1

N1

R1

S1

435

E1

R4

T3

A3

G3

P3

D2

436

E1

L1

Q1

V1

437

L3

R5

L3

K2

438

L3

F1

Codon

(M/G)TK
(M/G)SS
(M/T)(A/K)Y
(M/G)(M/G)(S/T)
Q2

M1

(M/G)(A/K)N
RRW

S2

H2

N2

Q1

K1

(M/G)(M/G)(S/T)
SWG

I2

Q2

M1

H1

N1

S1

M(R/T)(M/G)
YTK

1

WT denotes amino acid found in mALAS2 active site loop, while V refers to variants encoded within the library. Bold amino acids indicate amino
acids that are found in ALASs from different species. Codon indicates the nucleotide codon used to obtain the indicated mixture of amino acid residues.
Subscripts following amino acid designations are the number of different codons for that amino acid. Nucleotide degeneracies are represented in the
IUB code: Y, C/T; M, A/C; K, G/T; R, G/A; S, C/G; W, A/T; N, A/C/G/T.
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PCR product and covered the sequence for restriction enzyme sites used in subsequent
subcloning (i.e., Xba I and Bam HI). To minimize the wild-type ALAS “background”
during the screening of the library for functional ALAS variants, the synthetic shuffling
library was subcloned into a mock ALAS expression vector. The mock vector contained
the wild-type ALAS-encoding sequence from the pGF23 expression plasmid (17), with
the exception of the region encoding the active site loop and flanked by the Xba I and

Bam HI restriction enzyme sites, which was replaced with a non-ALAS related sequence.
The primers, conditions for the annealing reaction and PCR, and mock vector used in this
study are described in supplemental experimental procedures. The ligation reactions and
DNA digestions with restriction endonucleases were according to standard protocols in
molecular biology (18).

Screening of the ALAS synthetic shuffled library and isolation of functional
ALAS variants. Library screening and selection of functional variants was accomplished
by reversing the phenotype of E. coli hemA- (HU227) (19, 20). HemA- cells can only
survive if harboring a functional ALAS or when ALA (or hemin) is added to the medium

(20). Electrocompetent E. coli HU227 cells were transformed with the library and plated
onto LB/ampicillin medium without ALA to allow selection of the active ALAS variants
as previously described (19) (Figure 4.2).

To score the total number of colonies

produced and assess transformation efficiency, one-tenth of each transformation reaction
was spread onto LB/ampicillin plates containing 10 g/ml ALA. Functional ALAS
clones (i.e., isolated from the ALA minus plates) were then picked and plated onto
defined MOPS medium to induce protein overexpression (17) and screened for porphyrin
overproduction using fluorescence microscopy. Briefly, the plates with the functional
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ALA auxotrophic
E. coli strain
Transformation
of expression
hemA
bacterium
plasmids

LB agar+ ALA

Selection

Library of synthetically
shuffled variants

LB agar-- ALA

Ligation of PCR
product

Functional variants subjected
to fluorescence microscopy

PCR

PCR

Annealing &
fill-in

Single colony isolation and
sequencing of plasmid DNA
N

C

Figure 4.2. The generation and screening of the library. A library of over 330,000

possible ALAS variants was constructed with PCR using a series of degenerate mixed
base oligonucleotides. The PCR product was ligated into an expression vector. The
resulting plasmids were transformed into Escherichia coli strain HU227 and plated on LB
+ ampicillin agar with and without ALA. The colonies that grew in the absence of ALA
were identified as functional variants. Functional variants were screened for porphyrin
overproduction by fluorescence microscopy.
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ALAS clones were examined with a Nikon Eclipse E1000 fluorescence
microscope (Nikon, Tokyo) fitted with either a Nikon Triple Band filter set for excitation
at 385-400 nm and emission at 450-465 nm for 4′,6-diamidino-2-phenylindole (DAPI)
detection or a Nikon Cube BV2A excitation filter set for excitation at 400–440 nm and
emission at 450-465 nm with a 610 nm long pass filter and a band pass filter at 550 nm ±
20 nm for porphyrin detection. Photographs were taken with a CCIR high performance
COHU CCD camera and the images were processed with Image software Genus 2.81
from Applied Imaging. The level of porphyrin accumulated in the functional ALAS
clones was compared to that of bacterial cells harboring wild-type ALAS and grown
under the same experimental conditions (Figure 4.3). Bacterial cells harboring ALAS
variants, which accumulated greater porphyrin levels than bacterial cells with wild-type
ALAS, were grown in LB/ampicillin medium in 96-well plates, and the glycerol stocks
generated from overnight cultures were submitted to the ICBR Genomics Core at the
University of Florida for DNA sequencing of the corresponding plasmids.

Overexpression, purification and spectroscopic analyses of ALAS active site loop
variants. Overexpression was from the alkaline phosphatase (phoA) promoter, and the
conditions for promoter induction were as previously described for mALAS2 (17).
However, induction of the phoA promoter controlling the expression of the F1, SS2, F10
and H1 variants was accomplished by growing the bacterial cells harboring the
expression plasmids for these variants in MOPS, a low phosphate concentration and
defined medium (17), supplemented with 10mg/L ascorbic acid for 30 hours at 20oC.
Purification, storage, handling, and spectroscopic analysis of the mALAS2 variants were
conducted as described previously (21). Protein concentrations were determined by the
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Figure 4.3.

Differential fluorescence of ALAS variant isolates streaked on

expression agar. 1. DAPI visualized cells containing: K313A (negative control) (A),

wild-type ALAS (B), hyperactive variant SS2 (C).
fluorescence containing:

2.

Cells visualized for red

K313A (negative control) (A), wild-type ALAS (B),

hyperactive variant SS2 (C). 3. Overlay of DAPI and red fluorescence visualized cells:
K313A (negative control) (A), wild-type ALAS (B), hyperactive variant SS2 (C).
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bicinchoninic acid method using bovine serum albumin as the standard (17). Reported
enzyme concentrations are based on the monomeric molecular mass of 56 kDa (17).
Protein purity was assessed using SDS-PAGE.

Steady-state and pre-steady-state kinetic characterization of ALAS active site loop
variants.

ALAS steady-state activity of the ALAS active site loop variants was

determined at 20°C using a continuous spectrophotometric assay as described previously
for wild-type ALAS (22). The ALAS activity data, acquired using a Shimadzu UV 2100
dual-beam spectrophotometer, were plotted vs. substrate concentration in which one of
the substrate concentrations varied, while the second was kept constant. The steady-state
kinetic parameters were determined by fitting the data to the Michaelis-Menten equation
using non-linear regression analysis software as reported in (10). The ALAS steady-state
kinetic parameters of wild-type ALAS and the SS2 variant activity assays were also
determined at 15, 25, 30 and 35 ºC.
Rapid scanning stopped-flow measurements were performed using a model RSM100 stopped-flow spectrophotometer (OLIS, Inc.). This instrument has a dead-time of
approximately 2-ms and an observation chamber path length of 4 mm. Spectral scans
covering a wavelength range of 300-510 nm were collected at a rate of 1000 scans/s and
then averaged to 62 scans/s to reduce the data files to an appropriate size for global fit
analyses. The temperature of the syringes and the stopped-flow cell compartment was
maintained at 20oC by an external water bath. Pre-steady-state kinetic reactions of the
variant enzymes were examined under single turnover conditions, using final
concentrations of 60 μM enzyme, 120 mM glycine and 10 μM succinyl-CoA in 100 mM
HEPES, pH 7.5 and 10% (v/v) glycerol as previously described (23). Single turnover
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data were evaluated using either a three-kinetic-step, or a two-step kinetic mechanism as
described by Equations 4.1 and 4.2, respectively (23).

(Equation 4.1)
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k

(Equation 4.2)
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Observed rate constants were determined by Robust Global Fitting of the spectral data
using the single value decomposition software provided by OLIS, Inc. as previously
reported (21, 23). Quality of the calculated fits was judged by analysis of the calculated
residuals, and the simplest mechanism that described the experimental data was used.

Determination of the dissociation constants for the binding of glycine and ALA.
The equilibrium dissociation constant (KD) for the binding of glycine to the SS2 variant
was determined in 20 mM HEPES (pH 7.5) and 10% glycerol at 20oC and by titrating the
SS2 variant (60 μM) with increasing concentrations of glycine (0.6 mM-60 mM) and
monitoring the increase in absorbance at 420 nm upon formation of the external aldimine
between PLP and glycine (10). The KD value was determined by fitting the data to
Equation 4.3, where Y is the absorbance increase at 420 nm, Ymax is the maximum
increase in absorbance, and [Ligand] is the glycine concentration, using non-linear
regression analysis software.

(Equation 4.3)
Y 

Ymax [ Ligand ]
K D  [ Ligand ]
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Binding of ALA to the SS2 variant resulted in quenching of the fluorescence emission at
428 nm upon excitation at 330 nm due to formation of an external aldimine with the PLPcofactor. Thus to determine the dissociation constant for the binding of ALA to SS2, the
change in fluorescence emission at 428 nm (exc = 330 nm) was monitored upon titration
of SS2 (60 μM) with increasing concentrations of ALA (0.5 mM-128 mM). The changes
in fluorescence at 428 nm were plotted as a function of ALA concentration, and the KD
value was determined by fitting the data to Equation 4.3, using non-linear regression
analysis software.

In Equation 4.3, Y is the total change in fluorescence at 428 nm,

Ymax is the initial fluorescence, and [Ligand] is the ALA concentration.
Determination of the thermodynamic activation parameters. The temperature
dependence of the steady-state kinetic parameters of wild-type ALAS and the SS2 variant
were examined using the same experimental conditions as described above and covering
the temperature range of 15-35 C. The natural log the calculated values for the turnover
numbers (lnkcat) were plotted vs. the inverse of temperature and the data were fit to the
Arrhenius equation (Equation 4.4).

(Equation 4.4)
ln(k obs ) 

 Ea 1
 ln( A)
R T

where Ea is the activation energy, R is the universal gas constant, T is the absolute
temperature, and A is the frequency factor. The determined activation energies were then
used to calculate the thermodynamic activation parameters, ΔH, ΔG and ΔS, as
previously described (23).
Data analysis for the definition of the minimal kinetic mechanism of a selected
ALAS active site loop variant. The KinTekSim kinetic simulation software (24) was used
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to model the single wavelength kinetic traces at 510 nm for the reaction catalyzed by the
SS2 variant and thus estimate the forward and reverse rate constants. The interior rate
constants were allowed to float, while the previously determined KD values for binding of
glycine and ALA to the SS2 variant and wild-type ALAS were maintained constant (21).
Results

Construction of the synthetically shuffled library and screening of functional
ALAS variants. To the extent that the conserved active site lid in mALAS2 may limit
catalysis, synthetic shuffling was used to evaluate the contribution of amino acids that
comprise the lid make to motif dynamics and enzyme turnover. If all 18 amino acid
residues on the active site lid were mutated to all possible substitutions, there would be a
total of 1820 possibilities, an intractable number of combinations for our experimental
approach. Therefore, instead of a random mutagenesis approach, the number of potential
mutations at a single position was limited by utilizing mixed base oligonucleotides that
encode specific changes to the cDNA. Mixed base oligonucleotide primers encoding
amino acids that have a precedent in nature were incorporated into the primary sequence
of wild-type ALAS, from Y422-R439 (Table 4.1).

A multiple sequence alignment

quantifying the naturally occurring amino acid diversity present at specific positions in
the lid was performed (Figure 4.4). These ALAS sequences were incorporated into the
library. To preserve the functional integrity of ALAS, we always included the wild-type
nucleotides in the primers.

Further, the conserved residues of the active site lid were not

mutated; an additional consideration employed to reduce the possibility of recovering
inactive variants. Screening of the synthetically shuffled library included a two-pronged
approach (Figure 4.2). First, E. coli strain HU227 need aminolevulinate to thrive (25);
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mutants transformed into this strain are able to provide the depleted metabolite required
for colony formation on agar plates lacking ALA. Next, to elucidate which variants are
catalyzing the production of ALA at a rate faster than wild-type ALAS, the appearance of
fluorescence associated with excess porphyrin biosynthesis was used (Figure 4.3).
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Figure 4.4. Multiple alignment of the amino acid sequences of the ALAS loop region.
Active Site Loop
Y422...............R439
1 ALAS_DELLEU
FELMSEWERSYFGNM
2 ALAS_DLLLEU
FELMSEWERSYFGNM
3 ALAS_HOMSAP
FELMSEWERSYFGNM
4 ALAS_RATNOR
FELMSEWERSYFGNM
5 ALAS_RATRAT
FELMSEWERSYFGNM
6 ALAS_MUSMUS
FELMSEWERSYFGNM
7 ALAS_DANRER
FDLMSEWEKSYFGNM
8 ALAS_DANROS
FDLMSEWEKSYFGNM
9 ALAS_OPSTAU
FDLMSEWEKSYFGNM
10 ALAS_HOMSPN
FEVMSEREKSYFSGL
11 ALAS_DELDEL
FEVMSEREKSYFFGM
12 ALAS_MOUDOM
FEVMSEREKAYFSGM
13 ALAS_GALVAR
FEVMSERERSYFSGM
14 ALAS_XENLAE
-344
15 ALAS_OPSBET
FEVMNEREKSYFSGL
16 ALAS_OPSPAR
FEVMNEREKSYFSGL
17 ALAS_DANDAN
FEIMSEREKSYFSGL
18 ALAS_MYXGLU
FELMSEHDQVYFDGM
19 ALAS_STRDRO
FEELSSRERSFAEES
20 ALAS_DROMEL
WHQDTSPDLECGIPN

486

LLLSKHGIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMEDFVE KLLAAWTEVGLPLQD -VSIAACNFCRRPVH

486

LLLSKHGIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMEDFVE KLLAAWTEVGLPLQD -VSIAACNFCRRPVH

491

LLLSKHGIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMEDFVE KLLLAWTAVGLPLQD -VSVAACNFCRRPVH

491

LLLAKHSIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMENFVE KLLLAWTEVGLPLQD -VSVAACNFCRRPVH

491

LLLAKHSIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMENFVE KLLLAWTEVGLPLQD -VSVAACNFCRRPVH

491

LLLSKHSIYVQAINY PTVPRG-EELLRLAP SPHH-SPQMMENFVE KLLLAWTEVGLPLQD -VSVAACNFCHRPVH

486

ILLEKHNIYVQAINY PTVPRG-EELLRLAP SPFH-NPIMMNYFAE KLLDVWQEVGLPLNG -PAQASCTFCDRPLH

486

ILLEKHNIYVQAINY PTVPRG-EELLRLAP SPFH-NPIMMNYFAE KLLDVWQEVGLPLNG -PAQASCTFCDRPLH

486

SLLEKHNIYVQAINY PTVPRG-QELLRLAP SPHH-HPAMMEYFVD KLVEVWQEAGLLLNG -PATVSCTFCDRPLH

545

ELMSRHNIYVQAINY PTVPRG-EELLRIAP TPHH-TPQMMNYFLE NLLVTWKQVGLELKP -HSSAECNFCRRPLH

545

ELMSRHNIYVQAINY PTVRRG-EELLRIAP TPHH-TPQMMNYFVE NLLATWKRVGLELKP -HSSAECNFCRRPLH

546

ELMTRHNIYVQAINY PTVPRG-EELLRIAP TPHH-TPQMMNFFVE KLLVTWKRVGLELKP -HSSAECNFCRRPLH

540

KLMSQHSIYVQAINY PTVPRG-EELLRIAP TPHH-TPQMMSYFLE KLLATWKDVGLELKP -HSSAECNFCRRPLH

308

KLMRDYSIYVQAINY PTVPRG-EELLRIAP TPHH-NPQ------- --------------- --------------- -------------

532

LMMSHHNIYVQAINY PTVARG-DELLRIAP TPHH-TPEMMKYFVD RLVQTWKEVGLELKP -HSSAECTFCQQPLH

532

LMMSHHNIYVQAINY PTVARG-DELLRIAP TPHH-TPEMMKYFVD RLVQTWKEVGLELKP -HSSAECTFCQQPLH

518

IMMSRYNIYVQAINY PTVARG-EELLRIAP TPHH-TPQMMKYFVD KLTQTWTEVGLPLKP -HSSAECNFCRQPLH

565

ELMSRHNIYVQAINY PTVPRG-EEMLRVVV TPHH-TPQMMQYFVE HLTNSWKDIGLNLRP -HASAECNYCKMPIH

512

SLLEEHNIYVQAINS PTVPSG-EEKLRIAP SPXH-TPDMMDRFVA SLSEVWAKSGLRFNT PICPRECEFCKNPEK

463

VLIEQFGHYLQSINY PTVARG-QEKLRLAP TPFH-TFEMMNALVT DLKKVWEMVDLSTNV PLSPNACMFCNSESC

573
573
578
578
578
578
573
573
573
632
632
633
627

619
619
605
652
578
529
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21 ALAS_LIMPOL
560
22 ALAS_SEPOFF
603
23 ALAS_GLYDIB
586
24 ALAS_GALGAL
508
25 ALAS_SINMEL
405
26 ALAS_SMRMEL
334
27 ALAS_AGRTUM
423
28 ALAS_AGRRAD
405
29 ALAS_RHIRAD
335
30 ALAS_RHOPSE
403
31 ALAS_RHOPSE
407
32 ALAS_EUGGRA
409
33 ALAS_BRAJAP
409
34 ALAS_BRAJAP
339
35 ALAS_BRUMEL
425
36 ALAS_ZYMMOB
345
37 ALAS_RHOCAP
401
38 ALAS_RHOCAP
331
39 ALAS_PARDEN
339
40 ALAS_PARZEA
409
41 ALAS_RHOPSE
407
42 ALAS_EMENID
598

494

ELISMHGHYVQAINY PTVPRG-EEKLRIAP TPFH-TRPMMEAFVR DLVSVWRGLKLPLRD GICEKKCEFCEKPLY FEHLESRVL----

540

DLLIKHNIYVQAINY PTVARG-EEKLRVAA TPHH-TKEMMDHFVD CVVKVWLEHGLTLNP -DSTRPAEFNVKFKK FSI----------

516

ELMEEHGIYVQPINY PTVPRG-QELLRVAP TPHH-TKEMMDSFVN ATLSVFLNNNIELKS -TCGINCLYCHQPMK CEAFTNRER----

420

ALLEEHGLYVQAINH PTVPRGQELLLRIAP TPHH-SPPMLENLAD KLSECWGAVGLPRED -PPGPSCSSCHRPLH LSLLSPLER----

346

LLLDNFGIYVQPINY PTVPKK-TERLRITP TPMH-SDADIDHLVS ALHSLWSRCALARAV A-------------- -------------

275

LLLDNFGIYVQPINY PTVPKK-TERLRITP TPMH-SDADIDHLVS ALHSLWSRCALARAV A-------------- -------------

364

ILLDNHGVYVQPINY PTVPRK-TERLRITP TPLH-TDADIEQLVG ALHQLWSHCALARAV A-------------- -------------

346

ILLDSHGVYVQPINY PTVPRK-TERLRITP TPLH-SDADIEHLVG ALHQLWSHCALARAV A-------------- -------------

276

ILLDSHGVYVQPINY PTVPRK-TERLRITP TPLH-SDADIEHLVG ALHQLWSHCALARAV A-------------- -------------

344

ELINRYGIYVQPINY PTVPRG-TERLRITP SPQH-TDADIEHLVQ ALSEIWARVGLAKAA --------------- -------------

346

ALLARHAIYVQPINY PTVARG-QERFRLTP TPFH-TTSHMEALVE ALLAVGRDLGWAMSR RAA------------ -------------

343

LLLKRFQIYVQPINY PTVDVG-TERLRITV SPVH-TNEHMATLIT ALLQVWEELGLPLRP PVFDTEGYPEVEAAE WLPNSAMWR----

348

LLLEEHGIYIQPINY PTVAKG-SERLRITP SPYH-DDGLIDQLAE ALLQVWDRLGLPLKQ KSLAAE--------- -------------

275

LLLEEHGIYIQPINY PTVAKG-SERLRITP SPYH-DDGLIDQLAE ALLQVWDRLGLPLKQ KSLAAE--------- -------------

345

RLLEVHGIYIQPINY PTVPRG-TERLRITP SPLH-DDKLIDGLKD ALLEVWNELGIPFAE PSAPQAANSDRIIPL MVSKAGG------

287

ILLNEYGAYVQPINF PTVPRG-TERLRFTP GPTH-NEAMLRELTD SLVAIWHRLDMRFAA --------------- -------------

348

MLLSDYGVYVQPINF PTVPRG-TERLRFTP SPVH-DLKQIDGLVH AMDLLWARCA----- --------------- -------------

278

MLLSDYGVYVQPINF PTVPRG-TERLRFTP SPVH-DLKQIDGLVH AMDLLWARCA----- --------------- -------------

292

MLLADFSIYVQPINF PTVPRG-TERLRFTA SPVH-DPKQIDHLVK AMDSLWSQCKLNRST SAA------------ -------------

360

MLLADFSIYVQPINF PTVPRG-TERLRFTA SPVH-DPKQIDHLVK AMDSLWSQCKLNRST SAA------------ -------------

364

MLLIHFGIYVQPINF PTVPRG-TERLRFTP SPVH-DSGMIDHLVK AMDVLWQHCALNRAE VVA------------ -------------

510

KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-TQELRDHLVE AVNTVWNDLGIKRAS DWKAMGGFVGVGVEA AELENQPIWT---
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43 ALAS_EMENID
AELENQPIWTDAQLN
528
44 ALAS_ASPNID
AELENQPIWTDAQLN
528
45 ALAS_ASPORI
AEAENQPIWNDVQLG
596
46 ALAS_NEUCRA
EPVAPLWTDEQLG
421
47 ALAS_GIBFUJ
NVQEPLWTDKQLN
479
48 ALAS_YARLIP
VEPLWSEEQLS
489
49 ALAS_CANALB
AAKVEHIWTEEQLA
538
50 ALAS_CANALB
AAKVEHIWTEEQLA
468
51 ALAS_DEBHAN
IEPIEHIWTSEQLA
479
52 ALAS_SACCER
FVEESNLWTSSQLS
522
53 ALAS_SACCAS
FVEESNLWTSSQLS
452
54 ALAS_CANGLA
FVPEPNLWTEEQLS
434
55 ALAS_KLULAC
HVPQPNLWTKDQLT
474
56 ALAS_EREGOS
YVPEANLWTEEQMS
460
57 ALAS_AGABIS
AADDVQPIWTDEQIG
548
58 ALAS_AGADIV
AADDVQPIWTDEQIG
478
59 ALAS_SCHPOM
-558
60 ALAS_SCHMIK
-488
61 ALAS_RICPRO
-414
62 ALAS_RICTYP
-414
63 ALAS_RICPRO
-344
64 ALAS_RICCON
-426
65 ALAS_CHRVIO
--

440

KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-TQELRDHLVE AVNTVWNDLGIKRAS DWKAMGGFVGVGVEA

440

KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-TQELRDHLVE AVNTVWNDLGIKRAS DWKAMGGFVGVGVEA

508

KLLEEHGIYVQAINY PTVPRG-EERLRITP TPGH-IKEHRDHLVQ AVQTVWNELGIKRTS DWEAQGGFVGVGVDG

334

KLLNDHQIYVQSINY PTVPVG-QERLRITP TPGH-TKQFRDHLVA ALDSIWTELGIKRTS DWAAEGGFIGVGEAE A-

393

MLLNDYGIYVQAINY PTVPVG-QERLRVTP TPGH-IKEYRDQLVE AIDEIWTRLDIKRTS DWAAEGGFIGVGEQD --

404

LLLTKHQIYVQAINF PTVPIG-QERLRVTP TPGH-HEGLCDELVA ALEDVWQELDLKRVE DWTAEGGLCGVGEGV --E-

451

LLLNKHDIYVQAINF PTVPIG-EERLRITP TPGH-GPELSKQLVE AVDSVFTELNLNRIN DWKKLGGLVGVGVEG -

381

LLLNKHDIYVQAINF PTVPIG-EERLRITP TPGH-GPELSKQLVE AVDSVFTELNLNRIN DWKKLGGLVGVGVEG -

392

LLLDKYNIYVQAINF PTVPIG-QERLRITP TPGH-GPELSNQLIG ALDSVFNELSLSRIG DWEGKGGLCGVGEPD -

435

ILINKHQIYVQAINF PTVARG-TERLRITP TPGH-TNDLSDILIN AVDDVFNELQLPRVR DWESQGGLLGVGESG -

365

ILINKHQIYVQAINF PTVARG-TERLRITP TPGH-TNDLSDILIN AVDDVFNELQLPRVR DWESQGGLLGVGESG -

347

ILMEKHRIYVQAINF PTVSRG-TERLRITP TPGH-TNDLSDILIA AVDDVFNELQLPRIR DWEMQGGLLGVGDKN -

387

ILMDKHRIYVQAINF PTVARG-TERLRITP TPGH-TNDLSDILMD ALEDVWSTLQLPRVR DWEAQGGLLGVGDPN -

373

ILMEKHRIYVQAINF PTVPRG-TERLRITP TPGH-TNDLSDVLLD AMDDVWKTLQLPRVS DWAAHGGLLGVGEPD -

460

KLLSEHDIYVQAINY PTVARG-EERLRITV TPRH-TMEQMEGLIR SLNQVFEELNINRLS DWKLAGGRAGVGIPG

390

KLLSEHDIYVQAINY PTVARG-EERLRITV TPRH-TMEQMEGLIR SLNQVFEELNINRLS DWKLAGGRAGVGIPG

475

SLLHDHNIYVQSINF PTVSVG-TERLRITP TPAHNTEHYVQSLTN AMNDVWSKFNINRID GWEKRGIDVGRLCKF PVLPFTTTH----

405

SLLHDHNIYVQSINF PTVSVG-TERLRITP TPAHNTEHYVQSLTN AMNDVWSKFNINRID GWEKRGIDVGRLCKF PVLPFTTTH----

342

MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLST ALVHIFDELDIELSS AKELNKEVRLHLIA- -------------

342

MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLST ALVHIFAELDIELSS TKELNKEVRLHLIA- -------------

272

MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLST ALVHIFDELDIELSS AKELNKEVRLHLIA- -------------

354

MLLNEYGIYVQHINF PTVPRG-TERLRIIP TPAH-TDKMINDLSV ALVQIFAELDIELSS AKELNEEVRLNLIA- -------------

354

RLLEEFDIYVQPINY PSVPRG-GERFRLTV GPRR-SHEEIQRFVA ALKHCLA-------- --------------- -------------
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Figure 4.4. Multiple alignment of the amino acid sequences of the ALAS loop region. The amino acid sequences were
obtained from public databases (NCBI) using a BLAST search and aligned using CLUSTAL W (1). The 10 positions within
the 18-amino acid sequence targeted for synthetic shuffling are high-lighted in cyan. The amino acid numbering in red refers
to that of murine erythroid ALAS (mALAS2).
Represented proteins are: ALAS_DELLEU: Delphinapterus leucas ALAS (20138447); ALAS_DLLLEU: Delphinapterus leucas cook inlet subspecies
2 (5281116); ALAS_HOMSAP, Homo sapiens ALAS erythroid (4557299); ALAS_RATNOR, Rattus norvegicus erythroid ALAS (51980582);
ALAS_RATRAT, Rattus rattus erythroid ALAS (6978485); ALAS2_MUSMUS, Mus musculus erythroid ALAS (33859502); ALAS_DANRER, Danio
rerio ALAS (18858263); ALAS_DANROS, Danio roseus ALAS (20138448); ALAS_OPSTAU, Opsanus tau ALAS (1170202); ALAS_ORYLAT,
Oryzias latipes ALAS (49022596); ALAS_HOMSPN, Homo sapiens erythroid ALAS (4502025); ALAS_DELDEL, Delphinus delphis erythroid ALAS
(20138445); ALAS_MOUDOM, Mus musculus domesticus erythroid ALAS (23956102); ALAS_GALVAR, Gallus varius erythroid ALAS (122821);
ALAS_XENLAE, Xenopus laevis erythroid ALAS (44968228); ALAS_OPSBET, Opsanus beta ALAS (1170206); ALAS_OPSPAR, Opsanus pardus
ALAS (532630); ALAS_DANDAN, Danio danglia ALAS (32451642); ALAS2_MYXGLU, Myxine glutinosa erythroid ALAS (4433550);
ALAS1_BRALAN, Branchiostoma lanceolatum ALAS 1 (28630217); ALAS1_STRDRO, Strongylocentrotus droebachiensis ALAS 1 (4433548);
ALAS1_DROMEL, Drosophila melanogaster ALAS 1 (2330591); LAS1_LIMPOL, Limulus polyphemus ALAS 1 (4433540); ALAS1_SEPOFF, Sepia
officinalis ALAS 1 (4433546); ALAS2_GLYDIB, Glycera dibranchiate ALAS 2 (4433544); ALAS2_GALGAL, Gallus gallus gallus ALAS 2
(1170201); ALAS_SINMEL, Sinorhizobium meliloti 1021 ALAS (15966742); ALAS_SMRMEL, Sinorhizobium meliloti ALAS (18266808);
ALAS_AGRTUM, Agrobacterium tumefaciens ALAS (889869); ALAS_AGRRAD, Agrobacterium radiobacter ALAS (95069); ALAS_AGRTUM,
Agrobacterium tumefaciens ALAS (122818); ALAS_RHOPAL, Rhodopseudomonas palustris ALAS (4001678); ALAS_RHOSPO, Rhodobacter
sporagenes ALAS (541302); ALAS_EUGGRA, Euglena gracilis ALAS (12620813); ALAS_BRAELK, Bradyrhizobium elkanii ALAS (66534);
ALAS_BRAJAP, Bradyrhizobium japonicum ALAS (30179569); ALAS_BRUMEL, Brucella melitensis ALAS (25286547); ALAS_ZYMMOB,
Zymomonas mobilis ALAS (4511998); ALAS_RHOGLU, Rhodobacter gluconicum ALAS (97435); ALAS_RHOCAP, Rhodobacter capsulatus ALAS
(122828); ALAS_PARDEN, Paracoccus denitrificans ALAS (1170207); ALAS_PARZEA, Paracoccus zeaxanthinifaciens ALAS (537435);
ALAS_RHOSPH, Rhodobacter sphaeroides ALAS (541301); ALAS_EMENID, Emericella nidulans ALAS (418756); ALAS_EMCNID, Emericella
nidulans ALAS (585244); ALAS_ASPNID Aspergillus nidulans ALAS (40745239); ALAS_ASPORY, Aspergillus oryzae ALAS (5051989);
ALAS_NEUCRA, Neurospora crassa ALAS (52782908); ALAS_GIBFUJ, Gibberella fujikuroi ALAS (15721883); ALAS_YARLIP, Yarrowia
lipolytica ALAS (52782857); ALAS_CANBER, Candida berate ALAS (7493758); ALAS_CANALB, Candida albicans ALAS (10720014);
ALAS_DEBHAN, Debaryomyces hansenii ALAS (52782855); ALAS_SACCER, Saccharomyces cerevisiae ALAS (6320438); ALAS_SACCAS,
Saccharomyces castellii ALAS (122831); ALAS_CANGLA, Candida glabrata ALAS (52782865); ALAS_KLULAC, Kluyveromyces lactis ALAS
(52788271); ALAS_EREGOS, Eremothecium gossypii ALAS (52782894); ALAS_ASPBIS, Agaricus bisporus ALAS (1679599); ALAS_AGADIV,
Agaricus divoniensus ALAS (2492846); ALAS_SCHPOM, Schizosaccharomyces pombe ALAS (7492336); ALAS_SCHMIK, Schizosaccharomyces
mikatae ALAS (52782853); ALAS_RICCON, Rickettsia conorii ALAS (7433712); ALAS_RICTYP, Rickettsia typhi ALAS (51474008);
ALAS_RICPRO, Rickettsia prowazekii ALAS (6225494); ALAS_RICRIC, Rickettsia rickettsia ALAS (2528635); ALAS _CHRVIO,
Chromobacterium violaceum ALAS (34102112).
(1) Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Nucleic Acids Res. 22, 4673-4680
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Under these conditions, it was possible to isolate ALAS variants with turnover numbers
greater than that of wild-type ALAS. In panels (A1, B1 and C1) of Figure 4.3 cells are
visualized with a DAPI filter, which was used a means of assaying for single colony
isolates. The magnification for each image was identical, implying that colony size
differed between those cells harboring a hyperactive variant compared to wild-type and
the negative control (K313A) (26). This decrease is colonial diameter is likely due to
ALA toxicity (27).

The contrast between those cells harboring the inactive ALAS

(K313A) and those complemented with wild-type ALAS show clearly the lack of
porphyrin-derived red fluorescence in the negative control (Figure 4.3 Panels A2 and
B2). The dissimilarity in accumulated porphyrin levels between wild-type ALAS and the
SS2 variant is highlighted by the considerably greater red fluorescence present in the
library isolate compared to wild-type ALAS (Figure 2 Panels B3 and C3). In summary,
comparison of accumulated porphyrin levels present in cells as visualized by
fluorescence microscopy of bacterial colonies on expression agar proved a reliable
method for obtaining hyperactive isolates.
Qualitative analysis of the isolated active site lid variants. The mutations present
among the active site lid variants is shown in Table 4.2. Functional mutations were
detected at 9 of the 18 positions that comprise the lid. Based on our experimental design
it can be concluded that the mutation of Asn427 to His is most likely an artifact of the
primer design and PCR. Amino acid substitutions observed among the variants included
highly disruptive changes (e.g., A425P, P432E, L437K, E435K) as well as more
conservative variations (e.g., V423L, A425G, Y428H, R433K). This suggests that noncovalent forces including hydrogen bonding as well as Van der Waals and electrostatic
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Table 4.2. Amino acids substitutions in active site lid variants. Shuffled positions

are indicated in red.
Wild-type
ALAS
Single variants
A8
D8
G7
Quadruple
variant
F1
Penta variant
F10
Hexa variants
A4
F3
H1
Hepta variant
SS2

Y V Q A I N Y P T V P

R G E

E L

T
Q
H
K K Q

Q

Q N T

N

C
H
N

R K
N
H N K
N I E K

K
K

R

E I

K

I
I

L

P
G
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N Q

L R

interactions may be perturbed in the variants. Replacements at residues toward the
carboxy terminus of the lid, (P432-R439) favored conversion to basic amino acids, likely
positively charged at physiological pH, while residues that comprised the portion of the
lid proximal to the amino terminus (Y422-V431) showed less restriction toward which
amino acid was permissible. Several positions showed a propensity for a particular
substitution as demonstrated by the frequency of the observed mutation. At position 423,
valine was found substituted three times for leucine, indicating that hydrophobicity may
be a necessary characteristic at this position in the lid. Toward the C-terminal end of the
lid, E435 was found mutated twice to both glutamine and lysine, L437 was substituted for
lysine three times and glutamine twice. This indicates that the presence of positively
charged residues in this area of the lid may facilitate lid dynamics.
Steady-state kinetic analysis of the active site lid variants.

The steady-state

kinetic characterization of 9 variants from the library was carried out at 20oC (Table 4.3).
Compared to wild-type ALAS, all of enzymes had higher turnover numbers. The SS2
variant showed a kcat 16-fold higher than that of the wild-type enzyme. Similarly, the kcat
values for the quadruply, quintuply and hextuply mutated F1, F10 and H1 variants were
also markedly higher compared to wild-type ALAS. The remaining variants, including
the single point variants, also showed enhanced turnover, ranging from a 50% increase
observed in D8 to an 8-fold increased displayed by the A4 isolate. While the turnover
number data suggest that a single amino acid substitution is enough to increase enzyme
activity, it is the combination of amino acids substitutions toward the carboxy terminal
region of the lid that elicit the greatest increases in turnover number. As compared to that
of wild-type ALAS, the Michaelis constant for succinyl-CoA was notably different
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Table 4.3. Kinetic parameters for the reactions of hyperactive ALAS enzymes1
Steady-state parameters

Pre-steady-state
parameters
Gly

Qd1 3
s-1

Qd2 4
s-1

K mGly

K mSCoA

mM

μM

WT

0.02 ± 0.01

14 ± 2.0

11 ± 1.0

1.1x10-3

1.5x10-3

0.8

0.53

0.01

SS2

0.31 ± 0.06

12 ± 1.2

3.0 ± 0.3

0.02

0.10

16

1.7

N/A

A4

0.16 ± 0.01

14 ± 1.1

2.3 ± 0.4

0.01

0.07

7.1

1.7

0.07

F3

0.20 ± 0.01

13 ± 1.1

2.6 ± 0.4

0.02

0.08

7.7

1.1

0.17

H1

0.23 ± 0.14

13 ± 1.4

2.0 ± 0.3

0.02

0.11

10

1.5

N/A

F10

0.17 ± 0.01

16 ± 1.8

1.1 ± 0.7

0.01

0.16

3.7

0.98

0.15

F1

0.20 ± 0.02

16 ± 1.2

2.9 ± 0.4

0.01

0.07

4.0

1.1

N/A

A8

0.07 ± 0.01

25 ± 3.7

2.3 ± 0.4

2.5x10-3

0.03

4.8

0.81

0.12

D8

0.03 ± 0.01

24 ± 3.1

1.7 ± 0.7

1.3x10-3

2.0x10-3

5.4

0.44

0.02

G7

0.07 ± 0.01

15 ± 1.7

1.5 ± 0.1

4.4x10-3

0.05

4.4

0.87

0.12

kcat/ K m

mM-1 s-1

1

SCoA

Qf 2
s-1

kcat
s-1

Enzyme

kcat/ K m

μM-1 s-1

Enzymatic reactions monitored at 20 °C; 2Rate for quinonoid intermediate formation;
Rate for first step of quinonoid intermediate decay; 4Rate for second step of quinonoid
intermediate decay.

3
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among the active site lid variants. All of the variants showed at least a 3-fold reduction in
the K mSCoA .

Accordingly, due to the enhanced turnover evident among the multiply

mutated variants, the catalytic efficiency with respect to succinyl-CoA increased no less
than 10-fold. For the same reason, because the Km for glycine was relatively unaltered,
the catalytic efficiency with glycine also increased among the isolated variants. The
increase in affinity observed among the active site lid variants with respect to succinylCoA supports a hypothesis whereby the binding of this substrate switches a pre-existing
protein conformational equilibrium towards a closed, catalytically competent,
conformation (Lendrihas, et. al., submitted) (28).
Pre-steady-state reaction of the active site lid variant enzyme-glycine complexes
with succinyl-CoA. To understand the contribution that the active site lid makes toward
the reaction catalyzed by ALAS, the transient kinetic parameters of the library variants
were elucidated. The formation and decay rates of a key step in the chemical mechanism
were obtained (Table 4.3). Under single turnover reaction conditions, the lifetime of a
transient quinonoid intermediate was observed with respect to time as a change in
absorbance at 510 nm. The absorbance change timecourses were fit to a sequential
mechanism with either two or three-steps, equations 1 and 2, respectively. An initial
burst of quinonoid intermediate formation, followed by a two-step rate of decay was
characteristic to 6 of the enzymes tested (Figure 4.5A-F). Compared to wild-type ALAS
(0.8 s-1), the A4 and F3 multiply mutated lid variants, showed a 9-fold increase in the rate
of quinonoid intermediate formation (7.1 s-1 and 7.7 s-1, respectively). Additionally, the
rates corresponding with the first step of quinonoid intermediate decay in these variants
(1.7 s-1 and 1.1 s-1) were also increased over that of wild-type ALAS (0.53 s-1).
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Figure 4.5.

The single turnover

reactions

isolated

of

ALAS variants.

hyperactive

The pre-steady state

kinetic parameters were calculated under
single

turnover

conditions

(60μM

enzyme, 10μM succinyl-CoA, and 120
mM glycine) at 20oC and by monitoring
absorbance changes at 510 nm.

The

reaction catalyzed by the wild-type
enzyme is characterized by a single step
of quinonoid intermediate formation and
2-step process of decay. The reactions
catalyzed by the F10 and H1 variants
(panels G, and H, respectively) are
markedly different, they follow a single
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step of intermediate formation and
single step of intermediate decay. The
remaining variant catalyzed reactions:
A4, D8, G7, A8, F3 and F1 (panels A-F,
respectively) resemble that of the wildtype enzyme.
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Accordingly, the second step of quinonoid intermediate decay, a step hypothesized to
include the dissociation of product and opening of the putative active site lid was
markedly increased in these variants, with values of 0.07 s-1 and .017 s-1, rates 7- and 17fold higher when compared to 0.01 s-1 for wild-type ALAS. These data support the
increased catalytic efficiency observed from the experiments performed in the steadystate.

The singly mutated variants A8, D8 and G7 also formed the quinonoid

intermediate at least 4-fold faster when compared to wild-type ALAS (4.8 s-1, 5.4 s-1, 4.4
s-1, respectively). However, the first rate of biphasic quinonoid intermediate decay was
similar. The rates for all three proteins did not exceed that displayed by wild-type ALAS.
This suggests that the coordinated action of more than one residue may be responsible for
initiating active site lid dynamics, and altering the kinetic mechanism. In the remaining 3
variants, the lifetime of the transient quinonoid intermediate was dramatically different
(Figure 4.5H, 4.5I and 4.6A). Instead of proceeding by a mechanism similar to wild-type
ALAS, these enzymes appear to condense the biphasic rate of decay into a single step.
Consequently, the data are fitted to a two step sequential mechanism. SS2, H1, and F1 all
form the quinonoid intermediate faster than wild-type ALAS. Most notably, SS2 does so
at a rate that is 20-fold faster (16 s-1 vs.0.8 s-1 for wild-type ALAS) (Figure 4A). This
group of variants also show the greatest enhancement in the rate associated with
quinonoid intermediate decay. SS2, H1, F10 and F1 all display at least a 2-fold increase
in the rate of quinonoid decay. However, since the second step of quinonoid intermediate
decay is not observed among these variants it is possible that as the rate of decay
becomes monophasic and shows an observed rate that is significantly greater than that
measured for the slower second phase observed in wild-type ALAS, the true rate of
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quinonoid intermediate decay is no longer conformationally dependent, and approximates
the rate of product release.
Equilibrium Constants for the SS2 variant. The dissociation constants for the
binding of glycine and ALA to the SS2 variant at pH 7.5 and 20oC were used to model
the kinetic mechanism (Figure 4.6B and 4.6C). Schiff base formation between the
cofactor of the SS2 variant and glycine was monitored spectroscopically at 420 nm. The
glycine concentration dependent data were fit to a standard hyperbola and the KD for
glycine was found to be 4.12 ± 0.57. This value is 50% lower than that of the wild-type
enzyme. The increased affinity of SS2 for glycine suggests that the active site lid
mutations facilitate substrate binding, a finding coincident with increased catalytic
efficiency. The dissociation constant for ALA, as measured in the SS2 variant, was
determined by monitoring the change in fluorescence emitted at 428 nm upon excitation
at 330 nm. To determine the KD for the product, the enzyme was reacted with increasing
concentrations of ALA. The dissociation constant for ALA was determined to be 1.82 ±
0.19 mM, a value 62% higher compared to that of wild-type ALAS. This value, a notable
decrease in affinity between the product and the SS2 variant may be attributable to
increased active site lid flexibility, a circumstance supported by the hyperactivity
measured for SS2 in the steady- and pre-steady-state.
Thermodynamic properties of wild-type ALAS and the SS2 variant.

The

dependence of the turnover number (kcat) on temperature was characterized over the range
288–308 K for both wild-type ALAS and the SS2 variant (Figure 4.7). The kcat values
were calculated using the same experimental method and data treatment as was described
for the reported steady-state kinetic parameters. The turnover numbers for each enzyme
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Figure

4.6.

The

catalyzed reaction.

SS2

variant

The pre-steady

state kinetic parameters for SS2 were
calculated

under

single

turnover

conditions at 20oC and by:
monitoring

quinonoid

(A)

intermediate

absorbance changes at 510 nm; (B)
monitoring internal aldimine formation
absorbance changes at 420 nm, and;
(C)

monitoring

the

change

in

fluorescence emission at 428nm upon
excitation at 330 nm upon the addition
of ALA.
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were used to construct an Arrhenius plot, from which the thermodynamic activation
parameters were derived (Table 4.4).

The Arrhenius plot of the experimental data

showed a linear dependence in the temperature range for both enzymes. From the slope
of the straight line, an activation energy (Ea) of 0.5 kcal/mol was calculated for the wildtype enzyme. For the SS2 enzyme, Ea was determined to be 0.1 kcal/mol, a value 80%
lower compared to that of wild-type ALAS.

This suggests that the SS2-catalyzed

reaction may decrease the energy barrier for enzyme motions that are coupled to the
reaction. Different slope values were calculated from the linear relationship between the
kcat values for both enzymes and temperature. The slope value associated with wild-type
ALAS was -24, compared to -9.2 for the SS2 variant. These two dissimilar values
suggest that the SS2-catalyzed reaction proceeds by an alternate reaction pathway, where
chemistry and lid mobility determines the rate limiting step.
Figure 4.7. The thermal dependence of the SS2 variant catalyzed reaction. kcat

values were calculated by performing steady-state kinetics at different temperatures. (A)
an Arrhenius plot depicting the difference between the wild-type (●) and the SS2 variant
catalyzed (○) reactions at 288, 292, 297, 302 and 308K. Error bars are plotted over and
partially obscured by the data points.
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Table 4.4. Thermodynamic activation parameters of wild-type ALAS and the
SS2 variant.
Ea
H
G
S
Enzyme
Slope
(kcal/mol) (kcal/mol) (kcal/mol·K)
(kcal/mol)
SS2
-9.2
0.01 ± 0.003 -0.58
16
-56
WTALAS
-24
0.05 ± 0.002 -0.55
17
-58
Figure 4.8. The simulated kinetic mechanism of the SS2 variant catalyzed reaction.

Transition from an internal aldimine with lysine 313 to an external aldimine with glycine
is the first step. Succinyl-CoA binds second which is followed by quinonoid formation,
protonation of the quinonoid to yield an aldimine bound molecule of ALA. Finally, the
release of ALA from the active site is the rate limiting step.
E; SS2: G; glycine: EG; enzyme-glycine complex: SCoA; Succinyl-CoA: EGSCoA;
ALAS-glycine-Succinyl-CoA complex: EQ; enzyme bound to protonated quinonoid:
EALA; enzyme-ALA complex.

2.2 μM-1· s-1

E+G

EG+SCoA

KD = 4.28 mM

11 s

16 s-1

EQ

EGSCoA
-1

-1

0.22 s
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1.7 s-1

EALA
-1

1.5 s

E+ALA

KD = 1.82 mM

Discussion

Comparison of the X-ray crystal structures of holoenzymic ALAS and AONS
with the succinyl-CoA- and AON-bound structures, revealed the presence of a
conformationally mobile active site lid. The outermost part of the active site lid of ALAS
undergoes a 3.5 Å change in conformation in the presence of succinyl-CoA (Figure 4.1).
To address the role of this dynamic structure in the enzyme-catalyzed reaction we
employed synthetic shuffling to alter the amino acid composition of the active site lid in
mALAS2 (Y422-R439). Our results suggest that amino acid substitutions within the
active site lid lead to altered lid dynamics, a circumstance affecting enzymatic turnover,
and one that ultimately liberates the enzyme from a conformationally limited rate
determining step.
The approach used to evaluate the active site lid of ALAS utilized a mutagenic
technique called synthetic shuffling (14). Non-conserved amino acids that comprise the
lid vis á vis the multiple sequence alignment, tolerated sequence substitutions differently
based on their position in the motif (Figure 4.4 and Table 4.1). Shuffled residues
proximal to the amino terminus (V423, A425, Y428) were found to be mutated a total of
12 times in the isolated variants. This is in stark contrast to the 31 mutations identified
among the residues that comprise the carboxy terminal portion of the lid (P432, R433,
G434, E435, L437). The imbalance in mutational frequency evident between the two
halves of the lid suggest that the role of the carboxy terminal half of the lid may be less
structural in nature, as demonstrated by ability of drastically mutated variants such as SS2
and F1 to not only retain activity, but turnover product at rates 10- and 15-fold faster
compared to wild-type ALAS. All of the singly mutated variants had replacements in
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both halves of the lid (A8, D8 and G7). While the isolation of G7 may be an artifact of
the mutational approach, G7, coupled with A8 and D8 contained substitutions whereby
non-polar amino acids were swapped with residues capable of forming a hydrogen bond.
The A425T mutation present in the A8 variant could affect the orientation of the amino
terminal portion of the lid with the two α-helices (α2 and α3) of the adjacent monomer, a
scenario also possible in the multiply mutated variants SS2, A4, and F3. In fact, the
contribution of these abutting helical residues to ALAS function has been previously
addressed (19).

Gong et. al., found that mutating N150 to lysine, and I151 to

phenylalanine and leucine, in mALAS2, increased the Vmax over that of wild-type ALAS.
Indeed, the active site lid library data, coupled with the mutational data on residues N150
and I151 agrees with three previous models where specific interactions that drive ligandinduced closure and catalysis are proposed to be interdomain in nature (29-31).
Two characteristics are shared among all of the variants in the library with respect
to steady-state kinetic parameters (Table 4.3). First, all of the enzymes examined showed
an increase in turnover number. Second, the catalytic efficiency for both substrates was
enhanced. These characteristics indicate that the reaction catalyzed by ALAS may be
limited by a conformational change leading to product release, a mechanism evaluated
among other enzymes (32, 33). Accordingly, mutations that affect the mobility of a
conformationally mobile enzyme structure lead to consequences for reactions in which
the physical step of product release, rather than chemistry, is rate limiting. Therefore the
enhanced turnover observed among the active site lid variants potentially validates our
ALAS catalytic mechanism in which the enzyme conformation switches between closed
and open to stabilize reaction intermediates and release product, respectively; a
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mechanism recently proposed for another PLP-dependent enzyme, diaminopimelate
decarboxylase (34). The majority of variants which showed an increase in kcat were
found to have mutations that occur toward the carboxy terminal portion of the active site
lid. At position 433, the A4 and F1 variants contained mutations to lysine, compounded
with multiple mutations to the motif.

A previous study investigating single point

mutations to R433 (R433L and R433K), found that the kcat values increased 20% and
100% for the respective substitutions (11). Those data coupled with the findings of this
study suggest that position 433 may significantly contribute to lid mobility and the
dissociation of ALA from the enzyme.

However, the variants that had the largest

increases in turnover number and catalytic efficiency were those with mutations to both
regions of the lid, e.g., SS2 and F3. These data support the hypothesis, based on the
crystal structure of R. capsulatus ALAS, that variation to both regions of the active site
lid leads to relaxation of helices α2 and α3, with concomitant disruption of the active site
lid interaction with the aldimine-bound product, likely resulting in acceleration of the
conformationally limited release of ALA. Conversely, the single point mutant identified
in D8 (L437Q) showed only a modest increase in kcat compared to wild-type ALAS. This
finding implies that mutations to L437 alone are not sufficient to accelerate product
turnover. Supportively, since mutations to this residue were identified in concert with
multiple replacements in 5 variants, we believe that the major effect of enhancing the kcat
value for enzymes in the library was due to multiplex variation to the amino acid
composition of the motif.
With regard to the nature of the rate limiting step in variants isolated from the
library, a conformational change is likely the predominant kinetic barrier in the single-
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turnover reaction. That is, in a process that can only be limited by the second phase of
quinonoid intermediate decay or by the rate of product release, the latter must be the
more rapid, as evidenced by steady-state turnover numbers. The rate limiting step in 6 of
the variants from the library is identified as the opening of the active site lid triggered by
product formation (Figure 4.5A-F).

The function of this change in structure likely

disrupts the interaction between the carboxylate moiety of ALA, so that the aldimine
bond formed between the product and PLP can be strongly polarized, and ultimately
lysed. Additionally, lid opening enhances product dissociation (compared to wild-type
ALAS, the SS2 variant showed a 4-fold increase in the K DALA ) by potentially: uncovering
ALA from within a catalytic vacuole, restoring electron density to the site of α-carbon
bond scission, and minimizing contact between product and enzyme. Further, since the
second rate of quinonoid intermediate decay approximates kcat in wild-type ALAS and
these 6 variants it is likely that the there is a single dominant energy barrier, and that it is
thermodynamically advantageous to limit turnover by equalizing the energy of quinonoid
intermediate decay in the enzyme-catalyzed reaction.
The pre-steady-state behavior of three variants from the library differs from that
observed with the wild-type and other library isolates (Figure 4.5G, 4.5H and 4.6A). For
these three library isolates (SS2, F1 and H1) the observed rate of quinonoid intermediate
decay is condensed into a single step.

The quinonoid intermediate formation rate

immediately after mixing the SS2-glycine complex with succinyl-CoA is ~20-fold faster
than the corresponding rate in wild-type ALAS, suggesting that a step after catalysis is
only partially rate determining for this variant under these conditions. This model is
consistent with the decrease in the kcat-derived slope and Ea for this mutant when the
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temperature is varied (Table 4.4).

Together with the greater dissociation constant

determined for ALA with these specific mutations, the data suggest that a conformational
change leading to product release may no longer be rate limiting for the SS2-catalyzed
reaction. In several other enzymes where chemistry has been implicated as rate limiting
(35-37) it was suggested that the effects of conformational change on kcat were the result
of a thermodynamically driven commitment to catalysis. In the three variants that appear
condensed with respect to the rate of quinonoid intermediate decay, Qd is greater than
that of wild-type ALAS and all the active site lid variants tested (Table 4.3). This finding
suggests that the reactions catalyzed by SS2, F1 and H1 are energetically favorable.
Indeed a scenario that the increases in exothermy and positive differential activation
entropy identified in the SS2 variant strongly support.
Based on the kinetic simulation of the single turnover data corresponding to SS2,
quinonoid intermediate decay has condensed into a single step, indicating that the
opening of the active site lid to allow ALA dissociation is no longer a kinetically relevant
part of the mechanism (Figure 4.8).

Thermodynamic data further support this

spectroscopic observation (Figure 4.7 and Table 4.4). Comparison of the wild-type
ALAS- and SS2-catalyzed reactions indicates that there is a 6% difference in the Gibb's
free energy of the reaction. The decrease of net energy observed for the SS2-variant
catalyzed reaction, supports the loss of the kinetic step, as the excess energy required by
the wild-type enzyme will have to be absorbed from the environment, a circumstance
whereby the ALAS-catalyzed reaction compensates by requiring an additional step. This
interpretation is supported by the refined mechanism of the ALAS-catalyzed reaction by
Hunter et. al., wherein the reverse rate of enzyme-ALA1 conversion to enzyme-
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quinonoid is greater than the forward rate of enzyme-ALA1 conversion to enzyme-ALA2
(28). Overall the transient kinetic data suggest that active site lid flexibility and enzyme
activity are tightly coupled and that both the rate limitation to the enzyme reaction and
conformational motion are the same process dependent, in part, upon the spectrum of
amino acids that comprise the motif.
In conclusion, a mutational analysis of the active site lid of mALAS2, identified
by structural investigation, reveals a role of the lid in determining the rate limiting step of
the enzyme-catalyzed reaction. Variants isolated from the library contained mutations to
the non-conserved residues that comprise the active site lid, with a marked preference for
substitutions toward the carboxy terminal region of the motif. Kinetic characterization of
library isolates showed that mutations to the lid result in turnover numbers and catalytic
efficiencies that were always greater than those of wild-type ALAS; strongly suggesting
that the active site lid is a crucial determinant of both substrate binding and product
turnover. Additionally, in a subset of variants, the rate associated with product release
appears independent of a conformational change.

The development of tractable

fluorescent probes as well as solvent viscosity studies with the variants should prove
useful in determining the conformational dynamics of the ALAS-catalyzed reaction.
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Chapter Five
Summary and Conclusion

The three-dimensional structures of Rhodobacter capsulatus ALAS holoenzyme
and succinyl-CoA bound ALAS revealed “open” and “closed” conformational states of
the enzyme, respectively (1). The presence of these two conformational forms agrees
with a previous proposal, based on the transient kinetic characterization of the ALAS
pathway, in which the enzyme undergoes a transition from the open to the closed state
upon succinyl-CoA binding and returns to the open conformation upon ALA release (2,
3). A closer look at the active site shows that a conserved serine residue (S189 in R.
capsulatus ALAS and S254 in meALAS) changes the orientation of its hydrogenbonding pattern in a succinyl-CoA-dependent manner (1).

Succinyl-CoA binding

induced dramatic changes in the visible CD spectra of both the wild-type and S254A
proteins. Additionally, this amino acid substitution elicited a 2-fold increase in enzyme
activity, while simultaneously increasing the Km for succinyl-CoA 25-fold.

These

experimental findings coupled with the structural data suggest that this residue is an
important determinant in conformer equilibrium by promoting energetically favorable
interactions between the chromophore and succinyl-CoA, and by stabilizing a closed
Michaelis-complex configuration.
To address the functionality of S254 in the ALAS-catalyzed reaction, kinetics
experiments were performed on wild-type ALAS and two ALAS variants (S254A and
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S254T). Substitution of serine with alanine eliminates hydrogen bond formation between
the amino acid and the phenolic oxygen of PLP and succinyl-CoA. Notably, steady-state
kinetic parameters calculated for this variant indicate that both the turnover number and
the Michaelis constant for succinyl-CoA increased.

This finding implies unusual

functional complexity regarding the correlation between this mutation and the enzymecatalyzed reaction. The means by which the enzyme manages to increase activity despite
a reduction in affinity for the more complex of the two substrates may include a
mechanism whereby the equilibrium is predominantly shifted toward the closed
conformational state.
The S254A mutation has notable effects on the cofactor microenvironment as
determined by CD spectroscopy. CD spectroscopic evaluations of the conformational
effects of the S254A and S254T mutations illustrate the differences between the two
amino acid substitutions. Succinyl-CoA binding to the wild-type and S254T variant
induced changes in the CD spectra associated with the microenvironment of the
chromophore, while CD spectra corresponding to the S254A mutant were unchanged
under similar conditions. This dissimilarity between wild-type ALAS and S254A may be
the result of a partial conversion of the internal aldimine to free PLP aldehyde present in
the active site, a circumstance which is observed in three out of the four R. capsulatus
crystal structure active sites upon succinyl-CoA binding (1). In the crystal structures
these events are coincident with the closed conformation, from which it might be
concluded that the S254A variant retains the internal aldimine in the presence of
succinyl-CoA, and may not be induced to adopt a closed conformation upon binding of
this substrate.
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Pre-steady-state kinetic analyses of both the wild-type ALAS- and variantcatalyzed reactions show that upon decarboxylation, the ALA-bound quinonoid
intermediate is formed followed by two successively slower steps in which the
intermediate decays. These two steps are assigned to protonation of the ALA-quinonoid
intermediate and ALA release, respectively (3). For the S254T variant, the rate of
quinonoid intermediate formation decreased 4-fold compared to that of wild-type
enzyme. This reduction may indicate a change in the flow of electrons from the site of
bond scission to the resonance stabilized carbanion, induced by a shift of the
conformational equilibrium towards the closed conformation. Changes in the position of
PLP observed in the three-dimensional structures available for ALAS show a shift of 15
degrees when substrate is bound (1). These observations, coupled with experimental
evidence suggesting that even subtle changes to the stereoelectronic parameters of the
external aldimine and PLP modulate catalysis, indicate that the hydrogen bonding
potential of position 254 in ALAS may be an important feature in the regulation of the
transition from the open to the closed conformation (4, 5). Together the data for both
ALAS variants support a postulate whereby non-covalent forces between S254 and the
phenolic oxygen influence an induced fit mechanism in which substrate recognition is
coupled to conformational equilibria.
ALAS is a member of the -oxoamine synthase subfamily of pyridoxal 5'phosphate (PLP)-dependent enzymes and shares a high degree of structural similarity and
reactivity with the other members of the family (6). Despite the remarkable structural
and mechanistic similarities in this important group of enzymes the molecular
mechanisms underlying substrate specificity remain largely unexplored.
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The X-ray

crystal structure of ALAS from Rhodobacter capsulatus reveals that the alkanoate
component of succinyl-CoA is coordinated by a conserved arginine and a threonine (1).
The functions of the corresponding acyl-CoA-binding residues in murine erythroid ALAS
(R85 and T430) in relation to acyl-CoA binding and substrate discrimination were
examined using site-directed mutagenesis and a series of CoA-derivatives.
The acyl-CoA substrate binds to the enzyme through an interaction between the
pantetheine moiety of CoA with the enzyme surface and via hydrogen-bonding
interactions between the terminal alkanoate group and R85 and T430 (1). The steadystate kinetic analysis of the variants (R85K, R85L, and R85L/T430V) with the family of
CoA-derivatives showed that the apparent Michaelis parameters are dramatically
different when compared to those of wild-type ALAS. Acyl-CoA substrates of increased
hydrophobicity (e.g., octanoyl- and butyryl-CoA) bound with higher affinity to variants
where the substituted amino acid was aliphatic in nature (R85L and R85L/T430V). The
36-fold decrease in substrate binding for octanoyl-CoA in the R85L variant suggests that
the exclusion of water from the acyl-CoA-binding cleft is an important feature of
substrate binding.

It is likely that reaction specificity is driven by the chemical

characteristics of the CoA-derived tail and the hydrogen-bonding potential of the
invariant acyl-CoA-binding residues, a circumstance which has been proposed for the
acyl-CoA thioesterases of the peroxisome (7, 8).
The use of chemically different acyl-CoA-derivatives affects the transient kinetic
parameters of a variant enzyme (R85K) signifying potential alterations to a key
mechanistic step in the ALAS-catalyzed reaction. Single turnover reactions with a family
of CoA-derivatives were used to determine the rates of quinonoid intermediate formation
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and decay for the R85K variant. The R85K variant-catalyzed reaction was decelerated in
the first step of quinonoid intermediate decay, with a 10-fold lower rate for both
octanoyl-CoA and glutaryl-CoA when compared to the physiological substrate succinylCoA. When R85 is mutated to a lysine, the enzyme is chemically similar to wild-type
ALAS in many respects, presumably because this conservative replacement retains the
positive charge and hydrogen bonding capabilities. However, the molecular volume of
the amino acid side chain is different. With respect to their n-alkyl moieties, the npropylguanidine side chain of arginine is longer than the n-butylamine side chain of
lysine by 1.6 Å (9). The R85K substitution could therefore accommodate the additional
sp3 hybridized carbon atom present in glutaryl-CoA, allowing for a reduction in steric
strain and/or unfavorable van der Waals interactions. Both of these possibilities could be
contributing factors in molecular recognition of the physiological substrate succinyl-CoA.
In all, the experimental data support multifunctional roles for these amino acids (R85 and
T430) in regulating substrate specificity, and linking the bifurcate coordination of the
acyl-CoA tail with the mechanistic chemistry of the active site.
In X-ray crystal structures of 8-amino-7-oxononanoate synthase from E. coli and R.
capsulatus ALAS, a loop, covering a conserved sequence of amino acids, was shown to
migrate 3.5 and 5.5 Å between the holoenzymic forms and acyl-CoA-bound forms of the
two enzymes, respectively (1, 10). Comparison of holoenzymic ALAS and AONS with
the substrate- and product-bound forms of the enzymes indicates that binding of these
ligands within the active site precipitates movement of the loop.

These structural

observations suggest, but do not prove, that the dynamics of this active site lid may
signify a change in conformation. In order to examine the role of this active site loop (or
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“lid”) in the ALAS-catalyzed reaction, we used genetic manipulation to identify
functional amino acid mutations and to evaluate the contribution of lid residues to
catalysis. The approach used to evaluate the active site lid of ALAS utilized a mutagenic
technique called synthetic shuffling (11). The active site lid of ALAS contains 18
residues; 8 of these are completely conserved, while the remaining amino acids show no
pattern with respect to evolution (1). Mutations were observed throughout the entire
motif. However, more mutations were found in the carboxy-terminal portion of the lid
compared to the segment closer to the amino-terminus (31 to 12, respectively). This
inequality suggests that greater plasticity is associated with the C-terminal part of the
loop.
Each of the isolated variants was shown to have increased turnover numbers and
enhanced catalytic efficiency with both substrates.

These characteristics, identified

among active site lid variants, indicate that the reaction catalyzed by ALAS may be
limited by the amino acid composition of the lid. Further, conformational changes
centered in active site loops have been reported to have important mechanistic roles in
other enzymes (12, 13).

Accordingly, mutations that affect the mobility of a

conformationally mobile enzyme structure may have consequences in which the physical
step of product release, rather than chemistry, becomes rate limiting. Therefore the
enhanced turnover observed among the active site lid variants potentially validates our
ALAS catalytic mechanism in which the enzyme conformation switches between closed
and open to stabilize reaction intermediates and release product, respectively, a
mechanism recently proposed for another PLP-dependent enzyme, diaminopimelate
decarboxylase (14).
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The pre-steady-state behaviors of three variants from the library (SS2, F1 and
H1)differed from that observed with the wild-type enzyme and other library isolates: the
two steps associated with the quinonoid intermediate decay were condensed into a single
step. For the SS2 variant-catalyzed reaction, quinonoid intermediate formation is ~20fold faster than the corresponding rate in wild-type ALAS, suggesting that a step after
catalysis is only partially rate-determining for this variant. Together with the greater
dissociation constant of the SS2 variant for ALA (Table?), the data suggest that a
conformational change leading to product release no longer is rate-limiting for the SS2catalyzed reaction. Indeed, studies on several other enzymes where a chemical step has
been implicated as rate-limiting show that the effects of conformational changes on kcat
were the result of a thermodynamically driven commitment to catalysis (15-17). In fact,
increases in exothermy and positive differential activation entropy were also determined
for the SS2 variant-catalyzed reaction.
Based on the kinetic simulation of the single turnover data for the reaction
catalyzed by SS2, quinonoid intermediate decay has condensed into a single step,
indicating that the opening of the active site lid to allow ALA dissociation is no longer a
kinetically relevant part of the mechanism. Thermodynamic data further support this
spectroscopy-derived observation. The decrease of net energy observed for the SS2
variant-catalyzed reaction, supports the loss of this kinetic step. Conversely, the excess
energy required by the wild-type enzyme would likely have to be absorbed from the
environment, a circumstance whereby the ALAS-catalyzed reaction would compensate
by requiring an additional step (3).

This interpretation is supported by the refined

mechanism of the ALAS-catalyzed reaction by Hunter et. al., wherein the reverse rate of
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enzyme-ALA1 conversion to enzyme-quinonoid is greater than the forward rate of
enzyme-ALA1 conversion to enzyme-ALA2 (3).

Overall the transient kinetic data

suggest that active site lid flexibility and enzyme activity are tightly coupled and that
both the rate limitation to the enzyme reaction and conformational motion are the same
process, dependent, in part, upon the spectrum of amino acids that comprise the motif.
The kinetic parameters calculated for the library isolates show that these mutations
confer hyperactivity. Through these investigations, hypotheses pertaining to the reaction
mechanism of ALAS have implications in the pathways of disease involving both iron
metabolism and porphyrin biogenesis. Data presented here and conclusions set forth
regarding limits to ALA turnover and individual steps associated with substrate binding
and rates of reaction, specifically address facets of XLSA and the recently discovered
erythroid ALAS-related porphyria, X-linked dominant protoporphyria (19).

Many

mutations associated with diminished ALAS activity in vivo are located in the PLPbinding cleft (1, 19). Significantly, the conformationally responsive S254 residue forms
a hydrogen bond with the phenolic oxygen of the cofactor. Enhanced turnover of ALA,
and subsequent biosynthesis of porphyrins and porphyrin precursors are the foreseeable
consequences of the reactions catalyzed by isolates from the active site lid library.
Indeed, these circumstances resemble the pathology that is associated with X-linked
dominant protoporphyria (18).
The knowledge related to ALAS from the studies presented here contribute to the
goal of therapeutic intervention of porphyrin-accumulative diseases, like cancer.
Further, biochemical developments in the field of biotechnology will also be enhanced
through this research by addressing the molecular requirements of treatments like
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photodynamic therapy. In conclusion, these data are likely to provide insight into the
rate-determining step of enzymes limited by a product release, or a conformational
change leading to product release.
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